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ABSTRACT 
 
Salmonella enterica serovar Enteritidis (S. Enteritidis) is a major cause of 
gastrointestinal disease in humans worldwide that is mainly associated with the 
consumption of contaminated poultry meat and eggs. During the course of infection, S. 
Enteritidis uses two Type 3 Secretion Systems (T3SS), one of which is encoded by 
Salmonella Pathogenicity Island-1 (SPI-1). SPI-1 plays a major role in the invasion 
process. 
In order to study the role of SPI-1 in the colonization of chickens, we constructed 
deletion mutants affecting either the complete SPI-1 region (40 kb) or invG, a single gene 
located on this pathogenicity island. The mutants were impaired in the secretion of 
effector proteins and were less invasive compared to the wild type strain in polarized 
Caco-2 cells. Similarly, when chicken cecal and small intestinal explants were co-
infected with the wild type and ∆SPI-1 mutant strains we found that the ∆SPI-1 mutant 
strain was less invasive relative to the wild type strain. Oral challenge of 1-week-old 
chickens with the wild type or ∆SPI-1 strains demonstrated that there was no difference 
in chicken cecal colonization. However, systemic infection, measured as levels of 
Salmonella in the liver and spleen, was delayed in birds that were challenged with the 
∆SPI-1 strain. This demonstrates that SPI-1 facilitates systemic infection but is not 
essential for invasion and systemic spread of S. Enteritidis in chickens. 
 
Based on the above results, we examined the effect of sera against SPI-1 T3SS 
components to S. Enteritidis invasion. Anti-SipD serum protected Caco-2 cells against 
entry of wild type S. Enteritidis, but not against invasion of a mutant strain lacking sipD. 
On the other hand, sera against InvG, PrgI, SipA, SipC, SopB, SopE and SopE2 did not 
affect S. Enteritidis entry. To illustrate the specificity of anti-SipD mediated inhibition, 
SipD specific antibodies were depleted from the serum. Depleted serum restored the 
invasion of S. Enteritidis, demonstrating that the SipD protein may be an important target 
in blocking SPI-1 mediated virulence. 
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To determine if SPI-1 T3SS proteins were protective against S. Enteritidis oral 
challenge, chickens were vaccinated subcutaneously twice at 14 and 28 days of age with 
PrgI and SipD. The results indicate that these proteins induce strong IgG antibody 
responses and confer significant protection against infection of the livers in vaccinated 
birds. In another study, we vaccinated hens with selected SPI-1 T3SS proteins to 
determine if their progeny could be protected from S. Enteritidis oral challenge. The 
proteins induced strong antibody responses but did not affect the levels of the challenge 
strain in the ceca or internal organs of the vaccinates. Taken together, our results establish 
that S. Enteritidis SPI-1 is an important virulence factor in chickens and that the proteins 
associated with this T3SS may form components of a subunit vaccine used for protection 
against colonization by S. Enteritidis in poultry. 
 
 iii
ACKNOWLEDGEMENTS 
IN THE NAME OF ALLAH (GOD), THE MOST GRACIOUS AND THE MOST MERCIFUL 
I sincerely acknowledge the guidance, mentorship and support that I have 
received from my supervisors Dr. Wolfgang Köster and Dr. Andrew Potter. Dr. W. 
Köster was always available for guidance and spent countless hours reading through my 
manuscripts and thesis. Dr. A. Potter responded to my inquiries with incredible speed at 
all times, provided excellent advice and was an inspiration for me. Special thanks to my 
committee members: Dr. Philip Griebel, Dr. Lorne Babiuk, Dr. Peter Howard and Dr. 
Vikram Misra for their direction and feedback over the duration of my program. 
I am also grateful to Dr. Nanhi Parveen and Shirley Lam for their technical 
guidance. As well, Dr. Birgit Koch and Dr. Claudia Mickael taught me various technical 
skills over the years. Dr. Emil Berberov played a major role in my development as he had 
extensive research experience and taught me a lot about critical thinking in science. 
Special thanks to Amanda Wisner for doing the ELISA experiments, for always being 
there for me and for the nice discussions we had. I want to thank all the members of our 
Bacterial Vaccine Development Group for their input, VIDO animal care (especially 
Barry Carrol) and VIDO GMP for their services, Dr. Hugh Townsend for assistance with 
statistics and Joyce Sander for being so helpful throughout the years. 
I want to thank all the graduate students at VIDO for their friendship, especially 
Dr. Haitham Ghunaim, Dr. David Asper, Dr. Oudessa Dego, Audrey Chu, Chris Luby, 
Carolyn Paterson and Jean Potter. As well, members of Dr. Suresh Tikoo’s lab were very 
friendly, especially Niraj Makadiya, Sanjeev Anand and Satyender Hansra. I also 
acknowledge the VIDO volleyball team for helping me divert my attention from the 
stressful moments at work. 
I thank Dr. Erin Boyle and Dr. Brett Finlay (UBC) for providing us with the 
Caco-2 cells and for assistance in polarization. Dr. Susantha Gomis and Patrick Fries 
were very helpful when I worked with chicken intestinal tissue. Dr. Aaron White and Dr. 
Michael Surrette kindly provided us with the lambda red plasmids. Dr. Brenda Allan and 
other members of our lab worked very hard during our animal experiments. This project 
was funded by the Natural Sciences and Engineering Research Council (NSERC), 
Bioniche Life Sciences and the Saskatchewan Health Research Foundation (SHRF). 
 iv
DEDICATION 
 
This thesis is dedicated to: 
 
My parents, Mohammed Desin and Yasmeen Desin, and my sisters, Sara and Fatimah, 
who supported me in every possible way, always believed in higher education, were very 
encouraging and kept me going. 
 
My wife, Shakeeba Mustaan and my daughters, Maryam and Huda, who were always 
caring, supportive and patient while I did my work. 
 v
TABLE OF CONTENTS 
PERMISSION TO USE POSTGRADUATE THESIS ................................................... i 
ABSTRACT ....................................................................................................................... ii 
ACKNOWLEDGEMENTS ............................................................................................ iv 
DEDICATION................................................................................................................... v 
TABLE OF CONTENTS ................................................................................................ vi 
LIST OF TABLES ............................................................................................................ x 
LIST OF FIGURES ......................................................................................................... xi 
LIST OF ABBREVIATIONS ....................................................................................... xiv 
1.0 LITERATURE REVIEW .......................................................................................... 1 
1.1 Salmonella ............................................................................................................... 1 
1.1.1 Nomenclature ................................................................................................. 1 
1.1.2 Salmonella Enteritidis .................................................................................... 1 
1.1.3 Virulence factors ............................................................................................ 2 
1.1.3.1 Flagella .................................................................................................... 2 
1.1.3.2 Fimbriae .................................................................................................. 3 
1.1.3.3 Plasmids .................................................................................................. 4 
1.1.3.4 Type 3 Secretion Systems and Pathogenicity Islands ............................. 4 
1.2 Salmonella Pathogenicity Island-1 Type 3 Secretion System ................................. 5 
1.2.1 Structure ......................................................................................................... 5 
1.2.2 Assembly........................................................................................................ 8 
1.2.3 Secretion ........................................................................................................ 8 
1.2.4 Regulation .................................................................................................... 14 
1.2.5 Role in Virulence ......................................................................................... 18 
1.3 Salmonella Pathogenicity Island-2 Type 3 Secretion System ............................... 19 
1.3.1 Structure ....................................................................................................... 19 
1.3.2 Secretion ...................................................................................................... 19 
1.3.3 Regulation .................................................................................................... 25 
1.3.4 Role in virulence .......................................................................................... 25 
1.4 Salmonella Enteritidis in Poultry .......................................................................... 26 
1.4.1 Sources of infection ..................................................................................... 26 
 vi
1.4.2 Pathogenesis ................................................................................................. 27 
1.4.3 Immune response to S. Enteritidis ............................................................... 27 
1.4.3.1 Innate immune response ....................................................................... 27 
1.4.3.2 Adaptive immune response ................................................................... 29 
1.5 Control of Salmonella Enteritidis .......................................................................... 30 
1.5.1 Management practices ................................................................................. 30 
1.5.2 Bacteriophages ............................................................................................. 31 
1.5.3 Competitive Exclusion ................................................................................. 32 
1.5.4 Vaccination .................................................................................................. 33 
1.5.4.1 Live attenuated vaccines ....................................................................... 33 
1.5.4.2 Killed vaccines ...................................................................................... 36 
1.5.4.3 Subunit vaccines ................................................................................... 37 
1.5.5 Consumer Education .................................................................................... 39 
1.5.6 Testing.......................................................................................................... 42 
2.0 HYPOTHESIS AND OBJECTIVES ...................................................................... 43 
2.1 Hypothesis ............................................................................................................. 43 
2.2 Rationale................................................................................................................ 43 
2.3 Objectives .............................................................................................................. 43 
3.0 SALMONELLA ENTERICA SEROVAR ENTERITIDIS PATHOGENICITY 
ISLAND-1 IS NOT ESSENTIAL FOR, BUT FACILITATES RAPID SYSTEMIC 
INFECTION IN CHICKENS ........................................................................................ 44 
3.1 Introduction ........................................................................................................... 44 
3.2 Materials and Methods .......................................................................................... 47 
3.2.1 Bacterial strains and growth conditions ....................................................... 47 
3.2.2 Construction of mutants ............................................................................... 49 
3.2.3 Precipitation of SPI-1 secreted proteins ....................................................... 49 
3.2.4 Cloning of sipD and purification of His-tag SipD ....................................... 51 
3.2.5 Western immunoblots .................................................................................. 51 
3.2.6 Cell culture ................................................................................................... 52 
3.2.7 Invasion assay using polarized Caco-2 cells ................................................ 52 
3.2.8 Measurement of trans-epithelial resistance .................................................. 52 
 vii
3.2.9 Chicken intestinal tissue explants ................................................................ 53 
3.2.10 Passage of strains ....................................................................................... 53 
3.2.11 Infection of 1-week old chickens ............................................................... 53 
3.2.12 Statistical analysis ...................................................................................... 54 
3.3 Results ................................................................................................................... 54 
3.3.1 The ∆SPI-1 and ∆invG strains are impaired in the secretion of SipD ......... 54 
3.3.2 Salmonella Pathogenicity Island-1 is important for efficient invasion in 
polarized Caco-2 cells and causes a reduction in the trans-epithelial resistance .. 55 
3.3.3 The SPI-1 deficient strain is less invasive relative to the wild type strain in 
chicken intestinal tissue explants .......................................................................... 60 
3.3.4 Cecal colonization levels were similar in both the wild type and ∆SPI-1 
challenged groups ................................................................................................. 60 
3.3.5 The deletion of SPI-1 results in delayed systemic infection in chickens ..... 60 
3.4 Discussion ............................................................................................................. 66 
4.0 PROTECTION OF EPITHELIAL CELLS FROM SALMONELLA ENTERICA 
SEROVAR ENTERITIDIS BY ANTIBODIES AGAINST THE SPI-1 TYPE 3 
SECRETION SYSTEM ................................................................................................. 73 
4.1 Introduction ........................................................................................................... 73 
4.2 Materials and Methods .......................................................................................... 74 
4.2.1 Bacterial strains and growth conditions ....................................................... 74 
4.2.2 Preparation of SPI-1 secreted proteins ......................................................... 74 
4.2.3 Cloning and purification of His-tag proteins ............................................... 75 
4.2.4 Generation of rabbit polyclonal anti-sera .................................................... 75 
4.2.5 Cell culture ................................................................................................... 75 
4.2.6 Invasion inhibition assay.............................................................................. 75 
4.2.7 Trans-epithelial resistance ........................................................................... 76 
4.2.8 Western blots ............................................................................................... 76 
4.2.9 ELISA .......................................................................................................... 77 
4.2.10 Depletion of SipD specific antibodies ....................................................... 77 
4.2.11 Statistical analysis ...................................................................................... 77 
4.3 Results ................................................................................................................... 78 
 viii
4.3.1 Anti-SipD serum inhibits S. Enteritidis entry .............................................. 78 
4.3.2 Invasion inhibition is SipD specific ............................................................. 83 
4.4 Discussion ............................................................................................................. 88 
5.0 IMMUNIZATION OF CHICKENS WITH SALMONELLA ENTERICA 
SEROVAR ENTERITIDIS PATHOGENICITY ISLAND-1 STRUCTURAL 
PROTEINS INDUCES STRONG HUMORAL RESPONSES AND CONFERS 
PROTECTION FROM SYSTEMIC INFECTION ..................................................... 93 
5.1 Introduction ........................................................................................................... 93 
5.2 Materials and Methods .......................................................................................... 95 
5.2.1 Bacterial strains ............................................................................................ 95 
5.2.2 Protein expression and purification ............................................................. 95 
5.2.3 Vaccination of chickens ............................................................................... 96 
5.2.4 Immunization of laying hens ....................................................................... 96 
5.2.5 Antibody isolation from chicken egg yolks ............................................... 100 
5.2.6 ELISA ........................................................................................................ 100 
5.2.7 Statistical analysis ...................................................................................... 100 
5.3 Results ................................................................................................................. 101 
5.3.1 Vaccine Trial 1 ........................................................................................... 101 
5.3.2 Vaccine Trial 2 ........................................................................................... 101 
5.3.3 Vaccine Trial 3 ........................................................................................... 115 
5.4 Discussion ........................................................................................................... 121 
6.0 GENERAL DISCUSSION AND CONCLUSIONS ............................................. 126 
6.1 General Discussion .............................................................................................. 126 
6.2 General Conclusions ........................................................................................... 132 
REFERENCES .............................................................................................................. 133 
 
 ix
LIST OF TABLES 
 
Table 1.1  List of effector proteins secreted by the S. Enteritidis SPI-1 T3SS……………9 
Table 1.2  List of effector proteins secreted by the S. Enteritidis SPI-2 T3SS…………..22 
Table 1.3  Summary of major studies carried out to evaluate the efficacy of 
Salmonella vaccines in conferring protection against 
S. Enteritidis challenge…………………………………………..……………40 
Table 3.1  Bacterial strains used in this study……………………………………………48 
Table 3.2  Primers used in this study…………………………………………………….50 
 
 x
LIST OF FIGURES 
Figure 1.1. Schematic representation of Salmonella Pathogenicity Island-1 genes………6 
Figure 1.2. Structure of the S. Enteritidis SPI-1 T3SS…………………………………….7 
Figure 1.3. Summary of the main functions of S. Enteritidis SPI-1 T3SS effector 
proteins…………………………………………………………………..…..15 
Figure 1.4. Regulation of the S. Enteritidis SPI-1 T3SS by local and global 
regulators………………………………………………………………….…16 
Figure 1.5. Schematic representation of the S. Enteritidis SPI-2 T3SS genes…………...20 
Figure 1.6. Structure of the S. Enteritidis SPI-2 T3SS…………………………….……..21 
Figure 1.7. Summary of the main functions of S. Enteritidis SPI-2 effector proteins...…24 
Figure 1.8. Human Salmonella cases in the United Kingdom from 1981 – 2001……….34 
Figure 3.1. Western blot analysis of bacterial culture supernatants (A) and pellet 
fractions (B) of wild type S. Enteritidis and the mutant strains……………..56 
Figure 3.2. Single infection of polarized Caco-2 monolayers by either S. Enteritidis 
wildtype, ∆SPI-1, or ∆invG strains or E. coli DH5α at an MOI of 100….....58 
Figure 3.3. Mixed infection of polarized Caco-2 monolayers by S. Enteritidis 
wild type and ∆SPI-1 strains or wild type and ∆invG strains at 
a 1:1 ratio with an MOI of 100……………………………………………...59 
Figure 3.4. Invasion of chicken cecal and small-intestinal tissue explants by S. Enteritidis 
wild type and ∆SPI-1 strains at a 1:1 ratio………………………………….61 
Figure 3.5. Colonization of ceca from 1-week-old chickens by either wild type S. 
Enteritidis or ∆SPI-1…………………………...……………………………62 
Figure 3.6. Systemic infection of the liver in 1-week-old chickens challenged with 1010 
CFU of either wild type S. Enteritidis or ∆SPI-1……………………………63 
Figure 3.7. Systemic infection of the spleen in 1-week-old chickens challenged with 1010 
CFU of either wild type S. Enteritidis or ∆SPI-1……………………………65 
Figure 4.1. Antibodies against total SPI-1 secreted proteins inhibition S. Enteritidis 
invasion………………………………………………………..………….…79 
Figure 4.2. Pooled sera against SipA, SipC and SipD inhibit entry of S. Enteritidis…....80 
Figure 4.3. S. Typhimurium invasion is inhibited by pooled sera against SipA, SipC and 
SipD…………………………………………………………………………81 
 xi
Figure 4.4. Anti-SipD serum inhibits S. Enteritidis invasion………................................82 
Figure 4.5. Anti-SipD serum mediated inhibition is SPI-1 specific………..……………84 
Figure 4.6. Western blots of the cellular fraction from whole cell lysates of 
S. Enteritidis wild type and the mutant strain ∆sipD using 
(A) rabbit polyclonal pre-immune serum or (B) serum against SipD……….85 
Figure 4.7. Depletion of SipD specific antibodies from anti-SipD serum restores 
S. Enteritidis invasion……………………………………………………….87 
Figure 5.1. Experimental design for Vaccine Trial 1…………………………………….97 
Figure 5.2. Experimental design for Vaccine Trials 2 and 3…………………...………..99 
Figure 5.3. Vaccine Trial 1. Levels of S. Enteritidis expressed as median CFU / g in 
the cecal contents on days 1, 2 and 4 postchallenge (1010 CFU) 
in chickens vaccinated subcutaneously with either PBS or PrgI + SipD.…102 
Figure 5.4. Vaccine Trial 1. Levels of S. Enteritidis expressed as median CFU / g in 
the livers and spleens on days 1, 2 and 4 postchallenge (1010 CFU) 
in chickens vaccinated subcutaneously with either PBS or PrgI + SipD…..103 
Figure 5.5. Vaccine Trial 1. The number of birds positive for Salmonella after 
enrichment of liver and spleen homogenates………………………………104 
Figure 5.6. Vaccine Trial 1. Median IgG antibody titers specific for PrgI and SipD 
in sera obtained from chickens vaccinated subcutaneously 
with either PBS or PrgI + SipD……………………………………..……...105 
Figure 5.7. Median IgG antibody titers specific for SPI-1 T3SS proteins in sera and 
egg yolks obtained from laying hens vaccinated subcutaneously 
on days 0, 21 and 42 with either PBS or SPI-1 T3SS protein……………..107 
Figure 5.8. Median IgG antibody titers specific for AviPro® in sera and egg yolks 
obtained from laying hens vaccinated subcutaneously on days 0, 21 and 42 
with either PBS or AviPro®…………………………………………….….108 
Figure 5.9. Vaccine Trial 2, Experiment I. Levels of S. Enteritidis in the cecal contents  
of progeny obtained from vaccinated hens…………………………..…….109 
Figure 5.10. Vaccine Trial 2, Experiment I. Levels of S. Enteritidis in the livers of 
progeny obtained from vaccinated hens …………………………...…….110 
 xii
Figure 5.11. Vaccine Trial 2, Experiment I. Levels of S. Enteritidis in the spleens of 
progeny obtained from vaccinated hens ………………………...……….111 
Figure 5.12. Vaccine Trial 2, Experiment II. Levels of S. Enteritidis in the cecal contents 
of progeny obtained from vaccinated hens ………..…….……………….112 
Figure 5.13. Vaccine Trial 2, Experiment II. Levels of S. Enteritidis in the livers of 
progeny obtained from vaccinated hens..…..…………………………….113 
Figure 5.14. Vaccine Trial 2, Experiment II. Levels of S. Enteritidis in the spleens of 
progeny obtained from vaccinated hens.…….…………………..……….114 
Figure 5.15. Vaccine Trial 2, Experiment III. Levels of S. Enteritidis in the cecal contents 
of progeny obtained from vaccinated hens…………..…..……………….116 
Figure 5.16. Vaccine Trial 2, Experiment III. Levels of S. Enteritidis in the livers of 
progeny obtained from vaccinated hens…..……………..……………….117 
Figure 5.17. Vaccine Trial 2, Experiment III. Levels of S. Enteritidis in the spleens of 
progeny obtained from vaccinated hens…..……………..……………….118 
Figure 5.18. Vaccine Trial 3. Median levels of S. Enteritidis expressed as CFU/g in the 
cecal contents two days postchallenge in hens vaccinated with either PBS, 
SPI-1 T3SS proteins or AviPro®………………………..………………..119 
Figure 5.19. Vaccine Trial 3. Median levels of S. Enteritidis expressed as CFU/g in the 
livers and spleens two days postchallenge in hens vaccinated with either 
PBS, SPI-1 T3SS proteins or AviPro®………………………………...…120 
Figure 6.1. Schematic representation of Salmonella entry across the epithelial layer 
based on studies in mice…………………………….…………………....129 
 
 
 xiii
LIST OF ABBREVIATIONS 
AP-1   Activator Protein 1 
BBS   Borate Buffered Saline 
BGA   Brilliant Green Agar 
Caspase  Cysteine dependent aspartate specific protease 
CFU   Colony forming unit 
ddH2O  Double-distilled water 
DMEM  Dulbecco’s Modified Eagles Medium 
ELISA   Enzyme Linked Immunosorbent Assay 
E. coli   Escherichia coli  
ERK   Extracellular regulated kinase 
FBS   Fetal Bovine Serum 
Fis   Inversion stimulation 
Fur   Ferric uptake regulator 
GAP   GTPase Activating Protein 
GDP   Guanosine Diphosphate 
GEF   Guanine Nucleotide Exchange Factor 
GTP   Guanosine Triphosphate 
HACCP  Hazard Analysis Critical Control Point 
IFNγ   Interferon-gamma 
IgA   Immunoglobulin A 
IgG   Immunoglobulin G 
IgM   Immunoglobulin M 
IHF   Integration Host Factor 
IL   Interleukin 
LB   Luria Bertani 
LPS   Lipopolysaccharide 
MAPK   Mitogen Activated Protein Kinase 
Mbp   Mega base pairs 
MOI   Multiplicity of Infection 
NAP   Nucleoid Associated Proteins 
 xiv
 xv
NF-κB   Nuclear Factor Kappa B 
PAMP   Pathogen Associated Molecular Patterns 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
PFU   Plaque Forming Units 
PEF   Plasmid Encoded Fimbriae 
PMN   Polymorphonuclear Leukocytes 
SCV   Salmonella Containing Vacuole 
SDS-PAGE  Sodium Dodecyl Sulphate Polyacrylamide Gel Electophoresis 
S. Enteritidis  Salmonella enterica serovar Enteritidis 
SPF   Specific Pathogen Free 
SPI   Salmonella Pathogenicity Island 
S. Typhimurium Salmonela enterica serovar Typhimurium 
TCA   Trichloro-acetic acid 
TER   Trans-epithelial resistance 
TGF   Transforming Growth Factor 
TLR   Toll-Like Receptor 
T3SS   Type 3 Secretion System 
VIDO   Vaccine and Infectious Disease Organization 
WASP   Wiskott-Aldrich Syndrome Protein 
WT   Wild Type S. Enteritidis 
 
1.0 LITERATURE REVIEW 
 
1.1 Salmonella 
 
1.1.1 Nomenclature 
The bacterial genus Salmonella was named following the discovery of this 
pathogen by the United States Department of Agriculture (USDA) veterinary 
bacteriologist Dr. Daniel E. Salmon (1850-1914) [1]. Salmonella is a Gram negative, 
facultative intracellular, rod-shaped (0.7-1.5 µm wide x 2-5 µm long) and non-spore 
forming member of the enterobacteriacae family. Salmonella species are mostly 
peritrichously flagellated and motile. The optimal temperature for growth of this 
pathogen is 37° Celsius [2]. The genus Salmonella is divided into two species, 
Salmonella bongori and Salmonella enterica. S. enterica consists of six subspecies: 
enterica, salamae, arizonae, diarizonae, indica, and houtenae [3]. S. enterica subspecies 
enterica is mainly associated with infection in warm blooded animals, while the other 
subspecies and Salmonella bongori rarely cause infection in these animals [4, 5]. S. 
enterica subspecies enterica consists of more than 2000 serovars [6] which are classified 
based on the O factor (O antigen) of the lipopolysaccharide (LPS) and the H antigens of 
the flagella [7]. 
 
1.1.2 Salmonella Enteritidis 
S. enterica subspecies enterica serovar Enteritidis (S. Enteritidis) has a genome 
size of approximately 4.69 Mbp [8] and is one of the most prevalent serovars with respect 
to human Salmonella infections world wide [9]. The consumption of contaminated meat 
(mainly poultry) and eggs are major sources of S. Enteritidis human infections [10]. 
Typically human infections result in a localized gastrointestinal disease which is 
characterized by a massive influx of neutrophils (hallmark of these infections) in the 
terminal ileum and colon (enterocolitis) resulting in nausea, vomiting and diarrohea [11]. 
Mostly, such infections are self-limiting and clear within 3-5 days. However, S. 
Enteritidis infections can also cause systemic disease, requiring antibiotic treatment or 
even hospitalization. On rare occasions, S. Enteritidis infections can also lead to the 
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development of pain in the joints, eye irritation and painful urination (referred to as 
Reiter’s Syndrome) [12]. It is estimated that there are approximately 1.4 million cases of 
human salmonellosis in the United States annually [12], while in Canada the number of 
cases has been estimated to be close to 0.5 million every year [13]. The impact of these 
infections is massive on the U.S. and Canadian economies due to medical care, loss of 
work and death [14]. 
 
1.1.3 Virulence factors 
 
1.1.3.1 Flagella 
Salmonella species express flagella on their surface, which are organelles whose 
primary role is cell propulsion [15]. Rotation of the flagellar filament propels the 
bacterial cell either in a forward motion or random reorientation, depending on the 
chemical stimulus in the environment (chemotaxis). Although motility is its primary 
function, the flagella have also been shown to secrete SPI-1 T3SS effector proteins, SptP 
and SopE, under certain conditions [16]. 
 
The major components of the flagellum that are exposed on the surface consist of 
the proteins FliD (cap), FliC (filament – about 5 to 10 µm in length) and FlgE (hook – 
about 55 nm in length). The basal structure of the flagellum consists of an outer 
membrane anchored L ring (FlgH), a periplasmic rod, a periplasmic P ring (FlgI), an 
inner membrane MS ring (FliF), Mot proteins that constitute the stator element of the 
motor (Mot A and MotB), C ring (FliM and FliN) and a type 3 flagellar protein export 
apparatus (FlhA, FlhB, FliO, FliP, FliQ, FliR) [17]. The motility of the bacterial 
flagellum is powered by the proton motive force [16], while the assembly of the flagellar 
apparatus is powered by an ATPase known as FliI. The components of the basal structure 
of the flagellum share sequence homology to inner membrane components of T3SS, 
while components of the surface structure share little or no homology to T3SS 
components [17]. 
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Salmonella flagella have been shown to be important in adherence to and invasion 
of epithelial cells in vitro. Using mouse models of infection, it has been shown that 
flagellar mutants are not impaired in virulence, while in the bovine model of infection, 
the aforementioned mutants were found to cause less inflammation [18]. Hence, this 
suggests that flagella are not required, but are important for virulence in the mouse and 
bovine models of infection. However, recently it has been suggested that flagellin (major 
monomeric subunit of the filament) is a powerful inducer of host innate immunity via the 
toll-like receptor 5 (TLR5) [19]. 
 
1.1.3.2 Fimbriae 
Salmonella species contain hair-like structures present on their surfaces which are 
composed of polymeric protein subunits known as fimbriae. These structures play an 
important role in adhesion of the bacterium to the intestinal epithelium and hence form 
important virulence factors [20]. To date, 13 fimbrial loci have been identified [6], four 
of which are well defined in S. Enteritidis. These operons correspond to Type I fimbriae, 
SEF 14, thin aggregative fimbriae and plasmid encoded fimbriae [21]. The genes 
corresponding to type I fimbriae are located at centisome 15 and are encoded by the 
fimAICDHF operon. FimA forms the major structural monomer and these fimbriae are 
about 7-8 nm in diameter and up to 100 nm long. They are peritrichously distributed and 
bind α-D-mannose receptors on eukaryotic cells. SEF14 fimbriae are encoded by the sef 
operon and are less than 3 nm in diameter. SefA forms the major structural component 
and plays an important role in serological tests used for the detection of S. Enteritidis. 
Thin aggregative fimbriae (also knows as SEF 17 or curli) are located between centisome 
40 and 43.3 of the S. Enteritidis chromosome and are encoded by the agfBAC operon. 
The fimbriae are approximately 3-4 nm wide and AgfA forms the major structural unit. A 
fourth type of fimbriae is the plasmid-encoded fimbriae (PEF) whose genes are encoded 
by the pefBACD operon found on a Salmonella virulence plasmid (described below). PEF 
are thought to play an important role in attachment to intestinal epithelial cells in vivo. 
However, the tissue specificity of type I fimbriae, SEF 14 and SEF 17 has not been 
determined [20, 21]. 
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1.1.3.3 Plasmids 
S. Enteritidis strains carry a 59 kb virulence plasmid which is also present in other 
serovars (although the sizes may differ). The main virulence associated genes include 
spvRABCD (Salmonella plasmid virulence) genes, rck (resistance to complement killing), 
pef (plasmid-encoded fimbriae), srgA (SdiA-regulated gene, putative disulphide bond 
oxireductase) and mig-5 (macrophage-inducible gene encoding for putative carbonic 
anhydrase). The spv genes play an important role in macrophage survival and hence are 
important in causing systemic disease. The rck gene products increase the resistance of S. 
Enteritidis to complement mediated killing while the pef genes encode for a class of 
fimbriae described above. The roles of the srgA and mig-5 genes in virulence are not very 
well known [22]. Certain Salmonella species also carry other plasmids which confer 
antibiotic resistance [22] and the presence of such plasmids makes these strains difficult 
to treat in human infections. 
 
1.1.3.4 Type 3 Secretion Systems and Pathogenicity Islands 
In order to inject virulence factors directly into host cells, S. Enteritidis uses a 
secretion pathway that makes use of a complex syringe-like system known as the Type 3 
Secretion System (T3SS), which is also used by other gram negative pathogens. The 
T3SS is composed of more than 20 proteins that form a structure which spans the inner 
membrane, periplasmic space including peptidoglycan layer, outer membrane, and 
extracellular space. Bacterial virulence factors (known as effector proteins) are secreted 
and translocated into eukaryotic cells via a single step in a contact dependent manner, 
which results in the manipulation of host cellular architecture [23]. 
 
S. Enteritidis uses two T3SSs during the process of infection. These molecular 
syringes are encoded by regions of the chromosome known as Salmonella Pathogenicity 
Islands (SPI) which are thought to have been acquired during evolution via horizontal 
gene transfer. One of the T3SSs is encoded on Salmonella Pathogenicity Island 1 (SPI-1), 
while the other T3SS is located on SPI-2. The SPI-1 T3SS plays a very important role in 
invasion and inflammation during the process of infection. On the other hand, the SPI-2 
T3SS is crucial for intracellular survival and systemic spread of the bacterium [24-26]. 
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To date, twelve SPI’s have been discovered of which SPI-1 to SPI-5 are well 
characterized [27]. SPI-3, SPI-4 and SPI-5 are mainly involved in growth and survival of 
the bacteria in the host species. The SPI’s are characterized by a lower GC content 
(between 37 and 47 %) relative to the rest of the bacterial chromosome (approximately 52 
%), are flanked by direct repeats or insertion sequences (IS) and are generally conserved 
between the different Salmonella serovars [26]. 
 
1.2 Salmonella Pathogenicity Island-1 Type 3 Secretion System 
The SPI-1 T3SS is located at centisome 63 of the Salmonella chromosome and is 
about 40 kb in size (Figure 1.1) [25]. This T3SS is important for invasion of intestinal 
epithelial cells. During the process of infection, S. Enteritidis injects several effector 
proteins into the host cell which results in actin polymerization and membrane ruffling. 
This ultimately leads to uptake of the bacterium. Hence S. Enteritidis is able to breach the 
intestinal surface to gain access to underlying tissue and spread systemically [24, 26, 28]. 
 
1.2.1 Structure 
The SPI-1 T3SS apparatus (Figure 1.2) belongs to an injectisome family which 
includes T3SS structures from Shigella flexneri, Bordetella pseudomallei and Yersinia 
enterocolitica [17]. The surface structure of this apparatus consists of a needle like 
structure and a translocon (involved in pore formation). The SPI-1 needle is formed by 
PrgI, while the translocon consists of SipB, SipC, SipD. The basal structure of this 
apparatus consists of outer membrane and inner membrane proteins that are connected by 
a periplasmic protein. InvG is the outer membrane protein and forms a pair of rings [29]. 
This protein is a member of the secretin family of transporters which are also found in 
other secretion systems [17, 29, 30]. The InvG secretin is connected by PrgJ, a 
periplasmic protein, to the inner membrane structure that mainly consists of PrgH and 
PrgK [31]. InvA, SpaP, SpaQ, SpaR and SpaS form part of the export machinery that is 
connected to PrgH and PrgK [32]. The SPI-1 apparatus also contains a motor-like energy 
source known as the “ATPase” (InvC) that provides the energy required for the secretion 
of proteins through this channel [33]. 
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Effector genes
Regulatory genes
Unknown function
Structural genes
Chaperone genes
Translocon genes
 
Figure 1.1: Schematic representation of Salmonella Pathogenicity Island-1 genes. 
Arrows below the gene names represent transcripts. The sitABCD operon downstream of 
avrA is not shown since it does not play a part in invasion. Diagram was adapted and 
modified from [34]. 
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Figure 1.2. Structure of the S. Enteritidis SPI-1 Type 3 Secretion System. Diagram 
was adapted and modified from [17]. 
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1.2.2 Assembly 
The first step in the assembly process is the export of the inner membrane proteins 
PrgH and PrgK, and the outer membrane secretin InvG (which requires the help of a 
secretin specific protein InvH), by the general secretory (sec) pathway. This step is 
thought to occur in a sec-dependent fashion since all the aforementioned proteins contain 
N-terminal sec-dependent signal sequences [29, 35]. Moreover, proteins exported through 
this pathway are transported into the periplasm by two heterotrimeric complexes and an 
accessory protein found in the inner membrane (SecYEG, SecDFYajC and SecA, 
respectively) [36]. Once the assembly of PrgH, PrgK and InvG is completed, the export 
apparatus (InvA, SpaP, SpaQ, SpaR and SpaS) and the ATPase (InvC and SpaL), which 
conists of inner membrane components is formed. This completes the formation of the 
basal structure and is followed by the secretion of PrgI (needle) and PrgJ (inner rod) 
through the newly formed export apparatus in a type 3 dependent manner [29]. As the 
needle reaches a certain length (approximately 80 nm) another protein, InvJ, stops the 
export of PrgI [29, 37]. The SipD protein is secreted through this system, forms the tip of 
the PrgI needle and plays an important role in mediating Salmonella species attachment 
to host cells in order to secrete effector proteins. SipD is present at the tip of the needle 
complex prior to contact with host cells, while the other members of the translocase 
(SipB and SipC) are exposed after contact with host cells [38]. 
 
1.2.3 Secretion 
Salmonella species secrete many virulence factors (known as effector proteins) 
through the SPI-1 T3SS that are translocated into host cells. Contact with host cells [39] 
and the presence of cholesterol (host cell membrane) [40] are the main triggers of effector 
protein secretion. This is based on evidence from studies involving Yersinia 
pseudotuberculosis and Shigella flexneri, respectively. In addition, it has recently been 
proposed that the needle acts as a sensor and causes a change in the structure of the 
needle once in contact with host cells, leading to the secretion of effector proteins [41]. 
To date, at least 15 effectors (table 1.1) have been identified that are secreted using the 
SPI-1 T3SS. 
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Table 1.1: List of effector proteins secreted by the S. Enteritidis SPI-1 T3SS. Table was 
adapted and modified from [28]. 
Effector 
protein 
Gene location Function Reference 
AvrA SPI-1 Inhibits inflammation and apoptosis, 
stabilizes epithelial cell tight junctions. 
[42-44] 
SipA SPI-1 Promotes actin polymerization by binding 
to actin filaments, induces infiltration of 
PMN across the intestinal epithelial layer, 
maintains perinuclear position of SCV, 
stimulates intracellular replication. 
[45-49] 
SipB SPI-1 Forms part of translocon, binds to 
cholesterol and is involved in triggering 
secretion of effector proteins, contributes 
to inflammation and macrophage cell 
death. 
[50-53] 
SipC SPI-1 Forms part of translocon, enhances actin 
polymerization 
[54] 
SipD SPI-1 Forms part of translocon structure and the 
tip of the secretion system, is involved in 
mediating attachment to epithelial cells. 
[28, 38] 
SopA outside SPI-1 Induces migration of PMN’s across the 
intestinal epithelial layer, allows 
Salmonella to escape from the SCV. 
[55, 56] 
SopB SPI-5 Promotes actin polymerization, enhances 
membrane fission, induces expression of 
pro-inflammatory cytokines like IL-8, 
plays a role in SCV maturation. 
[28, 57-62] 
SopD outside SPI-1 Enhances membrane fission [59] 
SopE Bacteriophage Promotes actin polymerization through 
GEF activity, induces inflammation, 
enhances SCV maturation. 
[28, 60, 61, 
63] 
SopE2 Bacteriophage Promotes actin polymerization through 
GEF activity, induces inflammation. 
[60, 61, 63] 
SptP SPI-1 Allows cell to regain its original 
architecture following invasion, down 
regulates inflammatory response. 
[64-67] 
SlrP Outside SPI-1 Causes cell death in vitro. [68] 
SspH1 Bacteriophage 
Gifsy-3 
Inhibits NF-κB expression resulting in 
reduced inflammation. 
[69, 70] 
SteA outside SPI-1 Localizes to the Golgi network in infected 
cells. 
[71] 
SteB outside SPI-1 Unknown. [71] 
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 After the secretion of effector proteins into host cells by Salmonella, the host 
cellular architecture is modulated; leading to the formation of membrane ruffles and 
lamellipodial extensions, which triggers bacterial internalization. Salmonella species 
employ the concerted action of 7 effector proteins to directly (SipA and SipC) or 
indirectly (SipB, SopB, SopD, SopE and SopE2) modulate the dynamics of actin 
filaments [28], which are the most dominant structural components in the lamellipodium 
[72].  
 
The assembly of actin filaments is not a favourable process due to the instability 
of actin dimers and trimers [72]. Therefore, SipA promotes actin polymerization by 
binding to actin filaments and reducing the critical concentration for actin assembly as 
well as stabilizing the filaments [73]. In addition, SipA also enhances the activity of T-
plastin (a host cell actin bundling protein) and prevents the binding of ADF/cofilin (actin 
depolymerising proteins) to actin filaments [45, 46]. SipC on the other hand, forms part 
of the SPI-1 translocon and enhances the formation of actin trimers and bundles actin 
filaments [54]. Another SPI-1 effector protein, SipB, forms part of the SPI-1 apparatus 
translocon and has not been implicated with actin polymerization. However, SipB binds 
to cholesterol in the plasma membrane and it is thought that this may also represent one 
of the steps in triggering the secretion of SPI-1 effector proteins [53]. 
 
Salmonella also causes the polymerization of actin filaments indirectly through 
other pathways. This involves the activation of Cdc42 and Rac-1, which are members of 
the Rho subfamily of actin-organizing small guanine binding proteins. These proteins are 
active when they are bound to guanosine triphosphate (GTP) and inactive when 
guanosine diphosphate (GDP) is bound to them. The activity of Cdc42 and Rac-1 are 
controlled by two regulatory proteins: guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs). GEFs catalyze GTP loading to Cdc42 and Rac-1, 
while the latter (GAPs) enhance GTP hydrolysis to GDP [65, 74]. The SPI-1 effector 
protein SopE acts as a GEF through activation of Cdc42 and Rac1 by catalyzing the 
exchange of GDP with GTP, while SopE2 performs a similar function mainly in 
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association with Cdc42 [63]. Salmonella also activates Cdc42 and Rac-1 indirectly 
through the activity of SopB (phosphatidyl inositol phosphatase activity). SopB 
hydrolyzes many phosphatidyl inositol phosphates and inositol phosphates, generating 
secondary messengers (such as phosphatidyl inositol-4,5-diphosphate), which in turn also 
activate Cdc42 and Rac-1 [57, 58]. Hence, Cdc42 and Rac-1, in their active forms, 
activate members of the Wiskott-Aldrich Syndrome protein (WASP) family. Proteins of 
the WASP family recruit and activate the actin-related protein-2/3 (Arp2/3) complex, 
which plays a very important role in actin nucleation, branching and cross-linking actin 
filaments [61, 72, 75]. Another SPI-1 effector protein, SopD, enhances membrane fission 
and macropinosome formation, along with SopB, at the site of bacterial invasion. 
However, the exact mechanisms by which SopD performs its role are not known [59]. 
 
Following bacterial invasion, Salmonella employs SptP (SPI-1 effector protein) 
which has GAP activity. SptP hydrolyzes GTP to GDP on Cdc42 and Rac1, thus 
deactivating these proteins. Hence, this counteracts the effects of SopB, SopE and SopE2 
allowing the host cell to regain its original architecture [64, 65]. 
 
The secretion of effector proteins by the SPI-1 T3SS also results in the 
modulation of host pathways, leading to inflammation. SopB (as well as SopE and 
SopE2) mediated activation of Cdc42 results in the stimulation of different mitogen 
activated protein kinase (MAPK) cascades (Erk, Jnk and p38 pathways) that activate 
transcription factors: activator protein-1 (AP-1) and nuclear factor kappa B (NF-κB). This 
induces the expression of pro-inflammatory cytokines, like IL-8, causing an influx of 
polymorphonuclear leukocytes (PMN), and eventually causing diarrhoea [60, 61]. 
Similarly, the SPI-1 effector protein SipA, induces signalling pathways that activate 
protein kinase Cα, resulting in the secretion of PMN chemoattractant hepoxillin A3. This 
enhances the infiltration of PMN across the intestinal epithelial layer which contributes to 
intestinal inflammation and diarrhoea [47, 48]. The influx of neutrophils in the intestine 
is accompanied with fluid secretion by intestinal epithelial cells, which is regulated by 
chloride secretion. Increased levels of intracellular inositol phosphate (Ins[1,4,5,6]P4), as 
a result of SopB activity, affect different cellular pathways leading to an influx of 
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chloride ions. Hence, this process also contributes to the diarroheal response in the host 
[47]. Another SPI-1 effector protein, SipB, also contributes to the inflammatory response 
by inducing rapid macrophage cell death. This occurs when SipB binds to and activates a 
cysteine-dependent aspartate-specific protease (caspase) known as caspase-1 in 
macrophages [50]. Activated caspase-1 causes the activation and release of pro-
inflammatory cytokines IL-1β and IL-18, which stimulate the recruitment of immune 
cells and enhance the inflammatory response. Further, activated caspase-1, through other 
downstream processes, causes the formation of membrane pores leading to the release of 
cellular contents and cell lysis [51, 52]. The recruitment of PMNs across the intestinal 
epithelium is also promoted by the SPI-1 effector protein SopA, through its E3 ubiquitin 
ligase activity. Ubiquitination is the process of attaching ubiquitin (regulatory protein) to 
proteins, so that the proteins are either labeled for degradation or directed to different 
cellular compartments. It controls a variety of cellular processes and involves a cascade 
of enzymes including E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating 
enzyme) and E3 (ubiquitin protein ligase). SopA mimics host E3 enzymes by binding 
host E2 enzymes and catalyzing the transfer of ubiquitin to itself. Thereafter, 
ubiquitinated SopA induces migration of PMNs across the intestinal epithelial layer [55, 
56, 76]. 
 
The aforementioned inflammatory responses are suppressed by the SPI-1 effector 
proteins AvrA, SptP and SspH1. AvrA is a cysteine protease that possesses 
deubiquitinase and acetyltransferase activity. This effector removes ubiquitin 
(deubiquitinates) from IκBα and β–catenin (inhibitors of NF-κB signalling), preventing 
them from proteasomal degradation. Hence, IκBα and β–catenin are able to suppress NF-
κB signalling, leading to reduced inflammation and apoptosis [42]. In addition, AvrA 
also acetylates certain residues of upstream activators of MAPKs (MAPK Kinase 
MKK4/7) preventing their subsequent phosphorylation. This leads to the inhibition of 
MAPK pathways resulting in reduced inflammation [43]. Moreover, AvrA has also been 
associated with stabilizing epithelial cell tight junction structure, which is disrupted 
during Salmonella invasion [44]. Similarly, the SPI-1 effector SptP employs its tyrosine 
phosphatase activity to dampen inflammatory responses. Tyrosine kinases play an 
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important role in the activation of MAPK pathways during Salmonella infection, which 
leads to the secretion of pro-inflammatory cytokines. SptP dephosphorylates proteins 
involved in the extracellular-regulated kinase (ERK) MAPK pathway, resulting in an 
inhibition of the pathways. Hence, this process lowers the inflammatory response [66, 
67]. Likewise, SspH1, another SPI-1 effector protein, reverses the host inflammatory 
reaction to Salmonella infection through its E3 ubiquitin ligase activity by ubiquitinating 
protein kinase N1 (PKN1). Ubiquitinated PKN1 inhibits NF-κB dependent gene 
expression [69, 70]. 
 
SPI-1 effector proteins also play a role in processes following invasion (where 
SPI-2 effector proteins are the major players) including maturation and positioning of the 
Salmonella containing vacuole (SCV) and intracellular replication [6, 28]. SopB and 
SopE play important roles in maturation of the SCV, by recruiting cellular markers 
associated with early endosomes such as Rab5 (member of the Rab GTPase family). This 
in turn leads to the recruitment of other proteins (Vps34 and endosomal antigen-1) which 
results in the accumulation of phosphatidyl inositol 3 phosphate at the SCV membrane 
(important for SCV membrane maturation). SopB also prevents the SCV from entering 
the endosomal maturation pathway [28, 62].  As well, SopB mediated activation of a host 
kinase protein (Akt) prevents SCV phagosome-lysosomal fusion, thus allowing 
Salmonella to persist and replicate in the SCV [77]. The positioning of the SCV in close 
proximity to the nucleus (perinuclear position) is mediated in part by the SPI-1 effector, 
SipA, along with other SPI-2 effector proteins. SipA also plays a role in stimulating the 
replication of intracellular Salmonella [28, 49]. Another mechanism by which SPI-1 
effector proteins are involved in late stages of infection deals with Salmonella escaping 
from the SCV. SopA has been implicated in allowing Salmonella to escape from the SCV 
through interaction with another host E3 ligase known as the RING finger protein with 
membrane anchor (HsRMA-1) [55]. 
 
In addition to the aforementioned SPI-1 effector proteins, recently other effector 
proteins have been discovered that are also secreted using this system. This includes, 
SlrP, SteA and SteB. However, these proteins are also secreted by the SPI-2 T3SS. SlrP 
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ubiquitinates mammalian thioredoxin (regulatory protein) which ultimately causes cell 
death in vitro [68]. Despite being secreted by both SPI-1 and SPI-2 systems, the 
expression of SlrP is induced by a SPI-1 regulator [78]. SteA and SteB are secreted by 
both the SPI-1 and SPI-2 T3SS. SteA localizes to the Golgi network in infected cells and 
is required for colonization of mouse spleens, while SteB does not appear to play a role in 
the colonization of mice. The regulation of SteA and SteB is not known [71].  
 
In summary, SPI-1 effector proteins are involved in different functions including 
invasion, modulation of the inflammatory response and SCV maturation and positioning 
(Figure 1.3). 
 
1.2.4 Regulation 
The SPI-1 locus regulation is complex and involves local regulators, global 
regulators and environmental factors. The HilA protein (encoded on SPI-1) is one of the 
main local regulators of SPI-1 gene expression. This protein binds directly to promoters 
on the inv-spa and prg-org operons on SPI-1, which results in the activation of 
transcription. Read-through from the inv-spa operon also leads to the activation of InvF, a 
positive transcriptional regulator, and the sic-sip operon. InvF, along with SicA 
(chaperone), induces the expression of effector proteins located on SPI-1 (sic-sip operon) 
as well as non-SPI-1 effectors. Transcription of hilA is controlled by HilC, HilD and 
RtsA. Once HilD is expressed, it activates the transcription of hilC and rtsA. HilC and 
RtsA further enhance the expression of each other and themselves. Along with HilD, 
HilC and RtsA activate the transcription of hilA, which ultimately leads to the expression 
of SPI-1 genes (summarized in Figure 1.4) [34]. 
 
Many global regulators affect the expression of SPI-1 genes through the 
transcriptional activator HilD. One such system is the EnvZ/OmpR two component 
regulatory system. This system controls the expression of two major outer membrane 
proteins, OmpC and OmpF, in response to different stimuli including osmolarity. OmpC 
and OmpF form aqueous channels allowing passive diffusion of small molecules across 
the outer membrane. EnvZ acts as a sensor, monitoring conditions in the external 
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Figure 1.3. Summary of the main functions of S. Enteritidis SPI-1 T3SS effector 
proteins. 
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Figure 1.4. Regulation of the S. Enteritidis SPI-1 T3SS by local and global 
regulators. Blue arrows represent activation of gene expression. Red lines with blunt 
ends represent repression. Lines with dashes indicate that the exact mechanism of 
regulation is not known. Global regulators are in green while local regulators are in black. 
Diagram was adapted and modified from [34]. 
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environment and transfers this information to OmpR through phosphorylation [79]. Once 
phosphorylated, OmpR induces the expression of hilD (along with the regulation of 
several other bacterial genes) which ultimately leads to the expression of SPI-1 genes 
[80]. A second global regulator of SPI-1 genes is the BarA/SirA two component 
regulatory system which regulates various genes involved in metabolism, motility, 
biofilm formation and invasion [34]. BarA is a sensor kinase which phosphorylates SirA 
in response to certain environmental signals (unknown so far). Phosphorylated SirA 
activates expression of two small RNA molecules csrB and csrC, which in turn prevent 
CsrA action (repressor of hilD). Hence, HilD expression is increased and this leads to 
increased SPI-1 gene expression [34, 81]. The ferric uptake regulator (Fur) is one of the 
most important iron dependent regulators in Salmonella and is another global regulator of 
SPI-1 gene expression. In response to high iron levels (as in the intestinal lumen), Fur (a 
repressor) binds to Fe2+ and represses the expression of several genes involved in the 
uptake of iron and other metals. In addition, Fur has shown to affect hilA activity (SPI-1 
gene expression) by regulating HilD at the post-transcriptional level by either repressing 
a negative regulator of HilD or by controlling the level of HilD required to activate the 
hilD promoter and thus the expression of SPI-1 genes [82]. The PhoP/PhoQ two-
component system is yet another global regulator of SPI-1 gene expression. PhoQ 
(sensor) activates PhoP in response to low levels of Mg2+ and Ca2+ (as in the intracellular 
and phagosomal environment) [25, 83]. This results in the activation of hilE expression, 
which represses HilD leading to the repression of SPI-1 gene expression [34]. This 
regulation is an important mechanism of switching off or lowering the expression of the 
SPI-1 T3SS genes, since they are not major players in intracellular survival and 
replication (summarized in Figure 1.4). 
 
The expression of SPI-1 genes is also affected by several environmental signals. 
These environmental signals include pH, osmolarity, and the levels of oxygen and 
magnesium. Since the main site of invasion by Salmonella is the small intestine, the 
environmental conditions associated with it lead to increased expression of SPI-1 
virulence genes. The pH level of the small intestine is near neutral and has been shown to 
increase expression of genes associated with the SPI-1 locus. Similarly, the osmolarity of 
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the small intestine is high which increases expression of SPI-1 genes, possibly through 
the OmpR/EnvZ two component system. The intestinal lumen is anaerobic, while the 
brush border is microaerophilic. Low oxygen conditions have been shown to elevate the 
expression of SPI-1 genes. Finally, high levels of magnesium in the extracellular 
environment of the small intestine and elsewhere in the host result in repression of the 
PhoP/PhoQ system which normally represses SPI-1 gene expression. Taken together, this 
demonstrates that SPI-1 regulation is fairly complex and involves several parameters that 
include local, global and environmental regulators [84, 85]. 
 
1.2.5 Role in Virulence 
The role of the SPI-1 T3SS has been extensively studied in the bovine and murine 
(streptomycin-treated mice) models of infection [47]. These studies have been mainly 
performed with Salmonella enterica serovar Typhimurium (S. Typhimurium) which 
causes a similar non-typhoidal disease in humans and animal models. Oral infection of 
streptomycin treated mice and calves results in a massive neutrophil influx in the gastro-
intestinal tract causing inflammation, which is analogous to the clinical and histological 
manifestations of the disease in humans. As well, in mice, the infection also spreads to 
internal organs causing systemic disease [11]. SPI-1 mutants have been shown to cause 
reduced inflammation and fluid influx in the aforementioned animal models, 
demonstrating that SPI-1 is critical for the intestinal form of the disease [47]. Moreover, 
recently it has been demonstrated that SPI-1 effector proteins are also synthesized during 
later stages of infection in mice, suggesting that SPI-1 may play a role in systemic disease 
[86]. In chickens, the function of SPI-1 is not as well characterized and has mostly been 
observed using S. Typhimurium. Studies have revealed that SPI-1 mutants affect the 
colonization of chicken ceca [87, 88], while one report suggests that this effect is age 
dependent [89]. Further, it has been shown that the absence of SPI-1 can affect levels of 
Salmonella in internal organs [89, 90]. The major findings from these studies are 
discussed in sections 3.1 and 3.4. 
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1.3 Salmonella Pathogenicity Island-2 Type 3 Secretion System 
The SPI-2 T3SS is located between centisome 30 and 31 of the Salmonella 
chromosome and is 40 kb in size (Figure 1.5). It encodes approximately 31 genes that are 
organized in two operons. One operon encodes genes of the secretion system apparatus 
(ssa), secretion system effectors (sse) and secretion system chaperones (ssc), while the 
other operon encodes the SsrAB two-component secretion system regulator (ssr) [91]. 
The SPI-2 secretion system plays a major role in intracellular survival and replication 
[92]. 
 
1.3.1 Structure 
The surface structure of the SPI-2 apparatus (Figure 1.6) consists of a translocon, 
filament and needle. SseC and SseD form the translocon at the tip of the T3SS apparatus, 
while SseB forms a filament-like structure which connects the translocon to the needle 
protein, SsaG. The basal structure is composed of SsaC (outer membrane protein), SsaJ 
(periplasmic protein) and a complex of proteins that consist of the inner membrane and 
the export apparatus (SsaD, SsaR, SsaS, SsaT, SsaU and SsaV). The SPI-2 apparatus also 
contains an “ATPase” that provides the energy required for the secretion of effector 
proteins through this structure. The major candidates for this function are SsaN, SsaK and 
SsaQ [91]. 
 
1.3.2 Secretion 
Salmonella species secrete many effector proteins across the vacuolar membrane 
of the SCV. The secretion of these proteins is mainly triggered in response to the 
intracellular phagosomal environment encountered by Salmonella inside host cells [93]. 
However, expression of SPI-2 genes has recently been reported in the intestinal lumen of 
mice, suggesting that expression of these genes may occur prior to invasion of host cells 
[94]. To date, at least 19 effector proteins (table 1.2) have been identified that are 
secreted through the SPI-2 T3SS some of which are located on SPI-2, while others are 
located outside this pathogenicity island. These virulence factors are involved in SCV 
maturation, trafficking and positioning. In addition, the aforementioned proteins also 
modulate the inflammatory response associated with Salmonella infection [28]. 
 19
Apparatus
Translocon
Effectors
Chaperones
Master regulator
Unknown
Tetrathionate reductase system
tRNA
 
Figure 1.5. Schematic representation of the S. Enteritidis SPI-2 Type 3 Secretion 
System genes. Diagram was adapted and modified from [91]. 
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Figure 1.6. Structure of the S. Enteritidis SPI-2 Type 3 Secretion System. Diagram 
was adapted and modified from [91]. 
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Table 1.2: List of effector proteins secreted by the S. Enteritidis SPI-2 T3SS. Table was 
adapted and modified from [28]. 
Effector 
protein 
Gene location Function Reference 
GogB Bacteriophage Gifsy-1 Unknown [95] 
PipB SPI-5 Associates with the SCV and sifs 
but is not required for intracellular 
survival or virulence in mice 
[96] 
PipB2 Outside SPI-2 Enhances growth of sifs [97] 
SifA Outside SPI-2 SCV positioning, sif formation 
and re-directing traffic to SCV 
[28, 98] 
SifB Outside SPI-2 Localizes with SCV and travels 
away from  SCV along sifs 
[99] 
SopD2 Outside SPI-2 Localizes to the SCV membrane, 
involved in sif formation and is 
important for replication in 
macrophage and mice 
[100, 101] 
SpiC SPI-2 Prevents fusion of late endosomes 
with SCV, required for 
translocation of SPI-2 proteins, 
important for survival in 
macrophages and virulence in 
mice 
[102, 103] 
SseF SPI-2 Plays a role in Sif formation, re-
directs traffic to SCV and 
maintains perinuclear position 
[28, 98, 104] 
SseG SPI-2 Similar to SseF  
SseI Bacteriophage Gifsy-1 Involved in the formation of actin 
surrounding the SCV 
[105] 
SseJ Outside SPI-2 Maintains the integrity of the SCV 
membrane 
[61, 106] 
SseK1 Outside SPI-2 Localize to the host cytoplasm 
and has not been associated with 
virulence in mice 
[107] 
SseK2 Outside SPI-2 Similar to SseK1 [107] 
SseK3 Bacteriophage Unknown [107] 
SseL Outside SPI-2 Suppresses NF-κB activity and 
causes cell death  
[108, 109] 
SspH2 Bacteriophage Involved in the formation of actin 
surrounding the SCV 
[105] 
SteC Outside SPI-2 Involved in the formation of actin 
surrounding the SCV 
[110] 
SpvB spv plasmid Inhibits SCV associated actin 
polymerization 
[105] 
SpvC spv plasmid Down regulates the inflammatory 
response 
[111, 112] 
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The SPI-2 effector proteins SpiC, SseJ, SteC, SseI and SspH2 are involved in 
SCV maturation and trafficking. SpiC prevents the fusion of late endosomes with the 
SCV, which assists in delaying fusion of the SCV and lysosomes, allowing Salmonella to 
persist and replicate [103, 113]. The SPI-2 effector, SseJ, has deacylase activity and is 
involved in maintaining the integrity of the SCV membrane [61, 106]. SteC, SseI and 
SspH2 all play a role in the formation of a filamentous-actin (F-actin) meshwork 
surrounding the SCV [105, 110]. 
 
As the SCV continues to mature, it moves towards the nucleus (perinuclear 
position). The SPI-2 effector, SifA, is involved in maintaining the position of the SCV. 
The aforementioned protein, as well as SseF and SseG, are important for the formation of 
Salmonella induced filaments (sifs) [28], which are tube-like membranes that contain 
aggregates of lysosomal glycoproteins [98]. The growth of the Sifs are enhanced by the 
SPI-2 effector protein, PipB2 [97]. In addition, SifA, along with SseF and SseG, re-
directs transport of exocytic vesicles to the SCV, a process which allows Salmonella to 
gain access to nutrients for bacterial replication and for the growing SCV [98]. 
 
Effector proteins secreted by the SPI-2 secretion system also play a role in down 
regulating the inflammatory response associated with Salmonella infections and have 
been linked with causing cell death. The SPI-2 effector, SseL, suppresses NF-κB 
activation by inhibiting IκBα ubiquitination, as a result of its deubiquitinase activity. This 
prevents IκBα degradation and consequently, IκBα suppresses NF-κB activity leading to 
lower levels of inflammation [108]. This effector protein (SseL) has also been shown to 
cause cell death. Salmonella Typhimurium mutant strains (sseL-) have been shown to 
cause significantly less cytotoxicity in macrophages and have been shown to be 
attenuated for virulence in mice, relative to the wild type strain [109]. 
  
In summary, the main functions of SPI-2 effector proteins are SCV maturation 
and positioning, re-directing SCV traffic and modulating the inflammatory response 
(Figure 1.7). 
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Figure 1.7. Summary of the main functions of S. Enteritidis SPI-2 effector proteins. 
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1.3.3 Regulation 
The regulation of SPI-2 T3SS genes is complex and involves different systems. 
The SsrA/SsrB two component system is the master regulator of SPI-2 expression that is 
encoded on SPI-2. SsrA is a sensor kinase that, in response to environmental stimuli, 
phosphorylates the response regulator SsrB, which activates the expression of SPI-2 
T3SS genes encoded on SPI-2 and outside the pathogenicity island [114-116].  
 
The SsrA/SsrB two-component system is further regulated by the OmpR/EnvZ 
(described earlier in section 1.2.4) and PhoP/PhoQ two-component systems [116]. When 
Salmonella is grown under SPI-2 inducing conditions, EnvZ (sensor kinase) 
phosphorylates OmpR (response regulator) which in turn binds to the promoters of the 
SsrA/SsrB two component system, leading to activation of SPI-2 gene expression [117, 
118]. Similarly, in conditions of low magnesium and low pH (conditions resembling the 
SCV), PhoQ (inner membrane sensor kinase) phosphorylates PhoP (cytoplasmic response 
regulator) which then activates the expression of the SsrA/SsrB system [119, 120]. 
 
The transcription of SPI-2 T3SS genes is also controlled by a family of proteins 
known as nucleoid associated proteins (NAPs) [116]. These proteins bind to bacterial 
chromosomal DNA and thus play an important role in the organization and compaction 
of bacterial chromatin. Hence, the NAPs are able to repress or activate the transcription 
of certain genes depending on different cellular requirements [121]. H-NS, YgdT and 
Hha are three NAPs that repress the transcription of SPI-2 genes [116]. On the other 
hand, integration host factor (IHF) and inversion stimulation (Fis) are two NAPs that are 
required for complete expression of SPI-2 genes. IHF is important for DNA bending and 
compaction, while Fis directly activates the transcription of SPI-2 genes by binding to the 
promoters of spiR and ssaG genes [122-124]. 
 
1.3.4 Role in virulence 
The role of the SPI-2 T3SS has been studied extensively in mice, since they 
develop a systemic disease (explained in section 1.2.5). Using S. Typhimurium SPI-2 
mutants it has been demonstrated that these strains are highly attenuated in mice relative 
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to the wild type strain. This corresponds to lower levels of the mutant strains in the 
internal organs of infected mice, suggesting that these strains were impaired in their 
ability to survive and replicate in host organs [125, 126]. Moreover, recent experiments 
have illustrated that the SPI-2 T3SS contributes to the intestinal form of disease in the 
murine and bovine models of infection [127, 128]. This finding implies that the role of 
this secretion system may not be exclusive to systemic disease during non-host adapted 
Salmonella pathogenesis. The role of the SPI-2 secretion system has also been evaluated 
in chickens, but this has not been extensively studied relative to the studies in the mouse 
and bovine models. Three studies performed in chickens indicated that lower levels of 
SPI-2 mutants (non-host adapted Salmonella species) were recovered from the internal 
organs of chickens relative to the wild type strain, implying that the SPI-2 T3SS is an 
important virulence factor in chickens [89, 129, 130]. 
 
1.4 Salmonella Enteritidis in Poultry 
 
1.4.1 Sources of infection 
Poultry flocks become infected with S. Enteritidis from a variety of sources. 
Incubation of Salmonella contaminated eggs with Salmonella free eggs at the hatchery 
results in high numbers of Salmonella positive chicks, suggesting that the hatchery is an 
important source of Salmonella infection. Similarly, poultry can also become infected by 
the transmission of this pathogen via aerosols from infected birds. The litter in poultry 
barns is another source of contamination since chicks contaminate the litter with fecal 
content containing Salmonella. Hence, other chickens easily become infected with 
Salmonella when they pick on fecal droppings from their littermates. Poultry flocks can 
also become contaminated with Salmonella after consumption of water. This happens 
when the chicks are young and their drinkers are located close to the ground. The chicks 
often defecate in the drinkers resulting in the contamination of the water and spread of 
the organism to the rest of the flock. Rodents also form a major source of Salmonella 
infection in poultry houses. They often shed high levels of Salmonella species in their 
feces [131]. In addition to the aforementioned sources, the presence of insects on poultry 
houses can significantly contribute to the dissemination of Salmonella species in poultry 
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flocks. These include cockroaches, lesser mealworms, flies and darkling beetles [132-
135].  
 
1.4.2 Pathogenesis 
Chickens that come in contact with S. Enteritidis mostly develop gastrointestinal 
colonization, which results in shedding of the bacterium through the fecal contents. The 
bacteria may also cause a systemic infection leading to the spread of the organism to the 
internal organs (liver and spleen) [1, 131]. This occurs when S. Enteritidis breaches the 
intestinal epithelial surface via enterocytes, M cells or dendritic cells [136]. Once the 
bacteria reach the lamina propria they are internalized by macrophages and rapidly 
disseminate to the liver, spleen and other parts of the body through the thoracic duct [1, 
6]. Systemic infection may also lead to infection of chicken ovaries resulting in the 
production of contaminated eggs. Young chicks (first few days of life) are more 
susceptible to colonization by S. Enteritidis relative to older birds and younger birds are 
more likely to develop a systemic infection. On rare occasions, young chicks can develop 
clinical signs that include progressive somnolence, drooping wings, ruffled feathers, 
anorexia, and diarrohea. In addition, chickens infected with other infectious agents like 
Eimeria tenella or immunosuppressive pathogens become more susceptible to infection 
by Salmonella species. The detection of S. Enteritidis in poultry flocks is often difficult 
because S. Enteritidis colonization is mainly asymptomatic [1, 131]. 
 
1.4.3 Immune response to S. Enteritidis 
 
1.4.3.1 Innate immune response 
The innate immune system is the first line of defense encountered by S. Enteritidis 
during the process of infection. It is composed of several components including physical 
barriers (e.g. epithelial surfaces), antimicrobial chemical components, complement 
system and specialized cells (e.g. natural killer cells, macrophages, dendritic cells and 
heterophils) [137]. 
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Investigation of the dynamics of immune cell filtration in day old chicks after 
infection with S. Enteritidis has revealed that heterophils were the first group of cells that 
infiltrated the cecal lamina propria at 12 hours post infection, followed by macrophages 
and T-lymphocytes at 20 hours post infection, and B cells at 24 hours post infection [138, 
139]. This suggested that the chicken innate immune system was important in Salmonella 
infection. This notion was supported by a study in which heterophil depleted chickens 
were more susceptible to S. Enteritidis organ invasion [140, 141]. Moreover, recently it 
has been demonstrated that chicken heterophils release Cathelicidin-2 (antimicrobial 
peptide) upon contact with Salmonella which has potent bactericidal activity [142]. 
Cathelicidin-2 also has the capacity to bind to LPS in order to block LPS mediated 
proinflammatory gene expression [137]. 
 
Another important component of the chicken innate immune system are toll-like 
receptors (TLRs) which are composed of transmembrane sensor proteins that recognize 
pathogen associated molecular patterns (PAMPs) leading to the induction of innate 
immunity [143]. Chicken TLR-4 plays an important role during the host response to 
Salmonella infection. This receptor recognises Salmonella LPS leading to the activation 
of heterophils and an increase in the secretion of pro-inflammatory cytokines IL-1β, IL-6 
and IL-18 [144, 145]. In the same way, chicken TLR-5 recognizes Salmonella flagella 
leading to an upregulation of IL-1β (causing inflammation) in vitro and in chickens. 
Interestingly, aflagellar S. Typhimurium does not upregulate IL-1β but is isolated at 
higher levels from the internal organs of chickens infected with the aflagellar mutant 
strain relative to the wild type strain. This suggests that the absence of the flagella allows 
S. Typhimurium to evade recognition by the host immune system [143, 146]. 
 
Similarly, other experiments have revealed that oral inoculation of chickens with 
non-host adapted Salmonella species (S. Enteritidis or S. Typhimurium) resulted in the 
up-regulation of IL-1β, IL-18 and TGF-β4 mRNA levels (as determined by real-time 
reverse transcription (RT)-PCR) in the spleens of infected birds, while the level of IL-4 
was down-regulated [147-150]. In the ceca of infected chickens, it has been observed that 
the mRNA levels of IL-1β, IL-6, IL-8, IL-12, IL-18 and TGF-β4 have been upregulated 
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relative to non-infected control birds [149-152]. The cytokines IL-1β, IL-6 and IL-8 are 
pro-inflammatory cytokines that lead to the recruitment of immune cells leading to 
inflammation in the host tissue. On the other hand, the increase in the levels of IL-12 and 
IL-18, in response to Salmonella infection, is indicative of a cellular immune response 
[153]. 
 
1.4.3.2 Adaptive immune response 
Chickens infected orally with S. Typhimurium have been associated with higher 
levels of interferon-gamma (IFNγ) in splenocytes relative to control birds. In addition, 
levels of IFNγ gradually declined as the infection started to clear, suggesting that IFNγ (a 
strong indicator of cell mediated immunity) played an important role in clearance of S. 
Typhimurium infection [147]. As well, it has been demonstrated that intraperitoneal 
administration of IFNγ to chickens results in lower organ colonization following S. 
Typhimurium challenge [154]. Similarly, another group has shown that chickens infected 
with S. Typhimurium developed strong T cell responses (as measured by proliferation 
assays) relative to control birds and this also correlated with clearance of the infection 
[150]. In a more detailed study, the authors characterized the T cell composition of 
lymphocytes in the blood as well as in different organs following S. Typhimurium 
infection. CD8+ T cells were upregulated in the blood, ceca, bursa of fabricius and the 
spleen relative to the non-infected birds [155]. This provided further support to imply that 
cell mediated immunity was an important component in the defense against S. 
Typhimurium infections. 
 
Infection of chickens with S. Typhimurium has often been associated with 
significant serum IgM, IgG (IgY) and IgA antibody titers 5-7 days post-infection. 
However, despite having high antibody titers, this has not always resulted in lower levels 
of Salmonella or clearance of the organism [156]. To examine the role of antibodies in 
Salmonella infections, B cell depleted chickens have been used. Chickens that were 
chemically bursectomized (using cyclophosphamide or testosterone proprionate) have 
been shown to have higher levels of S. Enteritidis in cecal contents relative to healthy 
chickens, but this difference was not observed in internal organs. It was suggested that 
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this may indicate that secretory IgA plays a role in clearance of Salmonella infections 
from the chicken gut [157]. However, recently, it has been demonstrated that surgically 
bursectomized chickens had levels of Salmonella that were identical to healthy chickens 
in cecal contents as well as in internal organs. Moreover, the chickens were able to clear 
the infection at the same rate as healthy chickens [158]. This study suggests that the 
humoral response may not be critical for defense against Salmonella infections in 
chickens. Additionally, a recent report has indicated that using chemical methods to 
deplete B cells in chickens also affects other cells [156], adding further support to the 
findings in the study which used surgically bursectomized chickens [158]. Taken 
together, these studies imply that the humoral response to Salmonella infection may not 
be crucial in the clearance of infection. However, the role of antibodies has not been 
excluded in chickens since further work needs to be done to investigate the dynamics of 
the immune response to Salmonella infection [156]. 
 
1.5 Control of Salmonella Enteritidis 
 
1.5.1 Management practices 
Good flock management and sanitation practices are important since S. Enteritidis 
can be introduced into poultry houses from many different sources as discussed in section 
1.4.1. One of the most important aspects of poultry house management is to ensure that 
eggs or chicks coming into the facility are from a breeding flock that has been 
extensively tested for Salmonella species and is proven to be Salmonella free. Secondly, 
eggs that are set for hatching should be properly disinfected and hatched under strict 
conditions to minimize the chances of Salmonella contamination. In addition, between 
flocks, the poultry house should be cleaned and disinfected using an effective method 
since not all methods are effective in eliminating S. Enteritidis [159, 160]. Formaldehyde 
fumigation has been shown to highly effective and should be used to disinfect poultry 
facilities [161]. Fourthly, since rodents and insects are important vectors of Salmonella 
transmission in poultry houses (discussed in section 1.4.1), strict control of the 
aforementioned is critical given that a single mouse dropping can contain 105 S. 
Enteritidis cells [162]. Moreover, a study has shown that the levels of S. Enteritidis in 
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mice from a poultry house positive for this pathogen were four times higher than in mice 
from a facility negative for S. Enteritidis [163]. Biosecurity is also an important 
component of good management practices at poultry houses. This includes ensuring that 
all personnel entering the facility either change their footware or use the boot dip 
disinfection method. Additionally, equipment and machinery that either enters or that is 
in use at the facility should be cleaned and disinfected [160, 164]. The feed that is used 
for chickens at the poultry houses should not contain any animal proteins and should be 
Salmonella free [160]. This can be achieved by the addition of chemicals (antimicrobials) 
in the feed, using heat or irradiation [164]. Another important component of good 
management practices includes a Salmonella free water supply. This involves ensuring 
that the water supplied to the facility has been treated properly since water contaminated 
with S. Enteritidis has been associated with S. Enteritidis contamination of a laying flock 
[165]. Other factors that involve good management at facilities housing poultry flocks are 
controlling moisture levels and ensuring that there is adequate ventilation [160]. 
 
1.5.2 Bacteriophages 
Bacteriophage therapy in chickens involves the use of phages that are orally 
administered to chickens a few days after oral challenge with non-host specific 
Salmonella species (e.g. S. Enteritidis and S. Typhimurium). These phages recognize 
specific receptors on the surface of bacteria and inject their DNA into the bacterial cell. 
Using the cell’s machinery, the phage replicates and assembles virulent phages which 
then lyse the bacterial cell in order to infect other cells [166]. 
 
A recent study evaluated the efficacy of broad host range phages against S. 
Enteritidis. Chickens were treated orally with either 109 plaque forming units (pfu) or 
1011 pfu of phages two days after oral challenge with S. Enteritidis. At the higher dose, 
the levels of S. Enteritidis were significantly lower in the cecal contents (about 2 to 4 log 
units lower) relative to the control group. However, the study did not examine the effect 
of phage therapy on systemic levels of S. Enteritidis [167]. On the other hand, results 
from other studies have given variable results suggesting that phage therapy may have 
potential as a pre-harvest intervention measure and that more research needs to be 
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performed to investigate the effects of phage therapy on S. Enteritidis colonization in 
chickens [166]. 
 
1.5.3 Competitive Exclusion 
Competitive exclusion, in the context of poultry, refers to the administration of 
normal bacterial flora from the gastrointestinal tract of poultry to reduce colonization by 
enteric pathogens [168]. This inhibition effect is thought to occur by either interference 
with the attachment of the enteric pathogen to the host intestinal wall or inhibition of the 
growth of the pathogen due to a change in the intestinal environment. In the case of 
Salmonella species, competitive exclusion products from older chickens have been given 
orally to younger birds leading to reduced levels of Salmonella species in the 
gastrointestinal tract of these pathogens [160, 168]. The reduction in the levels of this 
pathogen has also been associated with lower numbers of carcass contamination [169]. 
Hence, the use of competitive exclusion products is an attractive strategy that can be used 
as one of the components to form part of a comprehensive Salmonella control program. 
However, the use of this approach also has certain limitations. First of all, many of these 
products are composed of undefined cultures. Thus, this involves introducing undefined 
live organisms into chickens and the poultry houses. Additionally, it may also lead to the 
introduction of antibiotic resistant bacteria and possibly result in the transfer of antibiotic 
resistance to other non-resistant bacterial strains. Nonetheless, attempts have been made 
to define competitive exclusion cultures and possible candidates responsible for the 
protective effect have been suggested that include Lactobacillus species, Bifidobacterium 
species, Escherichia coli, Bacillus subtilis and Streptococcus cristatus. Secondly, the 
protective effect of these cultures has been observed in younger birds which have not yet 
developed a mature intestinal microflora. Thus, the use of these products is not a reliable 
option for older birds. Thirdly, this treatment is not very effective in chickens that have 
an altered microflora due to antibiotic treatment or chickens that have been subject to 
feed or water withdrawal [160]. 
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1.5.4 Vaccination 
Vaccination of chickens for protection against non-host specific Salmonella 
serotypes has been widely used as an intervention strategy to reduce the prevalence of 
Salmonella in poultry flocks in order to protect consumers from food-borne disease 
transmission [160, 164, 170, 171]. This strategy aims to utilize the host’s immune system 
to decrease the levels of the pathogen that are associated with the animal upon infection. 
Moreover, extensive vaccination of chickens in the United Kingdom since 1997 (Figure 
1.8) has successfully reduced the incidence of human S. Enteritidis infections [10]. In the 
same way, vaccination along with other intervention strategies has drastically lowered the 
number of human S. Enteritidis infections in Belgium [172]. The Salmonella vaccines 
that have been used to date are generally classified into three categories: Live attenuated 
strains, killed Salmonella and subunit vaccines. 
 
1.5.4.1 Live attenuated vaccines 
Live attenuated strains of Salmonella are constructed mainly by the mutation or 
deletion of genes that are important for virulence, metabolism or survival. These strains 
are associated with several advantages. They can be administered orally and to young 
chicks, induce rapid protection, and activate both humoral and cell-mediated responses. 
However, the main concern with live attenuated strains is that they consist of a living 
organism which may persist for extended periods in the chickens as well as their 
environment, posing a threat to human health [170]. 
 
S. Enteritidis aroA mutants (strains impaired in the ability to synthesize aromatic 
compounds) have been tested as live vaccine candidates chickens. Oral vaccination with 
the aforementioned strain resulted in a reduction of the levels of S. Enteritidis in the 
livers, spleens, cecal contents and ovaries relative to the non-vaccinated group [173]. 
Similarly, a cya-crp S. Typhimurium double mutant (deletion in the genes encoding 
adenylate cyclase and cyclic adenosine monophosphate receptor protein) used for 
vaccinating chickens orally (108 cfu) at 1 and 14 days of age greatly reduced the levels of 
the challenge strain (106 cfu S. Typhimurium) in the ceca (approximately 6 log units) 
relative to the control group. As well, the levels of the challenge strain in the spleen were 
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Vaccination
 
Figure 1.8. Human Salmonella cases in the United Kingdom from 1981 – 2001. Diagram 
was adapted and modified from [10]. 
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not detectable in the vaccinated group. However, when the same vaccine was used for 
protection against S. Enteritidis oral challenge, the levels of the challenge strain in the 
ceca were only slightly lower relative to the control group, while the levels in the spleen 
were not detectable in the vaccinated group [174]. A temperature sensitive S. Enteritidis 
mutant (able to grow at 28°C and not at 37°C) has also been evaluated as a live 
attenuated vaccine strain in chickens. Chickens were immunized at 1 and 14 days of age 
orally or intra-peritoneally with 1010 cfu of the mutant strain and were challenged (orally) 
at 28 days of age with 108 cfu of virulent S. Enteritidis. All vaccinated groups 
demonstrated lower levels (several log units lower) of the challenge strain in the ceca and 
spleens compared to the control group [175]. 
  
The Salmonella enterica subspecies enterica serovar Gallinarum (S. Gallinarum) 
9R strain (modification in the LPS) is another live attenuated strain that has been widely 
used in chickens for protection against S. Enteritidis. This strain has been tested under 
field conditions where chickens were vaccinated subcutaneously at 6 weeks, followed by 
a booster injection at 14-16 weeks of age as per the recommendation of the commercial 
vaccine (Nobilis SG 9R). Chickens were monitored for S. Enteritidis shedding prior to 
the 1st vaccination and up to 6 weeks after the 1st vaccination. The results indicated that 
2.5 % of the flocks were positive for S. Enteritidis in the vaccinated groups relative to the 
control group (11.5 %) [176]. TAD Salmonella vac® E is a S. Enteritidis live vaccine 
constructed by chemical mutagenesis which has prolonged generation times and is less 
virulent. To evaluate the efficacy of this strain, chickens were vaccinated orally with 108 
cfu of TAD Salmonella vac® E at 1 day of age, followed by two boosters at 6 and 16 
weeks of age. The chickens were intravenously challenged at 24 weeks of age with 107 
cfu of S. Enteritidis. Vaccinated chickens had significantly lower numbers of positive 
livers (12/28) and oviducts (6/28) relative to the non-vaccinated chickens (23/30 livers 
and 15/29 oviducts). Similarly, eggs obtained from vaccinated chickens had fewer 
positive samples (9/35) compared to the control group (15/35) at 22 weeks of age [177]. 
 
In the aforementioned studies, different live attenuated Salmonella strains have 
been used for evaluating the efficacy of each strain to confer protection against 
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Salmonella challenge. However, in most of the experiments, the oral challenge was 
conducted shortly after immunization with the vaccine strain. Hence, it is possible that 
the vaccination strain may have colonization-inhibition effects that lead to reduced 
colonization and systemic spread of the challenge strain [170]. Moreover, not all the live 
attenuated strains (described above) have been tested under field conditions. In addition, 
these vaccine strains have not been very effective in inducing cross-protection against 
other non-host adapted serovars [160]. 
 
1.5.4.2 Killed vaccines 
Killed Salmonella vaccines consist of whole cell bacteria that are inactivated 
using either heat, formalin or acetone. Most of these strains are delivered subcutaneously 
and require at least two injections. A major advantage conferred by this class of vaccines 
is that they do not contain a live organism that could potentially survive in the 
environment and affect human health. However, the use of these vaccines has been 
mainly associated with strong antibody responses [160, 170]. 
 
Salenvac® is a commercially available killed vaccine licensed for use in the 
United Kingdom. It consists of an inactivated S. Enteritidis strain grown under iron 
limiting conditions (growth under iron limiting conditions is thought to stimulate the 
production of virulence factors in order to mimic the host environment). The efficacy of 
Salenvac® was evaluated in a study in which laying chickens were vaccinated 
subcutaneously at day 1 and 4 weeks of age (group 1), while the second group followed 
the same regime with a third immunization at 8 weeks of age (group 2). The chickens 
were challenged intravenously at different ages (8, 17, 23, 30 or 59 weeks) with 107 cfu 
of S. Enteritidis. Vaccinated birds had significantly lower S. Enteritidis fecal shedding, 
organ colonization and egg contamination (shells and internal contents) relative to the 
control birds [178]. It is obvious that the Salenvac® vaccine is highly effective in 
protecting laying chickens against a high dose of S. Enteritidis challenge. However, this 
study would have been more relevant if an oral challenge had been given since that 
would be closer to the real situation. 
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Layermune SE® is a killed S. Enteritidis vaccine that is commercially available. It 
is composed of multiple strains of S. Enteritidis formulated in an oil based adjuvant. This 
vaccine was tested in a study in which layers and broilers were vaccinated 
subcutaneously at five and nine weeks of age. The chickens were orally challenged at ten 
weeks of age with 108 cfu of S. Enteritidis. The vaccine reduced the levels of S. 
Enteritidis in the ceca, livers and spleens of the vaccinated group by several log units 
relative to the control group in layers but was not very effective in broiler chickens [179]. 
 
Similarly, Poulvac SE®, a commercially available killed S. Enteritidis vaccine 
(contains S. Enteritidis phage types 4, 8 and 13a), has been evaluated for protection in 
progeny derived from broiler breeders vaccinated with this strain. Broilers were 
vaccinated subcutaneously at twelve and twenty weeks of age. Progeny derived from 
these hens were orally challenged at 1 day or two weeks of age with 105 cfu or 109 cfu of 
S. Enteritidis, respectively. The results indicated that the number of birds positive for S. 
Enteritidis were much lower in the progeny derived from the vaccinated group (7/25) 
challenged at 1 day of age compared to the control group (25/25). However, the vaccine 
was not very effective in progeny challenged at two weeks of age relative to the control 
group. The vaccine did not have a major effect on the levels of S. Enteritidis (based on 
direct plating) in the livers, spleens and ceca of progeny obtained from the vaccinated 
chickens that were challenged at 1 day or at two weeks of age [180]. Another study 
evaluated the efficacy of a S. Enteritidis killed strain. In this study killed S. Enteritidis 
was formulated with microspheres and used to vaccinate chickens orally or 
intramuscularly at two weeks of age. The chickens were orally challenged at six weeks of 
age with 109 cfu of S. Enteritidis. Vaccination reduced the number of organs (ceca, liver 
and spleen) that were positive for S. Enteritidis (18-26 %) relative to the control group 
(44 %) [181].  
 
1.5.4.3 Subunit vaccines 
Subunit vaccines consist of a single protein or a mixture of proteins that are 
usually expressed on the surface of the cell and are considered to be important in 
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virulence. Such proteins are mainly delivered subcutaneously, unless they are formulated 
appropriately for oral delivery.  
A vaccine containing an extract of S. Enteritidis outer membrane proteins was 
evaluated in chickens. The chickens were immunized orally or subcutaneously at 8 weeks 
of age, followed by a booster at 11 weeks of age. At thirteen weeks of age, the chickens 
were orally challenged with 107 cfu of S. Enteritidis. The numbers of chickens positive 
for S. Enteritidis, as determined by cloacal swabbing, were mostly negative in the group 
vaccinated subcutaneously relative to the control group (100% positive). However, this 
study did not examine the levels of S. Enteritidis present in the liver, spleen or ceca [182]. 
In the same way, another group evaluated the effect of immunizing chickens with S. 
Enteritidis outer membrane proteins. The chickens were immunized subcutaneously at 
nine and eleven weeks of age. At twelve weeks of age, the chickens were orally 
challenged with 108 cfu of S. Enteritidis. Vaccinated chickens had lower levels of S. 
Enteritidis (2-3 log units) in the ceca and small intestine relative to the control group. 
However, the levels of the challenge strain were not determined in the internal organs 
[183]. 
 
S. Enteritidis type 1 fimbriae have been evaluated as potential subunit vaccine 
candidates. Chickens were vaccinated subcutaneously at 18 weeks of age with purified 
type 1 fimbriae, followed by a booster injection at 21 weeks of age. At 24 weeks of age, 
the birds were challenged intravenously with 107 cfu of S. Enteritidis. The results 
suggested that the vaccine did not have an effect on the levels of S. Enteritidis in the ceca, 
livers or spleens. However, there was a mild reduction in the number of egg shells and 
oviducts contaminated with S. Enteritidis in the vaccinated group compared to the non-
vaccinated control [184]. In another study, a peptide containing part of the FliC protein 
(forms the flagellar filament) was used to immunize chickens subcutaneously at 3 and 5 
week of age, with an oral challenge of 107 cfu of  S. Enteritidis at 7 weeks of age. The 
FliC based vaccine significantly reduced (2 log units) the levels of the challenge strain at 
3 weeks post challenge in the cecal contents based on direct plating relative to the control 
group. The vaccine did not affect the levels of the challenge strain in the livers and 
spleens of the vaccinated birds [185]. 
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Taken together, it can be concluded that vaccination of chickens with either live 
attenuated, killed or subunit vaccines has resulted in lowering the levels of S. Enteritidis 
(summarized in Table 1.3). Based on the data presented from different vaccine efficacy 
studies, it is difficult to infer that one class of vaccines confers greater protection than the 
other, although few studies have examined the efficacy of subunit vaccines. Recently, 
one study examined the efficacy of four commercially available Salmonella vaccines (3 
live attenuated strains and 1 killed strain) in the U.K. in reducing S. Enteritidis 
colonization of laying hens. Chickens vaccinated with the killed strain had significantly 
lower levels of S. Enteritidis relative to the other groups, suggesting that killed 
Salmonella strains may be more effective in controlling the prevalence of Salmonella in 
poultry [186]. Moreover, killed Salmonella strains and subunit vaccines have an 
advantage over live attenuated strains since the latter are composed of a living organism. 
With the continued prevalence of S. Enteritidis human infections, there is still a need for 
improved and well defined vaccines to control the spread of this bacterium along with 
other intervention strategies [170]. 
 
1.5.5 Consumer Education 
Since the aim of Salmonella control programs is to ultimately reduce the number 
of human Salmonella infections, it is crucial that consumers are also informed about 
strategies that can be applied in their daily lives to lower their chances of becoming 
infected with this pathogen. Consumption of undercooked poultry meat and eggs is a 
significant pathway for human exposure not only to Salmonella species, but also to other 
pathogens such as Campylobacter species. Therefore, informing consumers (through 
different educational tools) to thoroughly cook all foods that contain poultry meat or eggs 
is an important step in risk reduction. As well, labeling poultry meat and eggs or products 
containing the aforementioned will remind consumers to be cautious and follow 
procedures. Similarly, it has been determined that cross-contamination of food products 
with Salmonella species while handling poultry meat or eggs is also a major source of 
human exposure to this pathogen. Hence, consumers must be advised to use either 
separate cutting boards and utensils in the kitchen when handling poultry products or to 
properly wash and clean them before handling other food products [187]. 
 39
Table 1.3 Summary of major studies carried out to evaluate the efficacy of Salmonella 
vaccines in protection against S. Enteritidis challenge (for details please see text). 
Vaccine (type) Route of 
delivery 
Frequency of 
vaccination 
Bacterial 
challenge 
Results of 
vaccinated group 
S. Enteritidis 
∆aroA (live) 
Oral 105 or 109 
cfu 
1 day of age 108 cfu S. 
Enteritidis (oral) 
at 8 wks 
Levels of challenge 
strain were 1-2 log 
units lower in the 
liver and spleen and 
much lower in the 
ceca at 1 and 4 days 
postchallenge. 
S. Typhimurium 
∆cya-crp (live) 
Oral 108 cfu 1 and 14 days 
of age 
106 cfu 
S. Enteritidis 
(oral) at 4 wks 
Challenge strain was 
not detectable in the 
spleen and levels in 
the ceca were similar 
to the control at 2 
weeks postchallenge. 
Ts S. Enteritidis 
mutant (live) 
Oral 1010 cfu 
and/or 
intraperitoneal 
108 cfu 
1 and 14 days 
of age 
109 cfu S. 
Enteritidis (oral) 
at 4 wks 
Challenge strain was 
2-5 log units lower 
in the spleen and 5 
log units lower in the 
ceca upto 21 days 
postchallenge in 
orally vaccinated 
group. 
S. Gallinarum 9R 
Nobilis® (live) 
Subcutaneous 6 weeks and 
14-16 weeks 
Field conditions 2.5 % of the 
vaccinated flocks 
were positive for 
Salmonella relative 
to the control group 
(11.5%) as 
determined by fecal 
swabs. 
TAD Salmonella 
vac® E (live) 
Oral 108 cfu 1 day of age, 6 
weeks and 16 
weeks 
107 cfu S. 
Enteritidis (i.v.) 
at 24 weeks 
12/28 livers and 6/28 
oviducts were 
positive for 
Salmonella relative 
to the control, 23/30 
and 15/29, 
respectively, at 3 
weeks postchallenge. 
Salenvac® (killed) Subcutaneous Day 1 and 4 
weeks 
107 cfu S. 
Enteritidis (i.v.) 
at 17, 23, 30 and 
59 wks 
22.6% of cloacal 
swabs and 12.5% 
internal organs were 
positive for 
Salmonella over 21 
days postchallenge 
compared to the 
control (48.0% and 
28.0%, respectively). 
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Vaccine (type) Route of 
delivery 
Frequency of 
vaccination 
Bacterial 
challenge 
Results of 
vaccinated group 
Layermune SE® 
(killed) 
Subcutaneous 5 and 9 weeks 108 cfu S. 
Enteritidis (oral) 
Levels of challenge 
strain were 1-2 log 
units lower in liver, 
spleen and ceca of 
vaccinated layers but 
not broilers. 
Poulvac SE® 
(killed) 
Subcutaneous 12 and 20 
weeks 
105 cfu S. 
Enteritidis (oral) 
for day old 
progeny 
109 cfu S. 
Enteritidis for 
two week old 
progeny 
7/25 birds were 
positive for 
Salmonella relative 
to the control (25/25) 
in day old progeny, 
while 2/25 birds 
were positive 
relative to the control 
(9/25). 
S. Enteritidis 
outer membrane 
protein extract 
Oral or 
subcutaneous 
8 and 11 weeks 107 cfu S. 
Enteritidis (oral) 
at 13 weeks 
Very few chickens 
shed the challenge 
strain compared to 
the control (100%) 
up to 4 weeks 
postchallenge. 
75.6 and 82.3 
kDa S. Enteritidis 
outer membrane 
proteins 
Subcutaneous 9 and 11 weeks 108 cfu S. 
Enteritidis (oral) 
at 12 weeks 
Levels of the 
challenge strain were 
2-3 log units lower 
in the ceca relative to 
the control. 
S. Enteritidis 
Type I fimbriae 
Subcutaneous 18 and 21 
weeks 
107 cfu S. 
Enteritidis (i.v.) 
at 24 weeks 
Levels of the 
challenge strain were 
similar in the liver, 
spleen and ceca 
relative to the control 
upto 3 weeks 
postchallenge. 
S. Enteritidis FliC 
protein 
Subcutaneous 3 and 5 weeks 107 cfu S. 
Enteritidis (oral) 
at 7 weeks 
Levels of the 
challenge strain were 
3 log units lower in 
the cecal contents at 
3 weeks 
postchallenge 
relative to the 
control. 
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1.5.6 Testing 
In order to ensure that the above mentioned intervention strategies are successful 
in reducing the levels of S. Enteritidis, it is crucial that regular microbiological testing is 
carried out. This should include testing of chicken fecal shedding, internal organs, eggs 
and poultry facilities for the presence of S. Enteritidis [160]. As well, it is important that 
other post-slaughter intervention strategies are put in place that include microbiological 
testing for Salmonella species at slaughter houses and meat processing plants. This would 
be greatly enhanced by the adoption of Hazard Analysis Critical Control Point (HACCP) 
programs that have been developed by several government agencies like the Canadian 
Food Inspection Agency and the Food Safety and Inspection Service in the U.S. 
Department of Agriculture. These programs are specially designed to monitor, control 
and prevent food safety risks. 
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2.0 HYPOTHESIS AND OBJECTIVES 
 
2.1 Hypothesis 
 S. Enteritidis SPI-1 is important for cecal colonization and systemic spread in 
chickens and vaccination with SPI-1 T3SS proteins can be used to reduce colonization 
and systemic spread of the organism. 
 
2.2 Rationale 
 Salmonella Pathogenicity Island-1 has been shown to be an important virulence 
determinant in the bovine, murine and porcine models of infection. However, the role of 
the SPI-1 T3SS has not been well characterized in chickens. In addition, vaccination of 
chickens with live attenuated or killed Salmonella strains has resulted in the reduction of 
the prevalence of Salmonella Enteritidis in chickens. However, there are safety concerns 
associated with live attenuated strains and the protective antigens are not well defined in 
killed Salmonella strains. Based on this, we wanted to test the role of the S. Enteritidis 
SPI-1 T3SS in cecal colonization and systemic spread in chickens. Furthermore, we 
intended to identify T3SS proteins that could be used as vaccine candidates for protection 
against S. Enteritidis oral challenge. 
 
2.3 Objectives 
1. To construct S. Enteritidis SPI-1 mutants and test the role of SPI-1 in invasion in 
vitro using polarized Caco-2 cells and in vivo in chickens. 
2. To determine if sera against SPI-1 T3SS proteins effectively inhibit invasion by S. 
Enteritidis in vitro. 
3. To vaccinate chickens with SPI-1 T3SS proteins and test for protection against S. 
Enteritidis. 
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3.0 SALMONELLA ENTERICA SEROVAR ENTERITIDIS PATHOGENICITY 
ISLAND-1 IS NOT ESSENTIAL FOR, BUT FACILITATES RAPID SYSTEMIC 
INFECTION IN CHICKENS 
 
Published in Infection and Immunity (Desin et al, 2009) [188]. 
 
3.1 Introduction 
Salmonella enterica are Gram negative enteropathogenic bacteria. Within the S. 
enterica species, more than 2300 serovars have been identified, of which serovars 
Enteritidis and Typhimurium have been the most frequently associated with human 
infections [5]. S. Enteritidis is a well known zoonotic pathogen [25] and infected poultry 
are among the most common reservoir of salmonellae that can be transmitted through the 
food chain to humans [1]. In young chicks, S. Enteritidis infection can lead to increased 
incidence of illness, while older birds are less susceptible to the effects of this pathogen 
often experiencing intestinal colonization and even systemic dissemination without 
significant morbidity or mortality. Hence, a better understanding of the pathogenesis of S. 
Enteritidis in chicken may subsequently lower the rates of human disease caused by this 
pathogen. 
 
S. Enteritidis requires a substantial number of genes for virulence, which are 
clustered in large chromosomal regions known as Salmonella pathogenicity islands (SPI) 
[26]. Two of those pathogenicity islands encode two functionally distinct T3SS which are 
utilized as “molecular syringes” to translocate virulence determinants, called effector 
proteins, from the bacterial cytoplasm into [25, 189] or in the vicinity of the target cell 
[75]. Effector proteins delivered by the SPI-1 T3SS are mainly involved in host cell 
invasion by inducing membrane ruffling and disrupting actin polymerization to facilitate 
bacterial uptake [24]. The SPI-2 T3SS plays a major role in systemic virulence and in 
facilitating intracellular survival, especially within macrophages. However, recent 
evidence suggests that the SPI-2 T3SS also plays a role in intestinal colonization [127, 
128] and is expressed prior to bacterial uptake [94]. 
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Invasion of epithelial cells by Salmonella enterica subspecies enterica serovar 
Typhimurium (S. Typhimurium) has been shown to disrupt tight junctions [190-192], 
which along with other components form important intercellular junctions found in 
polarized epithelial cells. Tight junctions regulate the paracellular flow of ions and 
solutes across the intestinal epithelium. They also maintain distinct apical and basolateral 
domains with well defined plasma membrane components [193].  SPI-1 effector proteins 
have been associated with the disruption of tight junctions [191, 192, 194] by activating 
Cdc42 and Rac-1 (Rho family GTPases), which subsequently activate signal transduction 
pathways that lead to the reorganization of actin, resulting in uptake of Salmonella [65]. 
Further, S. Typhimurium SPI-1 effectors SopB, SopE, SopE2 and SipA have been 
identified as major contributors in the disruption of tight junctions [194]. 
 
The contribution of S. Typhimurium SPI-1 to intestinal cell invasion has been 
studied in cell culture using different SPI-1 deletion mutants. Mutations in the SPI-1 
regulatory gene hilA and sipB (SPI-1 effector gene) have been shown to be attenuated in 
invasion relative to the wild type strain in porcine intestinal epitheloid (IPI-21) cells. 
However, the use of polarized porcine intestinal epithelial cells (IPEC-J2) has revealed 
that in addition to hilA and sipB mutant strains, a sipA (SPI-1 effector gene) mutant strain 
was also recovered at a significantly lower rate as compared to the wild type strain [195], 
suggesting that SPI-1 is important for efficient invasion. In another study, it was 
demonstrated that S. Typhimurium SPI-1 effectors, SipA, SopA, SopB, SopD and SopE2 
all contributed to invasion of polarized human colon carcinoma cells (T84). Mutants 
lacking the genes for the aforementioned effector proteins were less invasive relative to 
the wild type strain [196]. Moreover, an S. Typhimurium strain lacking the invG gene 
(encoding an outer membrane component of the SPI-1 T3SS apparatus) was also 
impaired in invasion of COS-7 cells [197]. Taken together, the results from these 
invasion studies suggest that SPI-1 plays a role in invasion in cell culture. However, most 
of the data available is from research that has been conducted using S. Typhimurium. 
 
Several in vivo experiments have been performed to investigate the role of SPI-1 
during the course of a Salmonella infection in different animal species using deletion 
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mutants in SPI-1 genes. In the murine model of infection, it was observed that S. 
Typhimurium strains containing mutations in hilA and invG were recovered from 
intestinal contents and systemic sites at a lower frequency than the wild type strain [198]. 
Other groups have reported that a functional SPI-1 T3SS is required to induce intestinal 
inflammation and cause significant histopathological changes in the streptomycin treated 
mouse model of infectious enterocolitis [128, 197, 199]. Similarly, in the bovine model 
of enteritis, SPI-1 has been shown to be important for intestinal colonization [200]. In 
addition, it has been demonstrated that S. Typhimurium mutants in SPI-1 genes (sipA, 
sipB, hilA), were impaired in their ability to colonize the porcine gut in a ligated intestinal 
loop model [195]. However, a recent study has shown that a SPI-1 functional mutant 
induces intestinal pathology that is very similar to the wild type strain when studied 5 
days post challenge in a novel bovine ileal loop model [127]. 
 
Studies investigating the contribution of SPI-1 in chicken during the course of a S. 
Enteritidis infection are limited in number and have mostly observed colonization and 
systemic infection over a short time frame. Infection of one-day old birds with S. 
Enteritidis strains containing mutations in the invA, invB and invC genes (SPI-1 genes) 
have shown to be attenuated in the colonization of the gastrointestinal tract as well as in 
the systemic spread of the organism over a period of six days post-infection [87]. In 
another study, it was observed that S. Enteritidis sipD mutants were unable to colonize 
spleens as compared to the wild type strain three days post-infection in one day old 
chicks [90]. However, the colonization of the spleen was only measured at one time 
point, making it difficult to predict the effect of the mutant strain prior to and after, the 
third day following infection. A similar trend was seen in the ceca of one-day old chicks 
challenged with a S. Enteritidis hilA mutant strain over a period of twenty-eight days 
post-infection [88]. However, the hilA mutant strain did not have a significant impact on 
the infection of the livers and spleens. Recently, the impact of SPI-1 was examined using 
a S. Typhimurium spaS mutant strain in one-day old and one-week old birds [89]. 
Inactivation of spaS (SPI-1 structural protein) did not affect colonization of the liver or 
the ceca of 1-day old birds over a period of 72 hours post-infection. In 1-week old birds, 
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the same strain was recovered at lower levels from the ceca over a period of 14 days post-
infection, while the recovery from the liver was lower at 3 days post-infection [89]. 
 
Taken together, the experimental evidence from the in vitro studies suggests that 
S. Typhimurium SPI-1 has an impact on invasion. However, studies investigating the role 
of S. Enteritidis SPI-1 in vivo are limited. Moreover, research from the murine, bovine 
and porcine models of salmonellosis indicates that SPI-1 may play a role in breaching the 
intestinal epithelial layer during the course of an infection. Nevertheless, little is known 
about the virulence properties of the S. Enteritidis SPI-1 T3SS in the colonization of 
chickens. In addition, recent evidence suggests that S. enterica is capable of establishing 
infection without the presence of SPI-1 [127, 201, 202]. The objective of this study was 
to investigate the contribution of the S. Enteritidis SPI-1 T3SS in invasion of polarized 
Caco-2 cells, chicken intestinal explants, and in the colonization of chickens over a 
period of four days post challenge. Our data indicate that S. Enteritidis SPI-1 is important 
for invasion in polarized Caco-2 cells and intestinal epithelial cells in vitro. We also show 
that a ∆SPI-1 mutant strain is not impaired in cecal colonization of 1 week old chickens. 
However, the deletion of the SPI-1 region causes a delay in systemic infection.  
 
3.2 Materials and Methods 
 
3.2.1 Bacterial strains and growth conditions 
The bacterial strains used in this study are listed in Table 3.1. S. Enteritidis Sal 18 
was used as the wild type and parent strain for all gene disruptions. Escherichia coli K-12 
DH5α strain was used as a negative control for invasion assays. Unless otherwise stated, 
all strains were grown in Luria Bertani Broth (LB) at 37° C and bacterial cultures were 
agitated in an orbital shaker. SOC medium (2% Tryptone, 0.5% Yeast Extract, 10mM 
NaCl, 2.5mM KCl, 20mM Mg, 20mM Glucose) was used following transformation of the 
lambda red PCR products as described below. 
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Table 3.1 Bacterial Strains used in this study 
 
Bacterial Strain Description Reference 
Sal 18 S. enterica serovar Enteritidis wild type [131] 
LS 21 Sal 18, ∆SPI-1::cat This study 
LS 22 Sal 18, ∆invG::cat This study 
LS 29 Sal 18, glms::tet unpublished 
data 
LS 25 Sal 18, glms::cat unpublished 
data 
E. coli DH5α F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, 
endA1, hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, 
relA1 
Invitrogen 
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3.2.2 Construction of mutants 
Deletion mutants were made in the entire SPI-1 region (~40 kb) as well as in invG 
(~1.7 kb) using the phage lambda red one-step inactivation method [203]. Briefly, 
Polymerase Chain Reaction (PCR) primers (Table 3.2) were designed for the flanking 
regions of SPI-1 (SPI-1F and SPI-1R) and invG (invGF and invGR), based on the S. 
enterica serovar Enteritidis PT4 NCTC 13349 sequence provided by the Welcome Trust 
Sanger Institute (UK), and the Chloramphenicol resistance gene sequence on a template 
plasmid (pKD3). PCR products were transformed by electroporation into competent wild 
type S. Enteritidis expressing the lambda red recombinase (pKD46), under the control of 
an arabinose inducible promoter. Transformants were incubated in SOC [204] for three 
hours at 37° C in a shaker and plated initially on LB agar plates with 9 μg/ml 
chloramphenicol then transferred to plates with 34 μg/ml chloramphenicol to select for 
antibiotic resistant transformants. The ∆SPI-1 and ∆invG deletion mutants were 
confirmed by PCR using a 2720 Thermal Cycler (Applied Biosystems) and sequencing 
(Plant Biotechnology Institute) using a 3730 XL DNA Analyzer (Applied Biosystems). 
 
3.2.3 Precipitation of SPI-1 secreted proteins 
Overnight cultures of S. Enteritidis Sal 18 wild type, ΔSPI-1, and ΔinvG grown in 
LB containing 0.3M NaCl were subcultured in fresh medium at a 1:50 dilution and grown 
for 4 hours at 37° C with low aeration until the OD600 reached approximately 1.2. The 
cultures were centrifuged in Eppendorf tubes at 6,000 x g for 10 minutes (all 
centrifugation steps were at 4° C, unless stated otherwise). The supernatant was filtered 
into fresh tubes using a 0.2 μm filter, while the sediment fraction was dissolved in 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer 
until it was ready for use. Chilled 100% Trichloroacetic acid (TCA) was added to the 
filtered supernatant to 20% (v/v) and the mixtures were incubated on ice for 1 hour. The 
precipitated proteins were centrifuged at 13,000 x g for 30 minutes. The supernatant was 
discarded and 50 μl of PBS (136 mM NaCl, 2.6 mM KCl, 8.1 mM Na2HPO4, 1.5 mM 
KH2PO4), 20 μl 1.5 M Tris pH 8.8 and 1ml chilled (-20° C) acetone was added. The tubes 
were centrifuged at 13,000 x g for 15 minutes. The supernatant was discarded and the 
sediment was washed with 300 μl chilled acetone, followed by centrifugation at 13,000 x 
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Table 3.2 Primers used in this study; F and R refer to forward and reverse primer, 
respectively, used to amplify lambda red PCR products. 
 
Primer 
Name 
Sequence (5’ to 3’) 
SPI-1F GCT GTC GCG TAT GAA GCG ATT GGG TAT TGA TAA AGA CGC GTT AGC 
GTA AGT GTA GGC TGG AGC TGC TTC 
SPI-1R ATA TGG TCT TAA TTA TAT CAT GAT GAG TTC AGC CAA CGG TGA TAT 
GGC CCA TAT GAA TAT CCT CCT TA 
InvGF TCG GCG TTT CGC CGC GGA AAT TAT CAA ATA TTA TTC AAT TGG CAG 
ACA AGT GTA GGC TTG GAG CTG CTT C 
InvGR GCC GGG GAC AAT ATT CTG GAA AAT GAA ATA CCG GAG GTT GAG CCA 
GGA ACA TAT GAA TAT CCT CCT TA 
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g for 10 minutes. The acetone was discarded and the dried pellet was dissolved in 100 μl 
SDS-PAGE sample buffer and stored until it was ready for use. 
 
3.2.4 Cloning of sipD and purification of His-tag SipD 
The sipD gene was amplified using primers that were designed based on the S. 
Enteritidis PT4 NCTC 13349 sequence provided by the Welcome Trust Sanger Institute 
(UK). The gene was cloned downstream of a phage T5 promoter into a His-tag pQE-30 
vector (Qiagen). SipD was over-expressed in E. coli M15 (Qiagen) and purified using a 
nickel charged resin (Qiagen). Polyclonal anti-sera against SipD were raised in New 
Zealand white rabbits obtained from Charles River Canada. 
 
3.2.5 Western immunoblots 
Proteins secreted under SPI-1 inducing conditions were separated by SDS-PAGE 
and transferred to a nitrocellulose membrane using a semi-dry transfer apparatus 
(BioRad) according to the manufacturer’s instructions. The membranes were blocked 
overnight in TBST (8.8 g/L of NaCl, 0.2 g/L of KCl, 3 g/L of Tris base and 500 μL of 
Tween-20, pH adjusted to 7.4) in 3 % skimmed milk powder at 4° C. The membranes 
were washed four times with TBST with 10 minute incubations each time. Rabbit 
polyclonal anti-SipD serum was diluted in TBST (1:5000) and incubated with the 
membranes for 40 minutes at room temperature. This was followed by four washes with 
TBST (as described above). Secondary alkaline phosphatase labeled goat anti-rabbit IgG 
(KPL) was diluted in TBST (1:5000) and incubated with the membranes for 40 minutes 
at room temperature. The membranes were washed twice with TBST, followed by a wash 
with AP Buffer (12.11 g/L of Tris base, 5.84 g/L of NaCl, 1.04 g/L of MgCl2 6H2O, pH 
adjusted to 9.5). To develop the membranes, 33 µl of 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) (Sigma) and 33 µl of nitroblue tetrazolium (NBT) salt (Sigma) were 
added to 10ml of TBST. This mixture was applied to the membranes and they were 
allowed to develop at room temperature. The reaction was stopped by rinsing several 
times with ddH2O. 
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3.2.6 Cell culture 
Caco-2 cells were grown in Hyclone’s DMEM (Fischer) with 10% FBS 
(Seracare) and 1% non-essential amino acids (Invitrogen), at 37° Celsius and 5% CO2. To 
obtain polarized monolayers, Caco-2 cells were seeded onto Transwell inserts (24 mm 
diameter, 0.4 µm pore size, Corning) for about 21 days. The cells were used for 
gentamycin protection assays once the trans-epithelial resistance (TER) was determined 
to be between 250 and 300 ohms cm-2 as described elsewhere [194]. All assays were 
performed in triplicate and were repeated twice. 
 
3.2.7 Invasion assay using polarized Caco-2 cells 
Invasion was assessed using the gentamicin protection assay as described 
elsewhere [205]. Briefly, polarized Caco-2 cells were apically infected with either Sal 18 
wild type (LS 29), ∆SPI-1 (LS 21), ∆invG (LS 22), or E. coli DH5α strains grown in LB 
at an approximate MOI of 100 for 1 hour. For competition experiments, the cells were 
apically infected with a 1:1 ratio of wild type and ∆SPI-1 or wild type and ∆invG strains 
(total MOI of 100). The Caco-2 cells were washed three times with 200 μl PBS to remove 
excess bacteria. The cells were then incubated for 2h with DMEM containing gentamicin 
(400 μg/ml) to kill extracellular bacteria. The cells were washed two times with 200 μl 
PBS and lysed with 1% Triton. Serial dilutions were plated on LB Agar containing either 
tetracycline (5 μg/ml) for the wild type strain or chloramphenicol (34 μg/ml) for the 
∆SPI-1 and ∆invG strains. For competition experiments, serial dilutions were plated in 
duplicate on LB Agar containing tetracycline and LB Agar containing chloramphenicol. 
The invasiveness of the wild type strain (approximately 105 cfu/ml) was accepted to be 
100%, while the invasiveness of the mutant strains was calculated as a percentage of the 
wild type using a similar approach as published previously [206]. 
 
3.2.8 Measurement of trans-epithelial resistance 
The TER was measured using a Millicell – electrical resistance system (Millipore) 
to determine cell monolayer health and polarity as described elsewhere [194]. For 
bacterial invasion assays, the TER was measured prior to infection of the polarized Caco-
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2 cells with S. Enteritidis as well as after gentamicin treatment, to determine the effect of 
the bacterial strains on the trans-epithelial resistance. 
 
3.2.9 Chicken intestinal tissue explants 
Small intestinal and cecal tissue samples were obtained from chickens to assess S. 
Enteritidis invasion as described elsewhere [196]. Briefly, the tissue samples were placed 
on biopsy disks (25.4 x 2 mm, Fisher) with the mucosal side facing up in 6 well tissue 
culture plates (Corning) containing DMEM (Sigma) supplemented with 10% FBS. The 
tissues were co-infected with 107 cfu/well of S. Enteritidis wild type and ∆SPI-1 strains at 
a 1:1 ratio for 1 hour to allow for bacterial invasion. The plates were incubated at 41° C 
with gentle shaking (90 rpm) in an air-tight container under 95% O2. The samples were 
washed in DMEM and then incubated with DMEM containing gentamicin (400 μg/ml) 
for 1 hour, washed in DMEM and homogenized in PBS. Serial dilutions were plated on 
Brilliant Green Agar (BGA) containing either tetracycline (5 µg/ml) or chloramphenicol 
(9 µg/ml) to enumerate the bacteria. All assays were performed in triplicate and were 
repeated at least 3 times. The invasiveness of the wild type strain was accepted to be 
100% (approximately 105 cfu/ml), as described above, while the invasiveness of the 
mutant strain was calculated as a percentage of the wild type strain. Samples of the 
explants in all experiments were subjected to histopathological analysis and the integrity 
of the intestinal epithelial layers was confirmed.  
 
3.2.10 Passage of strains 
S. Enteritidis wild type (LS 25) and ∆SPI-1 (LS 21) strains were passaged through 
1 week old specific pathogen free (SPF) chickens prior to the colonization experiments. 
Isolates were obtained and processed from the liver or spleen as described below and 
confirmed by PCR and antibiotic selection.  
 
3.2.11 Infection of 1-week old chickens 
SPF eggs were obtained from Charles River Laboratories (USA) and were 
incubated for 21 days until hatch at the Department of Poultry Science (University of 
Saskatchewan). The chicks were transferred and housed in isolation rooms at VIDO for 
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the duration of the experiment. The birds were screened using fecal swabs that were 
plated on Brilliant Green Agar (BGA) to test for the presence of Salmonella species. At 
one week of age birds were randomly divided into two groups containing 40 birds each. 
The birds were orally challenged with 0.5ml (1 x 1010 cfu) of either wild type S. 
Enteritidis or the ∆SPI-1 mutant grown in LB that was administered using an oral gavage 
needle (18 gauge x 1.5 inches) down the throat. Ten birds from each group were 
euthanized on days 1, 2, 3 and 4 post challenge. Samples from the liver, spleen and cecal 
content were weighed, homogenized in saline (0.85 % sodium chloride) and serial 
dilutions were plated on BGA to determine bacterial counts. In addition, homogenates 
from the liver and spleen were enriched by incubation in Selenite Broth overnight at 37° 
C. Enriched samples were streaked on BGA to determine if they contain Salmonella 
species. 
 
3.2.12 Statistical analysis 
Statistical analysis was performed using Graph Pad Prism 5.0. The mean 
percentage of invasion was analyzed using a one-way ANOVA and Bonferroni’s 
Multiple Comparison Test was used to compare the different groups. The recovery of S. 
Enteritidis from the cecal contents, liver and spleen based on direct plating was analyzed 
by a non-parametric analysis using the Kruskal-Wallis test. Dunn’s Multiple Comparison 
Test was used to compare the different groups. Enrichment data from the liver and spleen 
was analyzed using the chi-squared test. Fisher’s Exact Test was used to compare the 
different groups. A P value less than 0.05 was considered significant. 
 
3.3 Results 
 
3.3.1 The ∆SPI-1 and ∆invG strains are impaired in the secretion of SipD 
In order to determine if the S. Enteritidis mutants constructed were impaired in 
their ability to secrete SPI-1 T3SS proteins, western blots of bacterial cell lysates and 
culture supernatants were probed with serum against the His-tag derivative (38.5 kDa) of 
the SipD protein, the gene of which is encoded by SPI-1 [207]. As expected, SipD (37 
kDa) was expressed in the wild type strain and was found in both the supernatant and  
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cellular fractions (Figures 3.1A and 3.1B, lane 2). Likewise, SipD was not detected in 
either the supernatant or cellular fractions of the ∆SPI-1 strain (Figures 3.1A and 3.1B, 
lane 3). The ∆invG strain was unable to secrete SipD into the culture supernatant (Figure 
3.1A, lane 4), though the protein was present in the cellular fraction (Figure 3.1B, lane 4).  
 
3.3.2 Salmonella Pathogenicity Island-1 is important for efficient invasion in 
polarized Caco-2 cells and causes a reduction in the trans-epithelial resistance 
S. Enteritidis ∆SPI-1 and ∆invG mutant strains were tested for their ability to 
invade polarized Caco-2 cells relative to the wild type strain, using the gentamicin 
protection assay. The ∆SPI-1 and ∆invG mutant strains were recovered at lower levels 
relative to the wild type strain, while the E. coli strain (control) was unable to invade the 
Caco-2 cells. Invasion by the ∆SPI-1 and ∆invG mutant strains was 6.02% and 8.79%, 
respectively, of the wild type colony forming units (Figure 3.2A). The TER (Figure 
3.2B), on the other hand, was significantly reduced in the wild type infected group 
(50.0% of the initial value) as compared to the ∆SPI-1 group (82.6% of the initial value), 
while the TER of the ∆invG infected group (70.8% of the initial value) was also reduced, 
though not to wild type levels, indicating that SPI-1 is important for tight junction 
disruption. The TER of the control group incubated with E. coli was reduced to 67.0% of 
the initial value. 
Using competition studies, polarized Caco-2 cells were infected with a 1:1 ratio of 
either S. Enteritidis wild type and ∆SPI-1 or wild type and ∆invG to test the ability of the 
mutant strains to invade Caco-2 cells in the presence of the wild type strain. ∆SPI-1 and 
∆invG strains were impaired in invasion as compared to the wild type strain, confirming 
what was seen in Figure 3.2A (single strain infection). The ∆SPI-1 and ∆invG strains 
showed reduced invasion (6.28% and 5.31%, respectively) relative to the wild type strain 
colony forming units (Figure 3.3A). The TER (Figure 3.3B) of the co-infected groups 
(wild type and ∆SPI-1 or wild type and ∆invG) was similar (54.0% and 58.0% of the 
initial TER, respectively) to that of the wild type infected group (50.0% of the initial 
TER). This was expected since the co-infected groups contained the wild type strain. 
 
 55
A1             2               3               4             5
75kDa
50
37
25
20
15
 
 
1               2                3                 4          5
75kDa
50
37
25
20
15
B
 
 
 
 
 
 
 56
Figure 3.1 Western blot analysis of bacterial culture supernatants (A) and pellet 
fractions (B) of wild type Sal 18 and the mutant strains constructed, using rabbit 
anti-His tag-SipD polyclonal serum. Lane 1: prestained protein marker, Lane 2: wild 
type Sal 18, Lane 3: Sal 18 Δ SPI-1, Lane 4: Sal 18 Δ invG, Lane 5: Purified His-tag 
SipD (38.5 kDa). The SipD protein (37 kDa) was present in the supernatant of the wild 
type strain (A, lane 2) but not in the Sal 18 Δ SPI-1 and Sal 18 Δ invG strains (A, lanes 3 
and 4, respectively). In the pellet fractions, SipD was present (*) in the wild type strain 
pellet (B, lane 2), but not in the Sal 18 Δ SPI-1 pellet (B, lane 3). The Sal 18 Δ invG 
pellet contained some SipD, but not as much as the wild type (B, lane 4). 
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Figure 3.2 Single infection of polarized Caco-2 monolayers by either S. Enteritidis 
wild type, ∆SPI-1, ∆invG or E. coli DH5α at an moi of 100. Values represent means + 
the standard error of the mean of at least two independent assays performed with 
triplicate wells. (A) Invasion is expressed as a percentage of the wild type strain (B) 
Change in TER is expressed as a percentage of the initial TER value. ***, P < 0.001. 
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Figure 3.3 Mixed infection of polarized Caco-2 monolayers by S. Enteritidis wild 
type and ∆SPI-1 or wild type and ∆invG at a 1:1 ratio with an moi of 100. Values 
represent means + the standard error of the mean of at least two independent assays 
performed with triplicate wells. (A) Invasion is expressed as a percentage of the wild type 
strain (B) Change in TER is expressed as a percentage of the initial TER value.
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 3.3.3 The SPI-1 deficient strain is less invasive relative to the wild type strain in 
chicken intestinal tissue explants 
 
Chicken intestinal tissue samples were used to test invasion of the S. Enteritidis 
wild type and ∆SPI-1 strains using the gentamicin protection assay as described above. In 
this competition experiment, the SPI-1 deficient strain was recovered at a lower rate from 
both the cecal and small intestinal tissue explants (29.3% and 17.2%, respectively) as 
compared to the wild type strain (Figure 3.4), while the E. coli strain (control) was not 
recovered (data not shown). This provided more evidence to suggest that SPI-1 plays a 
role in breaching the chicken intestinal epithelial barrier. However, the invasion defect of 
the ∆SPI-1 strain was relatively smaller in comparison with the invasion defect observed 
in polarized Caco-2 cells. 
 
3.3.4 Cecal colonization levels were similar in both the wild type and ∆SPI-1 
challenged groups 
One week old birds were orally challenged with 1 x 1010 cfu of either the wild 
type strain or the ∆SPI-1 strain as described in materials and methods. Birds were 
euthanized on days 1, 2, 3 and 4 post challenge. We did not see any statistical difference 
between the cecal colonization (Figure 3.5) of the wild type and the ∆SPI-1 challenged 
groups over the duration of the experiment. 
 
3.3.5 The deletion of SPI-1 results in delayed systemic infection in chickens 
Analysis of the bacterial load in the liver (Figure 3.6A) revealed that on the first 
day post-challenge, there was very little detectable S. Enteritidis wild type and ∆SPI-1 
strains, suggesting that the systemic spread of the bacteria was still in its early stages. 
This idea is supported by data from enriched samples (Figure 3.6B) which revealed that 
on day one post challenge, 9/10 livers were infected in the wild type challenged group, 
while only 3/10 livers (P < 0.05) were infected in the ∆SPI-1 challenged group. Two 
days post challenge the recovery of the ∆SPI-1 strain (Figure 3.6A), as evident from 
direct plating, was significantly lower (P < 0.05) in comparison to the wild type strain  
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Figure 3.4 Invasion of chicken cecal and small intestinal explants by S. Enteritidis 
wild type and ∆SPI-1 strains at a 1:1 ratio. Values represent means of at least three 
independent assays + the standard error of the mean performed with triplicate wells. 
Invasion is expressed as a percentage of the wild type strain. 
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Figure 3.5 Colonization of ceca from 1 week-old chicken by either wild type S. 
Enteritidis or ∆SPI-1. The chickens were orally challenged with 1 x 1010 cfu of either 
wild type or mutant. 10 birds per group were euthanized on days 1, 2, 3 and 4 post-
infection. 
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Figure 3.6 Systemic infection of the liver in 1 week old-chicken challenged with 1 x 
1010 cfu of either wild type S. Enteritidis or ∆SPI-1. Ten birds were euthanized per day 
in each group. (A) viable counts of Salmonella from direct plating represented as median 
cfu/g values (B) number of birds positive for Salmonella following enrichment. *, P < 
0.05. 
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(3.30 x 103 CFU/g). However, liver enrichment data (Figure 3.6B) demonstrated that the 
number of livers that were positive in the ∆SPI-1 challenged group (7/10) were only 
marginally lower than those in the wild type challenged group (10/10). On day 3 post 
challenge the levels of both the wild type and ∆SPI-1 strains (Figure 3.6A) based on 
direct counts, followed a similar trend. Data from enriched samples (Figure 3.6B) 
suggested that the infection was starting to clear in the wild type challenged group on the 
third day (8/10 livers were positive), while 10/10 livers were positive for Salmonella in 
the ∆SPI-1 inoculated group. After 4 days, the bacterial levels (Figure 3.6A) in both the 
wild type and ∆SPI-1 challenged groups was mostly below the detection limit using 
direct plating, which demonstrated that a clearing of the infection was in progress. As for 
the enriched liver samples (Figure 3.6B), 8/10 livers were still positive for the Salmonella 
wild type strain, compared to 6/10 livers in the ∆SPI-1 challenged group. This suggests 
that the ∆SPI-1 strain was initially slower in spreading systemically, but also started to 
clear faster relative to the wild type strain.  
 
The recovery of S. Enteritidis wild type and ∆SPI-1 strains from chicken spleens 
was similar to what was observed in the liver. On the first day post challenge (Figure 
3.7A) the infection was still at its early stage and therefore the median group CFU 
recovery, as determined by direct plating, was below the detection limit in the wild type 
and ΔSPI-1 challenged birds. Similarly, the data from enriched spleen samples (Figure 
3.7B) suggested that there was little difference in the number of spleens that were 
positive for Salmonella in both groups. On day two post challenge, the recovery of 
bacteria in the wild type challenged group was 7.20 x 102 cfu/g., while that of the ΔSPI-1 
challenged group remained unchanged (Figure 3.7A). Likewise, data from enriched 
samples showed that the number of spleens that were positive for wild type Salmonella 
were slightly higher (7/10) than that of the ∆SPI-1 challenged group (4/10). On the third 
day after challenge, bacterial levels in the spleen, measured by direct plating (Figure 
3.7A) and after enrichment (Figure 3.7B), by both the wild type and the ∆SPI-1 strains 
followed a similar pattern as on day two. On the last day after challenge (Figure 3.7A), 
only a few birds were found with countable Salmonella on BGA in either the wild type or  
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Figure 3.7 Systemic infection of the spleen in 1 week old-chicken challenged with 1 x 
1010 cfu of either wild type S. Enteritidis or ∆SPI-1. Ten birds were euthanized per day 
in each group. (A) viable counts of Salmonella from direct plating represented as median 
cfu/g values (B) number of birds positive for Salmonella following enrichment. 
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∆SPI-1 challenged groups. In accordance with this finding, data from enriched samples, 
showed a marginal difference between the number of spleens that were positive in both 
wild type and ∆SPI-1 challenged groups suggesting that the infection was clearing. The 
values described above represent median group numbers after statistical processing. For 
CFU, recovered from individual birds, please see Figures 3.5, 3.6 and 3.7. 
 
3.4 Discussion 
The role of SPI-1 in the pathogenesis of Salmonella enterica has been studied in 
detail in both the mouse enterocolitis and the bovine enteritis models of infection [86, 
127, 128, 201, 208]. However, the contribution of SPI-1 is still not fully understood in the 
chicken colonization model. The goal of this study was to determine the role of S. 
Enteritidis SPI-1 in invasion using polarized Caco-2 cells as well as chicken intestinal 
explants, and to test the effects of a SPI-1 deletion mutant on cecal colonization and 
systemic spread of the organism in chickens over a period of 4 days post challenge.  
 
We chose to construct deletion mutants in SPI-1 since it has been well 
documented that the SPI-1 T3SS is essential for the secretion of effector proteins and 
plays an important role in infection in different animal models [75, 88, 195, 198]. Thus, it 
would be expected that deletion of the pathogenicity island in its entire form or the 
knockout of certain individual genes, would not allow the bacterium to form a fully 
functional T3SS apparatus nor to secrete any of the SPI-1 related effectors in order to 
cause intestinal invasion and facilitate bacterial uptake. The ΔSPI-1 and ΔinvG mutants 
constructed were tested for their ability to secrete effector proteins in-vitro using western 
blot analysis, which has been previously used in several studies as a functional assay to 
determine the effect of SPI-1 deletions on secretion [37, 209, 210]. We chose to monitor 
the secretion of SipD in the supernatant and pellet fractions of the mutant strains, since 
SipD is secreted using this system and forms part of the SipB/C/D translocase complex at 
the tip of the SPI-1 T3SS apparatus [75]. The SipD protein was not detected in the 
supernatant or pellet fractions of the ΔSPI-1 mutant strain, confirming that SipD was not 
expressed in the cell, since the gene encoding SipD had been deleted. In addition, SipD 
was not detected in the supernatant fraction of the ∆invG strain, as suggested by reports 
 66
which show that ∆invG strains are unable to secrete effector proteins [211]. The presence 
of SipD in the cellular fraction of the ΔinvG strain is also expected since the sipD gene 
was not deleted in this strain. Interestingly, the level of SipD present in the cellular 
fraction of the ∆invG mutant strain was much lower than the amount present in the wild 
type fraction. We speculate that this may be due to the fact that the regulation of SPI-1 
involves several regulators, including the main regulator, HilA (encoded on SPI-1). The 
HilA protein is known to bind directly to promoters on the inv/spa and prg/org operons 
on SPI-1, thus activating the expression of several genes encoding components of the 
SPI-1 T3SS. Activation of the inv/spa operon by HilA eventually leads to the activation 
of the sic/sip operon, which encodes SipD. Further, activation of the inv/spa operon 
results in the expression of InvF (a positive transcriptional activator) which, along with 
the chaperone SicA, also induces expression of SPI-1 secreted proteins on the sic/sip 
operon and those located outside SPI-1 [34]. Therefore, it is possible that the deletion of 
invG affects the expression of genes in the inv/spa operon, which ultimately affects 
downstream genes like sipD in the sic/sip operon. 
 
In order to examine the contribution of S. Enteritidis SPI-1 to invasion, we used 
polarized Caco-2 cells. This cell line was chosen due to the absence of well characterized 
chicken epithelial cell lines. Moreover, Caco-2 cells are capable of polarizing on 
transwells, resulting in well defined apical and basolateral compartments, making them a 
good model for studying host cell invasion. Caco-2 cells also form well defined brush 
borders and express several markers that are present on small intestinal villus cells [190]. 
Further, it has been demonstrated that polarized epithelial cells reveal additional 
information, with respect to invasion, which would not have been possible with 
nonpolarized cells [196]. The choice of this cell line was also relevant to this study since 
S. Enteritidis is also a potential human pathogen [160]. Our results from the invasion 
assays using Caco-2 cells implied that ∆SPI-1 and ∆invG mutant strains were impaired in 
invasion relative to the wild type strain in both the single infection experiments and 
competition experiments. This was in line with other reports which demonstrated that 
SPI-1 was important for invasion in cell culture [197, 212-214]. The difference in 
invasion between the wild type and SPI-1 mutant strains was about 10-fold based on our 
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invasion assays, which is comparable to what has been observed by others in similar 
experiments with S. Typhimurium and S. enterica subspecies enterica serovar Typhi 
[195, 196, 206, 210, 215, 216]. This data also suggested that the role of S. Enteritidis SPI-
1 in tissue culture models was similar to that observed for S. Typhimurium. To our 
knowledge, this is the first time S. Enteritidis ∆SPI-1 and ∆invG mutants have been 
tested (both single and mixed infections) using polarized Caco-2 cells.  
 
The disruption of tight junctions is a strategy used by different bacterial 
pathogens, including Salmonella, to cause virulence, which in turn, damages the 
epithelial cell structure [217]. We used the TER as an indicator of cell monolayer health, 
which has been widely used by others to assess the affect of bacterial pathogens on tight 
junctions [190, 218, 219]. Our results from the invasion assays (single infection) suggest 
that both S. Enteritidis ∆SPI-1 and ∆invG mutant strains caused a smaller reduction of 
TER, in comparison to the wild type strain. This was expected since the SPI-1 mutants 
used in our study were impaired in the secretion of SPI-1 effector proteins. On the other 
hand, there was no difference in TER between the wild type alone and co-infected 
groups, which contained the wild-type and either ∆SPI-1 or ∆invG strains. This can be 
explained by the fact that the co-infected groups all contained the wild type strain, which 
is capable of secreting SPI-1 effector proteins. The E. coli strain also caused a reduction 
in the TER, which was similar to that caused by the SPI-1 mutant strains. This finding 
was not expected because the E. coli strain used was a non-pathogenic strain that was not 
able to invade Caco-2 cells in our assays. A possible reason for this could be that E. coli 
K12 may produce unidentified factors that reduce the TER. 
 
Intestinal tissue explants represent a valid model to study invasion since they 
bridge the gap between tissue culture based assays and animal experiments. They are 
commonly used to provide more insights into host-pathogen interactions [196, 220, 221]. 
Our data from the chicken cecal and small intestinal explants suggest that SPI-1 mediated 
invasion is important for breaching the chicken intestinal epithelial barrier. This is in 
agreement with data obtained from bovine intestinal explants that were infected with a 
SPI-1 mutant of S. Typhimurium [196]. However, we observed that the difference in 
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invasiveness between the wild type and ∆SPI-1 strain was smaller as compared to the 
difference observed in polarized Caco-2 cells. A similar finding reported in bovine 
intestinal explants [196], implies that other mechanisms besides SPI-1 may also be 
involved in the process of invasion. We have shown for the first time that SPI-1 mutants 
are impaired in invasion of chicken cecal and small intestinal tissue explants. 
 
To extend our observations from the in vitro studies using SPI-1 mutants, we 
tested the effect of the ∆SPI-1 mutant on the colonization and systemic spread of the 
organism in chickens. Only the ∆SPI-1 mutant was tested in chickens, since the ∆invG 
mutant strain was similar to the ∆SPI-1, in that both strains were impaired in the 
secretion of SipD and showed reduced invasion in polarized Caco-2 cells. In addition, to 
get a better understanding of the contribution of SPI-1 in chickens, we examined the 
effect of a SPI-1 deletion over a period of four days after oral challenge with either wild 
type S. Enteritidis or ∆SPI-1 mutant strains. The extended time frame is crucial since it is 
possible that the absence of SPI-1 may have a pronounced effect on pathogenesis at a 
certain stage of infection, while at other stages, the effect may not be obvious. 
 
Our data indicate that the absence of SPI-1 does not significantly affect cecal 
colonization on all four days following oral challenge. This is in agreement with what has 
been observed in day old chicks orally challenged with a S. Typhimurium ∆spaS (SPI-1 
gene deletion) mutant strain. A similar finding was reported when one-week old chicks 
were used in the same study. However, cecal colonization levels of the ∆spaS challenged 
group were lower relative to the wild type strain on day 14 post challenge [89]. Likewise, 
lower levels of cecal colonization were observed in day old chicks challenged with S. 
Enteritidis ∆hilA relative to the wild type only after day 6 post challenge [88]. As well, 
reduced levels of S. Typhimurium ∆SPI-1 were reported in cecal tissue of one-week old 
chickens over a 14 day period [130]. Hence, it is likely that differences between cecal 
colonization levels of wild type and SPI-1 mutant challenged groups are evident when the 
colonization is monitored over several weeks. We did not extend the chicken experiments 
past four days following oral inoculation since we have observed that the chickens start to 
clear the infection. 
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Our systemic infection data implies that the absence of SPI-1 affects systemic 
infection, as detected on days 2 and 3 following oral challenge. However, since the 
detection limit of viable Salmonella is 102 cfu/g in our sample processing regime (direct 
plating without enrichment), it is highly likely that many liver and spleen samples from 
infected birds appear as false negatives. The systemic infection data following 
enrichment of the liver and spleen samples provide a better insight into the effect of a 
SPI-1 deletion on systemic spread of S. Enteritidis. It is apparent from the enrichment 
data that the ∆SPI-1 strain causes a delay in infection of the liver (P < 0.05) and spleen 
on the first day post-challenge. Subsequently, the ∆SPI-1 strain was recovered from the 
liver and spleen at levels that were similar to the wild type strain. This is in line with 
what has been observed when chicken were challenged with a S. Enteritidis ∆hilA strain 
[88], S. Typhimurium ∆spaS strain [89] or S. Typhimurium ∆SPI-1 strain [130]. 
However, our results from the systemic infection data are in contrast to what has been 
seen when three week old chicks were challenged with S. Enteritidis ∆sipD where none 
of the spleens were infected on day 3 post-challenge [90]. A likely explanation for this 
might be that the birds were sampled at one time point and were only based on direct 
plating. Hence, it would be difficult to determine how the sipD mutant would have 
affected colonization over a longer time period, given the fact that our data indicates that 
there is a delay in systemic infection initially by the ∆SPI-1 mutant strain. As well, our 
results are not in agreement with the findings from a study in which the S. Typhimurium 
∆spaS strain was not detected on days 1, 7 and 14 post challenge in the livers of 1 week 
old chicken, relative to the wild type strain based on direct plating [89]. One possible 
explanation for this difference is that S. Typhimurium and S. Enteritidis are two different 
organisms and thus their method of establishing infection may be different in chickens. 
Alternatively, the ∆spaS strain may have been present, but below the detection limit, 
which is what we observed in our systemic infection data. 
 
The results from our in vivo study imply that the SPI-1 virulence determinant does 
not play a major part in S. Enteritidis infection in chicken. A possible hypothesis for this 
finding could be that S. Enteritidis SPI-1 genes are not expressed in vivo in chicken. 
However, data from our lab indicates that sera from chickens challenged with wild type 
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S. Enteritidis reacts with purified recombinant components of the SPI-1 T3SS (data not 
shown), suggesting that the SPI-1 T3SS is expressed during infection of chickens. Our 
systemic infection results (enrichment) illustrate that the absence of SPI-1 results in a 
delay in infection relative to the wild type strain. This further confirms the concept that 
the SPI-1 T3SS comes into play at some point during the process of infection in chicken. 
Recently, SipA, SopA, SopB, SopD and SopE2 (SPI-1 effector proteins) have been 
detected in the spleens of mice challenged with S. Typhimurium [86]. Although the 
murine model of salmonellosis is different from chicken, this finding not only confirms 
that SPI-1 is expressed in-vivo, it also provides support for the role of SPI-1 in systemic 
infection. A recent report has shown that SPI-1 genes are highly expressed at early and 
late stages of infection in cultured epithelial cells [222]. This finding, despite being from 
an in-vitro study, is significant since it provides further evidence to suggest that the role 
of SPI-1 can be extended to the systemic phase of infection and requires further 
investigation. 
 
The prevailing view has been that SPI-1 is essential for intestinal pathogenesis in 
different animal models. However, recent evidence from the bovine and murine models 
of infection suggests that S. Typhimurium can cause infection in a SPI-1 independent 
manner [127, 201, 223]. Further, it has been reported that SPI-1 mutants retain their 
ability to invade M cells in a murine gut loop model [224], implying that intestinal 
invasion may involve other factors, besides SPI-1. In addition, it has been shown that 
human isolates of S. enterica subspecies enterica serovar Senftenberg cause intestinal 
inflammation despite the fact that they are SPI-1 deficient [202]. Taken together, this, 
along with our data from the chicken colonization study, may suggest that the SPI-1 
T3SS is not a critical factor for crossing the intestinal epithelial barrier in some animals. 
 
Although there are differences between Salmonella infections that occur naturally 
under field conditions and those that occur under experimental conditions, the results 
from our chicken colonization study, as well as those by others provide insights into the 
mechanisms by which Salmonella enterica serovars Enteritidis and Typhimurium 
colonize chickens. We chose to use a high dose for oral challenge of chickens, unlike 
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what the birds would encounter in a natural setting, since we observed very low levels of 
colonization at lower doses (data not shown), making it difficult to interpret the data. In 
addition, other groups have also used high challenge doses in chicken experiments [88, 
89, 130], thus validating our findings.  
 
In summary, we have shown that S. Enteritidis ∆SPI-1 and ∆invG were unable to 
secrete effector proteins using SipD as an indicator of SPI-1 effector protein secretion. 
The mutants showed reduced invasion of both polarized Caco-2 cells and tissue explants 
obtained from chicken small intestine and ceca. Our data further suggest that the deletion 
of SPI-1 does not affect cecal colonization in one week old chicken, but causes a milder 
and delayed systemic infection, as revealed by samples from the liver and spleen. 
Additional work needs to be done to determine the individual SPI-1 effectors responsible 
for systemic infection in chicken. 
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4.0 PROTECTION OF EPITHELIAL CELLS FROM SALMONELLA ENTERICA 
SEROVAR ENTERITIDIS BY ANTIBODIES AGAINST THE SPI-1 TYPE 3 
SECRETION SYSTEM 
 
Excerpts from this chapter have been accepted for publication in the Canadian Journal of 
Microbiology (Desin et al, 2010). 
4.1 Introduction 
Many Salmonella enterica strains represent zoonotic pathogens that are associated 
with enteric food borne illness. The vast majority of human infections caused by 
Salmonella strains are linked to the consumption of contaminated food or water, which 
normally results in a self-liming gastrointestinal disease. In rare cases, the disease may 
become severe requiring antibiotic treatment or even hospitalization. S. Enteritidis is one 
of the most frequently isolated serovars with respect to human disease in North America 
[225]. 
During the process of infection, S. Enteritidis employs several virulence factors 
including LPS, flagella, fimbriae and Type 3 Secretion Systems (T3SS). The S. 
Enteritidis T3SS have been shown to be important virulence determinants in different 
animal species (murine, bovine, porcine and chicken models of infection) [127, 130, 195, 
208]. One of the T3SS, encoded on Salmonella Pathogenicity Island 1 (SPI-1), is used to 
inject effector proteins directly into the host cytosol [65]. This system is required for 
invasion of non-phagocytic cells in the host gastrointestinal tract [26]. The SPI-1 T3SS is 
composed of several proteins that span both the bacterial inner and outer membranes. 
Proteins that are exposed on the bacterial surface include the major T3SS component 
located in the outer membrane (InvG), the protein forming the needle (PrgI) and the 
translocon components (SipB, SipC and SipD) that upon contact with the host cell form a 
pore in the host cell membrane. At least 15 effector proteins (many of which are encoded 
on SPI-1) are known to be secreted into the host cytosol including SipA, SopB, SopE, 
SopE2 and SptP. This results in massive host cytoskeletal rearrangements triggering the 
uptake of the bacterium [28, 61].  
Invasion of the intestinal epithelial layer is a crucial step in S. Enteritidis 
pathogenesis, as this allows the bacterium to spread systemically to other sites. 
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Antibodies against different outer membrane components have been used in vitro in an 
attempt to block the initial interaction between S. Enteritidis and the host. In one study, it 
was revealed that sera against S. Enteritidis LPS but not flagella, prevented entry of the 
bacterium in Hep-2 cells [226]. The use of polarized Caco-2 and T84 cells demonstrated 
that anti-sera to both S. Enteritidis flagella and formalin inactivated S. Enteritidis 
inhibited invasion [227]. Similarly, antibodies against S. Typhimurium LPS have blocked 
S. Typhimurium invasion in MDCK cells [216, 228]. These studies present valuable 
information that can be used to devise strategies to prevent S. Enteritidis infection in 
animals. However, to date, there is limited data available on the use of antibodies directed 
against the SPI-1 T3SS as a method of blocking S. Enteritidis entry into epithelial cells in 
vitro. Consequently, the objectives of this study were to examine the role of sera against 
SPI-1 T3SS proteins in invasion of polarized Caco-2 cells and to identify which 
components, if any, are major players. 
 
4.2 Materials and Methods 
 
4.2.1 Bacterial strains and growth conditions 
S. Enteritidis Sal 18 wild type attTn7::tet, S. Enteritidis Sal 18 ∆SPI-1::cat [188], 
S. Enteritidis Sal 18 ∆sipD::cat (constructed using the phage lambda red system) and S. 
Typhimurium (S. Typhimurium) SL1344 [194] were used for the invasion inhibition 
assays. S. Enteritidis Sal 18 wild type and the ∆sipD mutant strain were used for 
preparing the lysates for the western blots. All bacterial strains were grown in Luria 
Bertani (LB) broth at 37° C and were agitated in an orbital shaker. 
 
4.2.2 Preparation of SPI-1 secreted proteins 
An overnight culture of the S. Enteritidis wild type strain was subcultured in LB 
containing 0.3 M NaCl at a 1:50 dilution and grown at 37° C with low aeration for 4 
hours (O.D. 600 = 1.2). The culture was centrifuged at 6,000 x g for 10 minutes 
(centrifugation was at 4° C, unless otherwise stated) after which the fraction containing 
the supernatant was precipitated using chilled 100 % Trichloroacetic acid (TCA) as 
described previously [229].  
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4.2.3 Cloning and purification of His-tag proteins 
The invG, prgI, sipA, sipC, sipD sopB, sopE and sopE2 genes were amplified 
under standard PCR conditions and cloned downstream of either (i) a phage T5 promoter 
into a His-tag pQE-30 vector (Qiagen) or (ii) a phage T7 promoter into a His-tag pET-
15b vector (Novagen). Genes cloned in pQE-30 vectors were over-expressed in E. coli 
M15 (Qiagen) cells, while genes cloned in pET-15b vectors were over-expressed in E. 
coli BL21 (Novagen) cells. Over-expressed His-tag proteins were purified using a nickel 
charged resin as recommended by the supplier (Qiagen). 
 
4.2.4 Generation of rabbit polyclonal anti-sera 
Polyclonal anti-sera to InvG, PrgI, SipA, SipC, SipD, SopB, SopE or SopE2 were 
raised in New Zealand white rabbits obtained from Charles River Canada. Briefly, rabbits 
were immunized subcutaneously on days 0 (with 400 µg protein in Freund’s complete 
adjuvant), 21 and 42 (with 200 µg protein in Freund’s incomplete adjuvant, respectively). 
Blood was collected from the rabbits on day 52. Serum antibody titers were determined 
using enzyme linked immunosorbent assay (ELISA). 
 
4.2.5 Cell culture 
Caco-2 cells were grown in Hyclone’s DMEM (Fischer) supplemented with 10 % 
FBS (Seracare) and 1 % non-essential amino acids (Invitrogen) at 37° Celsius and 5 % 
CO2 in a humidified incubator. The cells were seeded into Transwell inserts (24 mm 
diameter, 0.4 µm pore size, Corning) and cultured for about 21 days to obtain polarized 
monolayers. Once the transepithelial resistance (TER) was established to be between 250 
and 300 ohms cm-2 as described elsewhere [188, 194] the cells were used for invasion 
inhibition assays. All experiments were performed in triplicate and were repeated at least 
two times. 
 
4.2.6 Invasion inhibition assay 
Invasion was assessed using the gentamicin protection assay as described 
previously [188]. Briefly, polarized Caco-2 cells were apically infected with the 
appropriate bacterial strain grown in LB at an approximate multiplicity of infection 
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(MOI) of 100 for 1 hour, either in the presence or absence of sera (heat inactivated by 
incubation at 50° C for 30 minutes) against SPI-1 structural proteins at a 1:20 dilution 
which has been previously used by others [230-232]. Excess bacteria were removed by 
washing the cells three times with 200 µl PBS. The cells were incubated for 2h with 
DMEM containing gentamicin (400 µg ml-1) to kill the extracellular bacteria. The cells 
were washed two times with 200 µl PBS and lysed with 1% Triton. Serial dilutions were 
plated on LB agar and bacterial colony counts were measured. The invasiveness of the 
wild type strain without sera (approximately 105 cfu ml-1) was accepted to be 100%, 
while the invasiveness of other groups incubated with sera was calculated as a percentage 
of the wild type using an approach similar to that previously published [188, 206].  
 
4.2.7 Trans-epithelial resistance 
A Millicell – electrical resistance system (Millipore) was used to measure the 
TER as an indication of the polarity of the Caco-2 cells as described elsewhere [188, 
194]. The TER was measured prior to infection of the polarized Caco-2 cells with 
bacteria as well as after gentamicin treatment, to assess the effect of the bacteria on the 
transepithelial resistance. 
 
4.2.8 Western blots 
Whole cell lysates of S. Enteritidis wild type and ∆sipD were separated by SDS-
PAGE and transferred using a semidry transfer apparatus to nitrocellulose membranes 
(Bio-Rad) as per the manufacturer’s instructions. The membranes were blocked overnight 
in TBST (8.8 g/L of NaCl, 0.2 g/L of KCl, 3 g/L of Tris base and 500 μL of Tween-20, 
pH adjusted to 7.4) in 3 % skimmed milk powder at 4° C. The membranes were washed 
four times with TBST with 10 minute incubations each time. Rabbit polyclonal pre-
immune, anti-SipD or SipD depleted sera were diluted in TBST (1:5000) and incubated 
with the membranes for 40 minutes at room temperature. This was followed by four 
washes with TBST (as described above). Secondary alkaline phosphatase labeled goat 
anti-rabbit IgG (KPL) was diluted in TBST (1:5000) and incubated with the membranes 
for 40 minutes at room temperature. The membranes were washed twice with TBST, 
followed by a wash with AP Buffer (12.11 g/L of Tris base, 5.84 g/L of NaCl, 1.04 g/L of 
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MgCl2 6H2O, pH adjusted to 9.5). To develop the membranes, 33 µl of 5-bromo-4-
chloro-3-indolyl phosphate (BCIP) (Sigma) and 33 µl of nitroblue tetrazolium (NBT) salt 
(Sigma) were added to 10 ml of TBST. This mixture was applied to the membranes and 
they were allowed to develop at room temperature. The reaction was stopped by rinsing 
several times with ddH2O. 
 
4.2.9 ELISA 
ELISA plates (Immulon® 2 HB) were coated with 100 ng of antigen per well in 
coating buffer (12.5 mM Na2CO3 and 37.5 mM NaHCO3) for overnight incubation at 4° 
C. The plates were washed eight times (8x) with ddH2O and blocked with 200 µl of 
TBST for 2 hours at room temperature. After washing the plates with ddH2O (8x), 100 µl 
per well of rabbit polyclonal sera (1:100) was added to the first row and this was serially 
diluted along the plate. The primary sera was allowed to incubate for 1 hour at room 
temperature and washed with ddH2O (8x). This was followed by the addition of 100 µl of 
alkaline phosphatase labeled secondary goat anti-rabbit IgG (KPL) at a 1:5000 dilution 
which was allowed to incubate for 1 hour at room temperature. The plates were washed 
with ddH2O (8x) 100 µl of PNPP substrate (Sigma) was added to each well. After 
incubation at room temperature, the absorbances were read in a plate reader at a 
wavelength of 405 nm (490 nm as the reference). 
 
4.2.10 Depletion of SipD specific antibodies 
To deplete SipD specific antibodies from anti-SipD serum, 1ml of the serum was 
incubated overnight with 1 mg of purified recombinant SipD protein in an Eppendorf 
tube with gentle shaking on a nutator. The next day, the serum was stored at -20 C until 
further use. The depletion of SipD specific antibodies was confirmed by ELISA (section 
4.2.9). In addition, SipD depleted serum was tested in an invasion inhibition assay as 
described above in section 4.2.6. 
 
4.2.11 Statistical analysis 
Statistical analysis was performed by using GraphPad Prism 5.0. The mean percentage of 
invasion from each group in the invasion inhibition assays were analyzed using a one-
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way ANOVA. Bonferroni’s Multiple Comparison Test was used to compare the different 
groups in each experiment. For antibody titer determinations (ELISA) the cut-off value 
was considered to be the average of the blank and two standard deviations. Mean IgG 
titers were analyzed using a one-way ANOVA as described above. A P value of < 0.05 
was considered significant. 
 
4.3 Results 
 
4.3.1 Anti-SipD serum inhibits S. Enteritidis entry 
To determine the effect of antibodies against the SPI-1 related T3SS components 
on S. Enteritidis invasion in Caco-2 cells, sera against secreted effector proteins were 
tested first. Polyclonal serum against the secreted fraction of SPI-1 proteins significantly 
inhibited invasion (14.5 %) relative to the control group (no sera) (Figure 4.1), while 
antibodies against the individual effector proteins, SopB, SopE and SopE2 did not have 
an inhibitory effect on invasion. In order to identify the fraction(s) from the pool of 
polyclonal antibodies directed against total SPI-1 secreted proteins that blocked invasion, 
antibodies against individual structural T3SS proteins were tested. Pooled anti-PrgI and 
anti-InvG sera did not affect S. Enteritidis invasion (Figure 4.2). Interestingly, pooled 
sera against SipA, SipC and SipD significantly inhibited invasion (16.3 %) relative to the 
control group (100 %). Similarly, pooled sera against SipA, SipC and SipD also blocked 
invasion of S. Typhimurium (Figure 4.3), implying that a common strategy could be used 
to block both S. Enteritidis and S. Typhimurium invasion in vitro. In order to further 
investigate the effect of pooled sera against SipA, SipC and SipD on S. Enteritidis entry, 
the sera were individually tested to determine if sera against any or all three recombinant 
proteins inhibited invasion. The presence of anti-SipD serum significantly reduced S. 
Enteritidis entry into Caco-2 cells (3.95 %) relative to the control group (no sera) (100 
%), while sera against SipA and SipC had little effect (79.9 % and 94.4 %, respectively, 
Figure 4.4). To confirm and validate our findings, anti-SipD serum was incubated with a 
S. Enteritidis mutant strain lacking sipD, which has already been shown to be less 
invasive relative to the wild type strain [212, 229]. As expected from the previous study, 
antibodies against SipD did not further affect invasion of the mutant strain (2.80%)  
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Figure 4.1: Antibodies against total SPI-1 secreted proteins inhibit S. Enteritidis 
invasion. Caco-2 cells were infected with S. Enteritidis and were treated with no serum, 
pre-immune serum, sera against total SPI-1 secreted proteins, and individual components 
SopB, SopE and SopE2. The efficiency of bacterial entry is expressed as a percentage of 
the invasion of the control group (no sera). Values represent means + the standard error 
of the mean of at least two independent assays performed with triplicate wells. **, P < 
0.01. 
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Figure 4.2: Pooled sera against SipA, SipC and SipD inhibit entry of S. Enteritidis. Caco-
2 cells were infected with S. Enteritidis and were treated with no serum, pre-immune 
serum, pooled sera against PrgI and InvG, or pooled sera against SipA, SipC and SipD. 
The efficiency of bacterial entry is expressed as a percentage of the invasion of the 
control group (no serum). Values represent means + the standard error of the mean of at 
least two independent assays performed with triplicate wells. **, P < 0.01. 
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Figure 4.3: S. Typhimurium invasion is inhibited by pooled sera against SipA, SipC and 
SipD. Caco-2 cells were infected with S. Typhimurium and were treated with no serum, 
pre-immune serum, pooled sera against PrgI and InvG, or pooled sera against SipA, SipC 
and SipD. The efficiency of bacterial entry is expressed as a percentage of the invasion of 
the control group (no serum). Values represent means + the standard error of the mean of 
at least two independent assays performed with triplicate wells. *, P < 0.05. 
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Figure 4.4: Anti-SipD serum inhibits S. Enteritidis invasion. Caco-2 cells were infected 
with S. Enteritidis and were treated with no serum, pre-immune serum, and individual 
sera against SipA, SipC or SipD. The efficiency of bacterial entry is expressed as a 
percentage of the invasion of the control group (no serum). Values represent means + the 
standard error of the mean of at least two independent assays performed with triplicate 
wells. ***, P < 0.001. 
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relative to the mutant strain without serum (1.72 % - Figure 4.5). This strongly suggested 
that the invasion inhibition effect observed by the incubation of anti-SipD serum with S. 
Enteritidis was SipD specific and that any interference with non-SPI-1 related 
components could be excluded. 
 
4.3.2 Invasion inhibition is SipD specific 
In order to demonstrate the specificity of anti-SipD serum, cellular fractions of 
whole cell lysates from S. Enteritidis wild type and a ∆sipD mutant strain were probed 
with pre-immune serum and anti-SipD serum. As expected, pre-immune serum did not 
detect the SipD protein in the lysates of both wild type and ∆sipD mutant strains, nor did 
it detect the recombinant SipD protein (Figure 4.6A). On the other hand, anti-SipD serum 
detected the SipD protein in the lysates of wild type S. Enteritidis (confirming our 
previous observation) but not in the corresponding fraction of a ∆sipD mutant strain 
(Figure 4.6B). To further prove the specificity of anti-SipD serum, the serum was 
depleted of SipD specific antibodies as described in materials and methods. The serum 
was no longer able to detect the SipD protein in the lysate of wild type S. Enteritidis or in 
the recombinant protein fraction (Figure 4.6C). This was confirmed by ELISA where the 
depleted serum had significantly lower SipD specific antibody titers relative to the 
untreated SipD serum (Fig 4.7A). Additionally, the SipD depleted sera was used in an 
invasion inhibition assay to determine if the invasion inhibition effect observed earlier 
was SipD specific. As anticipated, the depleted serum restored S. Enteritidis entry to 73.3 
% relative to the control (no sera) giving further evidence to support the notion that 
antibodies against the SipD protein block S. Enteritidis invasion in polarized Caco-2 cells 
(Fig 4.7B). 
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Figure 4.5: Anti-SipD serum mediated inhibition is SPI-1 specific. Caco-2 cells were 
infected with S. Enteritidis (wild type or ∆SPI-1) and were treated with no serum, pre-
immune serum, and individual serum against SipD. The efficiency of bacterial entry is 
expressed as a percentage of the invasion of the control group (no serum). Values 
represent means + the standard error of the mean of at least two independent assays 
performed with triplicate wells. ***, P < 0.001. 
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 Figure 4.6: Western blots of the cellular fraction from whole cell lysates of S. 
Enteritidis wild type and the mutant strain ∆sipD. (A) rabbit polyclonal pre-immune 
serum (Lane 1, prestained marker; lane 2, S. Enteritidis wild type cell lysate; lane 3, S. 
Enteritidis ∆sipD cell lysate; lane 4, purified recombinant His-tag SipD (38.5 kDa)), (B) 
anti-SipD serum, (C) anti-SipD depleted serum (Lane 1, purified recombinant His-tag 
SipD (38.5 kDa); lane 2, prestained marker; lane 3, S. Enteritidis wild type cell lysate; 
lane 4, S. Enteritidis ∆sipD cell lysate. Arrows with solid lines point to positions where 
the SipD protein has been detected, while arrows with dashed lines point to positions 
where a band representing SipD would be expected. Pre-immune serum and the SipD 
depleted serum did not detect SipD (37 kDa) in the whole cell lysate fraction of wild type 
S. Enteritidis (A, lane 2 and C, lane 3) or the recombinant protein (38.5 kDa) (A, lane 4 
and C, lane 1). Anti-SipD serum detected SipD in the cellular fractions of wild type S. 
Enteritidis (B, lane 3) but not in the corresponding fraction of the ∆sipD mutant strain (B, 
lane 4).  
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Figure 4.7: Depletion of SipD specific antibodies from anti-SipD serum restores S. 
Enteritidis invasion. (A) Mean IgG titers (means + the standard error of the mean) of 
pre-immune serum, anti-SipD serum, and SipD depleted anti-serum. (B) Caco-2 cells 
were infected with S. Enteritidis and were treated with no serum, anti-SipD or SipD 
depleted anti-serum. The efficiency of bacterial entry is expressed as a percentage of the 
invasion of the control group (no serum). Values represent means + the standard error of 
the mean of at least two independent assays performed with triplicate wells. **, P < 0.01. 
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4.4 Discussion 
 
S. Enteritidis SPI-1 plays a central role as one of the hallmarks in Salmonella 
pathogenesis [25]. This virulence associated system allows the bacterium to gain access 
to host tissues in systemic sites. At least five effector proteins (SipA, SipC, SopE, SopE2 
and SopB) that are secreted by this system are involved in this process, which leads to 
actin cytoskeletal reorganization, membrane ruffling and bacterial internalization. In 
addition, the SPI-1 system also contributes significantly to intestinal inflammatory 
responses. Effector proteins SopB, SopE and SopE2 activate Rho GTPases, which 
activate other pathways that eventually result in increased production of pro-
inflammatory cytokines such as IL-8, leading to an inflammatory response and diarrhoea 
[61]. Recently, it has been discovered that the SPI-1 system is not only important in 
intestinal disease, but also in systemic infection [86, 188]. Taken together, this clearly 
suggests that intervention strategies that interfere with the virulence properties of the SPI-
1 secretion system should be an effective tool in controlling S. Enteritidis infection. 
 
The aim of the present study was to evaluate the effect of antibodies against 
selected SPI-1 encoded T3SS proteins on S. Enteritidis invasion in polarized Caco-2 
cells. The rational behind this approach was the observation by us [188] and others [212, 
214] that S. enterica SPI-1 mutants have impaired invasion activity in vitro. Polarized 
Caco-2 cells were used since they are known to establish a well developed microvilli 
forming brush border that closely resembles the intestinal lumen [190]. This makes the 
use of this cell line relevant to the present study since the first major barrier encountered 
by S. Enteritidis and other enteric pathogens during host infection is the intestinal 
epithelial surface. As well, studies have demonstrated that the use of polarized cells 
reveal additional information with respect to invasion [196] and invasion inhibition [233], 
which may not be the case with non-polarized cells. For our invasion inhibition assays, 
initially, we used pooled sera to determine if sera against combinations of different SPI-1 
proteins had an effect on S. Enteritidis entry. This approach was adopted in order to 
screen different combinations of sera (effector proteins, translocon proteins and structural 
proteins). If a particular combination protected Caco-2 cells against S. Enteritidis 
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invasion, we would be able to test sera against individual proteins in that particular group 
to identify the key player in the process. Moreover, it is unlikely that serum against a 
particular SPI-1 protein would have an effect when tested individually, but not when 
tested with a combination of other proteins. 
 
Our data demonstrate for the first time that serum against the SPI-1 SipD protein 
protects Caco-2 cells against S. Enteritidis entry. This is a significant finding since we 
have identified a mechanism of blocking S. Enteritidis invasion by interfering with SPI-1 
T3SS mediated virulence in vitro. Our results are also in agreement with recent work that 
illustrates that the SipD protein is critical for attachment to non-phagocytic cells and is 
present on the tip of the SPI-1 needle prior to bacterial–host cell contact [38]. The fact 
that sera against total SPI-1 secreted proteins inhibited invasion was anticipated since we 
have previously shown, using western blot analysis, that SipD is secreted in the total SPI-
1 secreted protein fraction [188]. The absence of an effect on bacterial entry in the 
presence of sera against SipA, SopB, SopE and SopE2 was expected since the 
aforementioned proteins are secreted effector proteins whose function is intracellular 
after being injected into the host cytosol [75]. The observation that serum against SipC, 
although being part of the SPI-1 translocon, did not affect invasion can be explained by 
the recent finding which indicates that SipD is expressed prior to bacterial contact, while 
SipC is expressed only upon contact [38]. Hence, SipD might be easily accessible to 
antibodies relative to SipC. Moreover, it is possible that SipD plays a more pronounced 
role in attachment to epithelial cells compared to the latter. The fact that we did not 
observe an effect on S. Enteritidis entry in the presence of sera against PrgI and InvG was 
expected since these proteins have not been associated with attachment and bacterial 
entry. 
 
In order to confirm the specificity of the invasion inhibition effect observed in the 
presence of anti-SipD serum, we tested the effect of this serum on the invasion of a 
mutant strain lacking sipD. For this purpose, we used a ∆SPI-1 mutant strain since the 
sipD gene is encoded on SPI-1. Moreover, SPI-1 mutant strains are less invasive 
compared to the wild type strain, but still retain their ability to invade tissue culture cells 
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[195, 196, 206, 210, 215, 216]. As expected, the invasiveness of the mutant strain was not 
affected by the presence of anti-SipD serum. This suggested that the invasion inhibition 
effect observed was indeed SipD specific. Moreover, the SipD protein, as well as the 
other seven SPI-1 proteins used in this study were over-expressed and purified using the 
same procedure from an E. coli K-12 strain that does not have a T3SS. Therefore, it is 
highly unlikely that antibodies against a protein that co-purified with the SipD protein 
would cause inhibition of S. Enteritidis invasion. Further, the notion that antibodies 
against SipD affect S. Enteritidis entry in Caco-2 cells, is also supported by evidence 
from studies involving the analysis of T3SS tip proteins (BipD, IpaD and LcrV) in other 
bacterial pathogens which provide compelling evidence to suggest that the SipD protein 
is localized to the S. Enteritidis needle tip [234-236].  
 
To further investigate the specificity of the antibodies against SipD, we performed 
western blots using pre-immune and anti-SipD serum. Our results clearly indicate that 
pre-immune serum does not detect the SipD protein in the lysate from wild type S. 
Enteritidis or the recombinant protein, while SipD anti-serum detected the protein in the 
aforementioned fractions. This finding implies that the antibodies raised against SipD 
were highly specific to the protein. Furthermore, SipD specific antibodies were depleted 
from SipD anti-serum to enable us to investigate the invasion inhibition properties of the 
depleted serum. As expected, the depleted serum was unable to detect the SipD protein in 
the lysates of wild type S. Enteritidis or in the SipD recombinant protein fraction. 
However, SipD specific antibody titers were still present in this serum, but at 
significantly lower levels compared to the untreated serum. This is possible since it is 
difficult to completely deplete all the SipD specific antibodies. Likewise, when the 
depleted serum was used in an S. Enteritidis invasion inhibition assay, the rate of invasion 
was restored to approximately 73.3 % of the control group. The fact that the invasion rate 
did not return to 100 % can be explained by the low levels of SipD specific titers still 
present in the depleted serum fraction. Taken together, these experiments establish 
beyond reasonable doubt that the protection of epithelial cells from S. Enteritidis entry is 
mediated by SipD specific antibodies. 
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Tight junctions form important intercellular structures found in polarized 
epithelial cells [193]. Many bacterial pathogens, including Salmonella, disrupt these 
junctions to damage the integrity of the epithelial cell layer [217]. We used the TER as an 
indicator of cell monolayer health since it has been extensively used by others to evaluate 
the effect of bacterial pathogens on tight junctions [218, 219]. Our results from the 
invasion inhibition assays illustrate that incubation of anti-SipD with S. Enteritidis not 
only had a significant effect on bacterial entry, but also caused a lower reduction in TER 
relative to the group with no sera (data not shown). However, it is important to note that 
invasion does not always result in a reduction in the TER. This observation can be 
explained by the fact that bacterial invasion takes place very quickly, while the disruption 
of tight junctions are more noticeable after longer periods of infection [194]. The fact that 
sera against SipD would cause a lower reduction in TER relative to the control group 
(data not shown) is expected since SPI-1 effector proteins have been identified as major 
players in the disruption of tight junctions [190, 194]. 
 
In the present study, we used polyclonal IgG antibodies obtained from rabbits 
immunized with different SPI-1 T3SS proteins. Although, we were able to protect Caco-2 
cells from S. Enteritidis invasion, an IgA antibody response may be more desirable to 
prevent invasion at mucosal surfaces since this antibody isotype is resistant to 
degradation in the harsh protease-rich environment found in mucosal secretions [237]. As 
well, the levels of IgA antibodies in the intestinal environment are much higher than IgG 
antibodies, making the former antibody isotype a better candidate at blocking and 
interfering with S. Enteritidis interactions with host cells. Despite the advantages of 
having an IgA antibody response at mucosal surfaces, we cannot rule out the effect of 
IgG antibodies in preventing S. Enteritidis infection to systemic sites, since recent work 
suggests that SPI-1 may also contribute to systemic spread of this pathogen [86, 130, 
188]. In addition, to date, there is little evidence to suggest that IgA antibodies are 
required for the clearance of S. Enteritidis infection in different animal models [170]. 
 
The observation that sera against SipD blocks bacterial entry of S. Typhimurium 
in Caco-2 cells is not surprising, but is significant because both S. Typhimurium and S. 
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Enteritidis have a significant impact on human health and are most commonly associated 
with human infections. This finding is important in designing strategies to control 
infection by the two aforementioned serovars, since many intervention strategies that are 
commercially available do not confer protection against both serovars [170]. 
Consequently, our strategy of blocking invasion via antibodies against SipD does not 
have to be limited to these two serovars and may be extended to other host-specific and 
non-host specific S. enterica serovars. 
 
In summary, this work has illustrated for the first time that anti-SipD antibodies 
inhibit S. Enteritidis entry in polarized Caco-2 cells, while sera against other SPI-1 T3SS 
proteins do not. In addition, our results establish that the aforementioned invasion 
inhibition effect is SipD specific. This data is significant since it adds more support to 
recent work which indicates that the SPI-1 T3SS is involved in intimate attachment and 
forms the tip of the needle [38]. As well, from a therapeutic point of view, the SipD 
protein may be used for protection assays using in vivo models in future experiments. 
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5.0 IMMUNIZATION OF CHICKENS WITH SALMONELLA ENTERICA 
SEROVAR ENTERITIDIS PATHOGENICITY ISLAND-1 STRUCTURAL 
PROTEINS INDUCES STRONG HUMORAL RESPONSES AND CONFERS 
PROTECTION FROM SYSTEMIC INFECTION 
 
In preparation for publication. 
 
5.1 Introduction 
Infections by non-host adapted strains of Salmonella enterica typically cause 
gastrointestinal disease in animals [136]. Within this species, over 2500 serovars have 
been identified [5]. S. enterica serovar Enteritidis is one of the most frequently isolated 
serovars with respect to human infections worldwide [9]. This disease results in 
significant costs associated with health care and patient recovery. Normally, S. Enteritidis 
infection in humans manifests in gastroenteritis leading to diarrohea, abdominal cramps, 
vomiting and fever. The disease is self-limiting and usually clears within 2 to 7 days. In 
rare cases, the disease can become systemic (septicemia) requiring antibiotic treatment as 
well as hospitalization and may lead to the development of Reiter’s Syndrome, which is 
characterized by pain in the joints, irritation in the eyes and painful urination [12, 238]. 
Infected poultry meat and eggs are most frequently associated with human illness 
[239-242]. In Europe studies have revealed that approximately 23.7 % of commercial 
broiler flocks were positive for Salmonella species while 20.4 % of layer flocks were 
positive for either S. Enteritidis or Salmonella enterica serovar Typhimurium [160]. 
Similarly, a recent study examined twenty commercial broiler processing plants across 
the United States and found that Salmonella species were detected on 72.0 % of carcasses 
at the time of slaughter [243]. Chickens are highly susceptible to infection by S. 
Enteritidis in their first few weeks of life. This translates into intestinal colonization and 
may also lead to systemic infection. Older birds are less likely to get systemic infection, 
but do get colonized with Salmonella in the gastro-intestinal tract. Once chickens are 
colonized, they continue to shed the bacterium for long periods [131]. This can lead to 
carcass contamination by Salmonella at the time of slaughter, and subsequent transfer to 
the consumer via poultry products or directly through contaminated eggs, posing a 
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substantial threat to human health [160]. Consequently, efforts to reduce the prevalence 
of S. Enteritidis in chickens will ultimately reduce the incidence of human infections 
[241]. 
 
Vaccination, along with other intervention strategies, has been used to reduce the 
prevalence of S. Enteritidis in poultry flocks [170, 244, 245]. Three classes of vaccines 
exist: live attenuated, killed Salmonella and subunit vaccines [170].  Live attenuated 
strains contain mutations or deletions in genes that are important for metabolism, 
virulence or survival. They confer several advantages including the possibility of oral 
delivery, rapid protection, induction of both humoral and cell-mediated responses, and 
they can be administered to young chicks [170, 246, 247]. A major drawback of live 
attenuated strains is that they consist of a living organism that is being introduced into the 
field and it is possible that attenuated Salmonella strains may persist in chickens for 
prolonged periods resulting in their transmission to humans. Hence, there is a school of 
thought which considers killed Salmonella and sub-unit vaccines to be more favourable 
from a consumer safety perspective.  Several groups have demonstrated that killed 
vaccines induce significant humoral responses and reduce S. Enteritidis colonization and 
egg contamination in chickens [170]. However, the protective antigens in these vaccine 
formulations are not well defined. Thus, with the continued prevalence of S. Enteritidis, 
there is still a need for improved vaccines that are well defined and capable of inducing 
significant protection in chickens. 
 
During the process of infection, S. Enteritidis uses two specialized nanomachines 
(T3SS) encoded by SPI-1 and SPI-2, respectively, to inject virulence factors directly into 
host cells [24]. The SPI-1 secretion system is an important virulence determinant that is 
mainly associated with breaching the intestinal epithelial surface [25, 26]. The major 
components of this system that are exposed on the bacterial surface include PrgI (a low-
molecular weight protein forming the needle) and the SipB, SipC and SipD proteins 
(constituting the translocon in the host cell membrane) [24]. Recently, it has been 
demonstrated that SipD also forms the tip of the SPI-1 T3SS needle and is involved in 
attachment to epithelial cells in vitro [38]. Therefore, SipD, along with the 
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aforementioned T3SS structures represent key targets for vaccination. Previously, it was 
found by other groups and by us that the SPI-1 secretion system is an important virulence 
factor in chickens [87-89, 130, 188]. In addition, work from our lab has recently 
demonstrated that antibodies against the tip of the SPI-1 secretion machinery (SipD) 
block invasion of polarized Caco-2 cells by S. Enteritidis (unpublished data). Taken 
together, this strongly suggests that the SPI-1 secretion apparatus may be an important 
target for therapeutic measures aimed at inhibiting virulence properties of this system. 
 
The aim of the present study was to evaluate the efficacy of S. Enteritidis SPI-1 
T3SS proteins in protection against bacterial challenge in layers using an oral challenge 
model as well as via maternal antibody transfer in progeny derived from vaccinated hens 
using both an oral challenge and seeder model of infection. We show for the first time 
that proteins encoded by SPI-1 are immunogenic in chickens and confer significant 
protection against S. Enteritidis colonization of the livers, but not ceca of vaccinates. 
 
5.2 Materials and Methods 
 
5.2.1 Bacterial strains 
S. Enteritidis isolate Sal 18 wild type [188] was used for experimental challenge 
in vaccine trial 1, while S. Enteritidis isolate Sal 8 wild type [131] was used for 
experimental challenge in vaccine trails 2 and 3. The strains were grown in Luria-Bertani 
(LB) broth at 37° C using an orbital shaker (250 rpm) to an OD600 of 0.7. 
 
5.2.2 Protein expression and purification 
The S. Enteritidis SPI-1 genes, invG, prgI, sipC, sipD and sopB (encoding 
structural components and effector proteins) were amplified by PCR (Applied 
Biosystems) and cloned into either pQE-30 (Qiagen) or pET-15b (Novagen) His-tag 
expression vectors (unpublished data). The constructs were verified by PCR and 
sequencing (Plant Biotechnology Institute, Saskatoon). The corresponding proteins were 
expressed and purified using nickel charged resins (Qiagen) following standard 
procedures. 
 95
5.2.3 Vaccination of chickens 
Specific pathogen free (SPF) eggs were obtained from Charles River Laboratories 
(USA) and incubated at the Department of Poultry Science (University of Saskatchewan). 
After hatch, the chicks were screened by plating fecal swabs on Brilliant Green Agar 
(BGA) to ensure that they were Salmonella free. Subsequently, the chicks were used for 
vaccine trial 1. 
 
Vaccine Trial 1 
Newly hatched chicks were randomly divided into two groups (30 birds per 
group) and vaccinated subcutaneously at days 14 and 28 of age with either phosphate 
buffered saline (PBS) or PrgI + SipD. The concentration of each protein per dose was 50 
µg and each vaccine group was formulated with 30 % Emulsigen® D. The birds were 
orally challenged with 0.5 ml (1010 CFU) of S. Enteritidis at 35 days of age. Ten birds per 
group were euthanized on days 1, 2 and 4 after challenge. The liver, spleen and cecal 
contents were sampled and homogenized in saline (0.85 % sodium chloride). Serial 
dilutions were plated on BGA to determine the levels of S. Enteritidis. In addition, liver 
and spleen homogenates were incubated in selenite broth overnight at 37°C for 
enrichment. Enriched samples were plated on BGA to determine the number of samples 
that were positive for Salmonella species. Sera were collected for antibody titer 
determination at 28 days of age (pre-boost) and after euthanizing the birds (1, 2 and 4 
days postchallenge). The experimental design is summarized in Figure 5.1. 
 
5.2.4 Immunization of laying hens 
Leghorn chickens were obtained and housed at the Department of Poultry Science 
(University of Saskatchewan). The hens were screened using fecal swabs by plating on 
BGA to ensure that they were Salmonella free. Subsequently, the hens were used for 
vaccine trials 2 and 3. 
 
Vaccine Trial 2 – seeder challenge model 
Laying hens were randomly divided into three groups (12 birds each) and 
vaccinated subcutaneously with 0.5 ml of either PBS, AviPro® 109 SE4 (positive control 
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Obtain SPF eggs and incubate until hatch
Day 0 – screen for the presence of Salmonella
Day 14 – Vaccinate chickens subcutaneously
Day 28 – Vaccinate chickens subcutaneously
Day 35 – Orally challenge with 1010 CFU S. Enteritidis
Collect sera for ELISA
Day 36, 37, 39 – Euthanize chickens and obtain
samples of the liver, spleen and cecal contents
Determine levels of S. Enteritidis by plating
Figure 5.1: Experimental Design for Vaccine Trial 1. 
 97
- L.A.H.I.) or PrgI + InvG + SipC + SipD + SopB (20 µg of each protein) on day 0, 
followed by two boosts on days 21 and 42 (all vaccines were formulated with 30% 
Emulsigen® D, except AviPro®). Sera were collected from the hens on days 0, 21, 42, and 
63 for measuring antibody titers. Subsequently, the hens were artificially inseminated and 
eggs were collected on days 64, 65 and 71 for determining antibody titers as described 
below. Three batches of 50 eggs from each group (experiments I, II and III) were set for 
incubation until hatch at the Department of Poultry Science. For experiments I, II and III, 
we used a seeder model of infection as described elsewhere [248, 249]. In experiment I, 
after hatch, the progeny were transferred to isolation rooms at VIDO and approximately 
70 % of the chicks per group (seeder birds) were orally challenged with 0.5 ml (108 CFU) 
of S. Enteritidis at 1 day of age, while the other chicks were allowed to co-mingle with 
the rest of the flock (contact birds). Fifty percent of the seeder and contact chicks per 
group were euthanized on days 2 and 3 postchallenge. Samples from the chicks were 
collected and processed as described for vaccine trial 1. Similarly, in experiment II, after 
hatch, approximately 60 % of the chicks per group (seeder birds) were orally challenged 
with 0.5 ml (108 CFU) of S. Enteritidis at 1 day of age, while the remaining chicks were 
allowed to commingle with the rest (contact birds). Fifty percent of the chicks per group 
(seeder and contact birds) were euthanized on days 2 and 3 postchallenge and samples 
were collected and processed as described for vaccine trial 1. In experiment III, after 
hatch, ten percent of the progeny per group (seeder birds) were orally inoculated with 0.5 
ml (108 CFU) of S. Enteritidis at 1 day of age, while the remaining chicks were allowed 
to commingle with the rest (contact birds). Fifty percent of the chicks per group (seeder 
and contact birds) were euthanized on days 2 and 3 postchallenge and samples were 
collected and processed as described for vaccine trial 1. The experimental design is 
summarized in Figure 5.2. 
 
Vaccine Trial 3 – oral challenge model 
Six adult immunized leghorn chickens from each group in vaccine trial 2 were 
transferred to the VIDO animal care facility and were orally challenged with 0.5 ml (108 
CFU) of S. Enteritidis. The hens were euthanized 2 days postchallenge and samples were 
collected and processed as described above. 
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Day 0, 21, 42 – Immunize hens subcutaneously
Day 63 – Collect sera Use sera for ELISA
Days 64, 65, 71 – Collect eggs &
determine antibody titers in egg yolks
Day 71
Day 84
Day 113
Day 118 – Orally challenge hens
Experiment I
Experiment II
Experiment III
Set eggs for hatch
Set eggs for hatch
Set eggs for hatch
Orally challenge day-old chicks
70%
60%
10%
 
Figure 5.2: Experimental design for Vaccine Trials 2 and 3. 
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5.2.5 Antibody isolation from chicken egg yolks 
One ml of chicken egg yolk was mixed with 4 ml of acidified ddH2O (pH 2.5) in a 
14 ml tube (BD Falcon™). The mixture was incubated on a nutator for 15 minutes at 
room temperature. The tubes were transferred to a freezer (-20° C) for two days and then 
allowed to thaw at room temperature. Thereafter, the tubes were centrifuged at 3500 xg 
for 30 minutes at 4° C to precipitate the lipoproteins. The supernatant was collected and 
used for antibody titer determination using ELISA.  
 
5.2.6 ELISA 
Immulon® 2HB plates were coated with 100 ng of antigen per well in coating 
buffer (12.5 mM Na2CO3 and 37.5 mM NaHCO3) and incubated overnight at 4° C. The 
plates were washed three times with double distilled water (ddH2O) and blocked with 100 
µl of Borate Buffered Saline - BBS  (0.17 M H3BO3, 0.12 M NaCl, 0.05 % Tween 20, 1 
mM EDTA and 0.25 % BSA) for 30 minutes at room temperature. The plates were 
washed three times with ddH2O and chicken sera was added to the first set of wells 
(1:33). This was serially diluted for 4 fold dilutions down the plate. The sera were 
incubated for 30 minutes at room temperature after which the plates were washed three 
times with ddH2O. The plates were blocked with 50 µl of BBS for 10 minutes at room 
temperature and washed with ddH2O three times. Thereafter, 50 µl of horse radish 
peroxidase labeled goat anti-chicken IgG (KPL) at a concentration of 1:100 was added to 
each well and the plates were incubated for 30 minutes at room temperature. The plates 
were washed (3x) with ddH2O and 75 µl of the ABTS peroxidase substrate (KPL) was 
added to each well and incubated for 30 minutes at room temperature. The reaction was 
stopped by adding 75 µl peroxidase stop solution (1:5 in ddH2O - KPL) per well. The 
absorbances were read at a wavelength of 405 nm (490 nm as the reference). 
 
5.2.7 Statistical analysis 
Statistical analysis was performed by using GraphPad Prism 5.0. A nonparametric 
analysis using the Kruskal-Wallis test was used to analyze the recovery of S. Enteritidis 
from the cecal contents, livers and spleens based on direct plating. The different groups 
were compared using Dunn’s multiple comparison test. Data from the enrichment of the 
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liver and spleen samples were analyzed by using the chi-squared test. The Fishers exact 
test was used to compare the different groups. For antibody titer determinations (ELISA) 
the cut-off value was considered to be the average of the blank and two standard 
deviations. Antibody titers were analyzed using a nonparametric analysis (Kruskal-Wallis 
test) and individual groups were tested using Dunn’s multiple comparison test. A P value 
of < 0.05 was considered significant. 
 
5.3 Results 
 
5.3.1 Vaccine Trial 1 
Vaccination of chickens with PrgI (major SPI-1 needle component) and SipD 
(needle-tip) did not affect the levels of S. Enteritidis in the cecal contents relative to the 
control over the duration of the experiment (Figure 5.3). The levels of S. Enteritidis in the 
livers of the vaccinated group were lower on days three and four after challenge relative 
to the control, with a statistically significant difference (P < 0.001) on the fourth day 
postchallenge based on direct plating (Figure 5.4A). A similar trend was evident in the 
spleens of the vaccinated group two days postchallenge (Figure 5.4B). On the other hand, 
data from enriched samples of the livers and spleens revealed that the number of chickens 
positive for Salmonella species was similar in the vaccinated and control groups on all 
three days post challenge (Figure 5.5). This indicated that vaccination with the SPI-1 
proteins, PrgI and SipD, decreased the bacterial load in internal organs, but not the 
number of birds positive for Salmonella. Additionally, immunization with the 
aforementioned proteins induced significantly higher antibody titers relative to the 
control group (Figure 5.6). 
 
5.3.2 Vaccine Trial 2 
The SPI-1 proteins InvG, PrgI, SipC, SipD and SopB (SPI-1 needle base, needle, 
translocon component, needle tip and effector protein, respectively) were tested for their 
ability to protect against S. Enteritidis challenge via maternal antibodies using a chicken 
seeder model. Immunization of hens with the aforementioned proteins, followed by two 
booster injections, revealed that the SPI-1 proteins induced a significant antibody  
 101
100
102
104
106
108
1010
PBS
PrgI + SipD
Day 1 Day 2 Day 4
C
FU
 / 
g
 
Figure 5.3: Vaccine Trial 1. Levels of S. Enteritidis expressed as median colony 
forming units per gram (CFU / g) in the cecal contents on days 1, 2 and 4 postchallenge 
(1010 CFU) in chickens vaccinated subcutaneously with either PBS or PrgI + SipD. 
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Figure 5.4: Vaccine Trial 1. Levels of S. Enteritidis expressed as median colony 
forming units per gram (CFU / g) in the livers (A) and spleens (B) on days 1, 2 and 4 
postchallenge (1010 CFU) in chickens vaccinated subcutaneously with either PBS or PrgI 
+ SipD. ***, P < 0.001. 
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Figure 5.5: Vaccine Trial 1. The number of birds positive for Salmonella after 
enrichment of liver and spleen homogenates (chickens that were positive for Salmonella 
in either liver or spleen were considered as birds positive for Salmonella). 
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Figure 5.6: Vaccine Trial 1. Median levels of IgG antibody titers specific for PrgI 
and SipD in sera obtained from chickens vaccinated subcutaneously with either PBS 
or PrgI + SipD. The chickens were vaccinated twice (14 and 28 days of age) and orally 
challenged with 1010 CFU of S. Enteritidis at 35 days of age. **, P < 0.01; ***, P < 
0.001. 
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response compared to the PBS vaccinated group (Figure 5.7) as in vaccine trial 1. This 
observation was also true for sera obtained from hens vaccinated with our positive 
control, AviPro® (Figure 5.8). 
 
In experiment I, 70% of the chicks were orally challenged with S. Enteritidis 
(seeder birds) in each group, while the remaining chicks were allowed to commingle 
(contact exposed birds). No difference was evident in the levels of S. Enteritidis in the 
cecal contents of both the seeder and contact exposed chicks obtained from the 
vaccinated group (SPI-1 proteins) relative to the control groups (Figures 5.9A and 5.9B). 
On day two postchallenge, the median value of S. Enteritidis in the livers, based on direct 
plating, was lower (though not statistically significant) in the progeny (contact exposed 
birds) that were obtained from the AviPro® (positive control) vaccinates relative to the 
progeny from the PBS group (Figure 5.10B). In the same way, lower levels of bacteria 
were observed in the spleens of the progeny from the AviPro® vaccinated group in both 
seeder and contact exposed chicks compared to the control group over the duration of the 
experiment (Figures 5.11A and 5.11B). However, immunization of the parent flock with 
the SPI-1 proteins did not reduce levels of challenge strain in the samples obtained from 
the progeny (seeder and contact birds). 
In experiment II, 60 % of the chicks were orally challenged (seeder birds), while 
the remaining chicks were allowed to commingle (contact exposed birds). As in 
experiment I, the levels of Salmonella in the cecal contents of the progeny from the SPI-1 
vaccinated group were comparable to the levels in the progeny from the AviPro® and 
PBS vaccinated groups (Figures 5.12A and 5.12B). The recovery of S. Enteritidis from 
the livers and spleens of chicks (contact exposed group) obtained from hens vaccinated 
with AviPro® was significantly lower on day two postchallenge in the liver and on both 
days postchallenge in the spleen (Figures 5.13B and 5.14B). This observation did not 
hold true for the livers and spleens of chicks that were experimentally challenged by oral 
inoculation (seeder birds) in all the groups (Figures 5.13A and 5.14A). Likewise, 
vaccination of hens with SPI-1 proteins did not translate into a reduction of the levels of 
S. Enteritidis in the internal organs of their progeny (both seeder and contact exposed 
birds). 
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Figure 5.7: Median IgG antibody titers specific for SPI-1 T3SS proteins in sera and 
egg yolks obtained from laying hens vaccinated subcutaneously on days 0, 21 and 42 
with either PBS or SPI-1 T3SS proteins. Sera were collected from the hens on days 0, 
21, 42 and 63 for measuring IgG levels. IgG titers were also measured from egg yolks 
that were extracted from eggs collected on days 64, 65 and 71. **, P < 0.01; ***, P < 
0.001. 
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Figure 5.8: Median IgG antibody titers specific for AviPro® in sera and egg yolks 
obtained from laying hens vaccinated subcutaneously on days 0, 21 and 42 with 
either PBS or AviPro®. Sera were collected from the hens on days 0, 21, 42 and 63 for 
measuring IgG levels. IgG titers were also measured from egg yolks that were extracted 
from eggs collected on days 64, 65 and 71.*, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Figure 5.9: Vaccine Trial 2, Experiment I. Levels of S. Enteritidis in the cecal 
contents of progeny obtained from vaccinated hens. Hens were vaccinated 
subcutaneously with either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS 
proteins (closed triangles) where 70 % of the seeder birds were orally inoculated with the 
challenge strain. Values are expressed as median colony forming units per gram (CFU / 
g). Bacterial levels in the cecal contents of seeder (A) and contact exposed (B) birds on 
days 2 and 3 postchallenge (108 CFU). 
 109
 PB
S
Av
iPr
o
SP
I-1 PB
S
Av
iPr
o
SP
I-1
100
101
102
103
104
105
106
107
Day 2 Day 3
A
C
FU
 / 
g
PB
S
Av
iPr
o
SP
I-1 PB
S
Av
iPr
o
SP
I-1
100
101
102
103
104
105
106
107
Day 2 Day 3
B
C
FU
 / 
g
 
Figure 5.10: Vaccine Trial 2, Experiment I. Levels of S. Enteritidis in the livers of 
progeny obtained from vaccinated hens. Hens were vaccinated subcutaneously with 
either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS proteins (closed 
triangles) where 70 % of the seeder birds were orally inoculated with the challenge strain. 
Values are expressed as median colony forming units per gram (CFU / g). Bacterial 
levels in the livers of seeder (A) and contact exposed (B) birds on days 2 and 3 
postchallenge (108 CFU). 
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Figure 5.11: Vaccine Trial 2, Experiment I. Levels of S. Enteritidis in the spleens of 
progeny obtained from vaccinated hens. Hens were vaccinated subcutaneously with 
either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS proteins (closed 
triangles) where 70 % of the seeder birds were orally inoculated with the challenge strain. 
Values are expressed as median colony forming units per gram (CFU / g). Bacterial 
levels in the spleens of seeder (A) and contact exposed (B) birds on days 2 and 3 
postchallenge (108 CFU). 
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Figure 5.12: Vaccine Trial 2, Experiment II. Levels of S. Enteritidis in the cecal 
contents of progeny obtained from vaccinated hens. Hens were vaccinated 
subcutaneously with either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS 
proteins (closed triangles) where 70 % of the seeder birds were orally inoculated with the 
challenge strain. Values are expressed as median colony forming units per gram (CFU / 
g). Bacterial levels in the cecal contents of seeder (A) and contact exposed (B) birds on 
days 2 and 3 postchallenge (108 CFU). 
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Figure 5.13: Vaccine Trial 2, Experiment II. Levels of S. Enteritidis in the livers of 
progeny obtained from vaccinated hens. Hens were vaccinated subcutaneously with 
either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS proteins (closed 
triangles) where 60 % of the seeder birds were orally inoculated with the challenge strain. 
Values are expressed as median colony forming units per gram (CFU / g). Bacterial 
levels in the livers of seeder (A) and contact exposed (B) birds on days 2 and 3 
postchallenge (108 CFU). **, P < 0.01. 
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Figure 5.14: Vaccine Trial 2, Experiment II. Levels of S. Enteritidis in the spleens of 
progeny obtained from vaccinated hens. Hens were vaccinated subcutaneously with 
either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS proteins (closed 
triangles) where 60 % of the seeder birds were orally inoculated with the challenge strain. 
Values are expressed as median colony forming units per gram (CFU / g). Bacterial 
levels in the spleens of seeder (A) and contact exposed (B) birds on days 2 and 3 
postchallenge (108 CFU). ***, P < 0.001. 
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In an effort to better simulate natural infection, in experiment III, only 10 % of the 
chicks (seeder birds) obtained from the hens were orally challenged while the remaining 
90 % were allowed to commingle with the rest of the flock (contact exposed birds). Like 
experiments I and II, the levels of cecal colonization were not affected as a result of 
vaccination with SPI-1 proteins (Figures 5.15A and 5.15B). Interestingly, the colony 
counts in the liver homogenates of the progeny (contact exposed group) from the SPI-1 
vaccinated hens were significantly lower (P < 0.05) than the progeny from the PBS 
vaccinated group two days after bacterial challenge (Figure 5.16B). Liver bacterial 
colony counts were also arithmetically lower (no statistical difference) in the chicks 
(contact exposed group) obtained from the AviPro® vaccinated group two days 
postchallenge. As well, the recovery of the challenge strain from the spleen homogenates 
was lower in the chicks (contact exposed group) obtained from the AviPro® vaccinated 
group on both days postchallenge (Figure 5.17B), but not from the chicks (seeder and 
contact exposed groups) obtained from the SPI-1 vaccinated hens.  
 
5.3.3 Vaccine Trial 3 
To determine if SPI-1 proteins can protect older hens against S. Enteritidis 
challenge, we orally challenged the hens that were immunized in vaccine trial 2. The 
levels of the challenge strain in the cecal contents were significantly lower (P < 0.05) in 
the AviPro® but not the SPI-1 vaccinated groups relative to the control (Figure 5.18). 
However, the recovery of Salmonella from the internal organ homogenates as a result of 
direct plating was mostly below the detection limit (Figures 5.19A and 5.19B). Data from 
the enrichment of the aforementioned homogenates was difficult to interpret since most 
of the birds were negative for Salmonella species (data not shown). In addition, the 
recovery of Salmonella from the homogenates of ovaries obtained from immunized hens 
was negative based on direct plating and enrichment (data not shown). Likewise, we were 
not able to detect Salmonella in the blood samples obtained from these hens after 
enrichment (data not shown). 
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Figure 5.15: Vaccine Trial 2, Experiment III. Levels of S. Enteritidis in the cecal 
contents of progeny obtained from vaccinated hens. Hens were vaccinated 
subcutaneously with either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS 
proteins (closed triangles) where 10 % of the seeder birds were orally inoculated with the 
challenge strain. Values are expressed as either mean (A) or median (B) colony forming 
units per gram (CFU / g). Bacterial levels in the cecal contents of seeder (A) and contact 
exposed (B) birds on days 2 and 3 postchallenge (108 CFU). 
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Figure 5.16: Vaccine Trial 2, Experiment III. Levels of S. Enteritidis in the livers of 
progeny obtained from vaccinated hens. Hens were vaccinated subcutaneously with 
either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS proteins (closed 
triangles) where 10 % of the seeder birds were orally inoculated with the challenge strain. 
Values are expressed as either mean (A) or median (B) colony forming units per gram 
(CFU / g). Bacterial levels in the livers of seeder (A) and contact exposed (B) birds on 
days 2 and 3 postchallenge (108 CFU). *, P < 0.05. 
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Figure 5.17: Vaccine Trial 2, Experiment III. Levels of S. Enteritidis in the spleens 
of progeny obtained from vaccinated hens. Hens were vaccinated subcutaneously with 
either PBS (open circles), AviPro® (closed squares) or SPI-1 T3SS proteins (closed 
triangles) where 10 % of the seeder birds were orally inoculated with the challenge strain. 
Values are expressed as either mean (A) or median (B) colony forming units per gram 
(CFU / g). Bacterial levels in the spleens of seeder (A) and contact exposed (B) birds on 
days 2 and 3 postchallenge (108 CFU). ***, P < 0.001. 
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Figure 5.18: Vaccine Trial 3. Median levels of S. Enteritidis expressed as colony 
forming units per gram (CFU / g) in the cecal contents two days following oral challenge 
(108 CFU) in hens vaccinated subcutaneously with either PBS, SPI-1 T3SS proteins or 
AviPro®. *, P < 0.05. 
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Figure 5.19: Vaccine Trial 3. Median levels of S. Enteritidis expressed as colony 
forming units per gram (CFU / g) in the livers (A) and spleens (B) two days following 
oral challenge (108 CFU) in hens vaccinated subcutaneously with either PBS, SPI-1 T3SS 
proteins or AviPro®. *, P < 0.05. 
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5.4 Discussion 
 
Salmonella Pathogenicity Island 1 has been established as a major virulence 
determinant in Salmonella pathogenesis. Several studies have shown that SPI-1 is 
important during the process of infection in chickens [87, 89, 90, 130]. We have also 
recently shown that SPI-1 enhances invasion in chicken small intestinal and cecal tissue 
explants and its absence causes a delay in systemic infection in chickens [188]. Not only 
has the SPI-1 encoded secretion system been associated with virulence in chickens, it has 
also been implicated in pathogenesis in the bovine, murine and porcine models of 
infection [127, 195, 200, 201, 208]. Moreover, recent in vitro work suggests that the SPI-
1 T3SS mediates intimate attachment to epithelial cells [38] and that antibodies directed 
against this system block S. Enteritidis entry into polarized Caco-2 cells (unpublished 
data). Taken together, this strongly indicates that the aforementioned secretion system is 
an important therapeutic target to control infection by this pathogen. Hence, the goal of 
this work was to test the potential of SPI-1 proteins as vaccine candidates against S. 
Enteritids challenge in chickens. 
 
To our knowledge, prior to this work, only one study was performed in pigs to 
evaluate the efficacy of proteins secreted by the SPI-1 T3SS as vaccine targets [250]. The 
authors of that study used crude extracts of total SPI-1 secreted proteins to vaccinate pigs 
and found that the recovery of S. Typhimurium from intestinal contents was lower in the 
ileum and colon of vaccinates, but not in the intestinal lymph nodes and mucosa. 
However, they found that the group vaccinated with a prgH mutant (SPI-1 secretion 
defective) also had lower levels in the intestinal contents, suggesting that the protection 
observed was not SPI-1 specific. The fact that the vaccine based on secreted proteins 
from the wild type strain did not confer protection is not surprising since the SPI-1 
effector proteins are injected directly into the host cell cytosol [24]. Consequently 
antibodies directed against these effector proteins may not be protective against S. 
Typhimurium challenge. 
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In the present study, we used structural proteins of the SPI-1 secretion system as 
vaccine candidates, since these proteins are present on the surface of the bacterial cell and 
hence may be more “visible” to the host immune system relative to the effector proteins, 
which are secreted into host cells. PrgI and SipD were used for vaccine trial 1, since they 
form part of the SPI-1 encoded secretion apparatus that is exposed on the surface of the 
bacterial cell [24]. Further, recent in vitro experiments have suggested that the tip of the 
SPI-1 secretion system, SipD, is a critical player in infection of epithelial cells 
(unpublished data) [38]. In vaccine trial 1, we demonstrated for the first time, that 
vaccination of chickens with PrgI and SipD significantly reduced levels of the challenge 
strain in the livers of the vaccinated group, while a similar trend, though not statistically 
significant, was observed in the spleens of the birds. The reduction in the levels of S. 
Enteritidis in the livers of chickens vaccinated with PrgI and SipD was about 1000 fold 
relative to the control groups. This is comparable with data from other vaccine efficacy 
studies where a similar reduction was observed after challenge with either S. Enteritidis 
or S. Typhimurium  [175, 249, 251]. In addition, both PrgI and SipD induced strong IgG 
titers. The fact that we observed lower levels of S. Enteritidis in the internal organs based 
on direct plating and not from enrichment indicates that immunization with the SPI-1 
proteins reduced the bacterial load in the vaccinates but did not affect the number of birds 
positive for Salmonella. 
 
In order to further test the protective effect of SPI-1 antigens, we immunized hens 
with a combination of SPI-1 proteins and challenged their progeny (vaccine trial 2) with 
S. Enteritidis. We used a seeder model of infection because this model comes closer to 
natural infection compared to a high oral challenge dose and is well established [248, 
249]. Three independent batches of progeny were tested where we challenged 70 % 
(experiment I), 60 % (experiment II) or 10 % (experiment III) of the chicks in each group 
(seeder birds), respectively. Our results demonstrate that vaccination with SPI-1 proteins 
or AviPro® (positive control) resulted in significant antibody titers in both sera from the 
hens and egg yolks, but did not have a major effect on the levels of the challenge strain in 
the progeny (seeder birds). This is not surprising since these birds were orally inoculated 
with 108 CFU of S. Enteritidis and this is a high dose for day old chicks. However, lower 
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numbers (P < 0.05) of S. Enteritidis were observed in the livers of progeny immunized 
with SPI-1 proteins on day two postchallenge in experiment III, but not in the other 
samples nor in experiments I and II. A possible hypothesis for this finding could be that 
SPI-1 may not play a major role in S. Enteritidis virulence in day old chicks. This notion 
is supported by the observation in a study where S. Typhimurium SPI-1 mutants were not 
impaired in the colonization of chicken ceca or in systemic infection of day old chicks 
[89]. Alternatively, the antibody titers to the SPI-1 antigens may not be high enough in 
the progeny from the vaccinated hens to induce protection as in vaccine trial 1. The fact 
that the levels of bacteria in the cecal contents of progeny from SPI-1 vaccinates were 
similar to the levels in the control group is in line with our previous observations where 
we demonstrated that deletion of SPI-1 does not affect cecal colonization [188]. The 
groups vaccinated with AviPro® in experiments II and III had significantly lower levels 
of the challenge strain in the internal organs, suggesting that progeny from immunized 
hens can be protected using a seeder model of infection. Similarly, oral challenge of the 
immunized hens (vaccine trial 3) resulted in lower levels of S. Enteritidis in the cecal 
contents of the AviPro® vaccinated group, but not the SPI-1 vaccinated group. However, 
data from the livers and spleens of all the hens, based on both direct plating and 
enrichment, was difficult to interpret since most of the birds were negative for 
Salmonella. This is not unusual since these birds are much older and are known to be 
more resistant to infection by S. Enteritidis. Taken together, this suggests that SPI-1 
antigens play a minor role in protection against systemic disease via passive immunity 
based on our vaccine formulation and route of vaccine delivery. 
 
The use of T3SS as targets for intervention strategies has also been used in other 
Gram negative pathogens including, Escherichia coli, Yersinia species, Shigella species 
and Pseudomonas species [252]. Antibodies against the major T3SS components of the 
aforementioned pathogens have shown to inhibit their virulence associated functions in 
vitro [231, 253, 254]. As well, vaccination with T3SS proteins of these pathogens has 
also resulted in protection from bacterial challenge in different animal models, including 
mice, rabbits, guinea pigs and cattle [255-258]. Additionally, this strategy of targeting 
T3SS has led to the development of a commercially available vaccine (Econiche™) that 
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protects cattle against E. coli O157:H7 infection [258, 259], which is the first licensed 
vaccine based on T3SS. Although S. Enteritidis employs a different strategy for causing 
infection compared to E. coli and the other pathogens mentioned above, the SPI-1 T3SS 
is an important virulence factor during Salmonella pathogenesis in chickens as well as 
other animal models of infection [188, 195, 197, 200]. Therefore, the Salmonella T3SS 
proteins represent good vaccine candidates for immunization of chickens. 
 
The protection of chickens from S. Enteritidis systemic infection observed in this 
study is mainly based on IgG antibody titers to the SPI-1 T3SS proteins in the sera of 
vaccinated birds. Since Salmonella is an intracellular pathogen, it would be expected that 
a cell-mediated response is critical for clearance of infection. Based on studies in mice, 
the prevailing view is that cell-mediated immunity is a critical component of the host 
response to Salmonella infection relative to the humoral response [170, 260]. However, 
mice lacking B cells are able to clear infection of attenuated Salmonella strains but not of 
virulent strains. This clearly demonstrates that antibodies are important in the immune 
response to Salmonella [261, 262]. In chickens, the role of cell-mediated immunity is not 
as well defined, since fewer immunological tools are available. However, Salmonella 
infections have always been associated with high antibody titers in the sera (IgG) as well 
as in the intestinal mucosa (IgA) [156]. Similarly, infections by non-host adapted 
Salmonella strains have also been associated with up-regulation of T cells and IFNγ 
levels in chickens, suggesting that cellular immunity also plays a role [147, 155]. As in 
mice, B cell depleted chickens also possess the ability to effectively clear Salmonella 
infections [158]. Nevertheless, the role of antibodies has not been excluded [156]. 
Further, several killed Salmonella vaccines are currently in use, which mainly induce an 
antibody response and confer protection against oral Salmonella challenge [170]. Hence, 
the humoral response alone may not eliminate Salmonella species, but can significantly 
reduce the levels of Salmonella species in chickens which will ultimately improve human 
health. 
 
In summary, we have shown for the first time that immunization of chickens with 
SPI-1 structural proteins results in high antibody titers and confers protection against S. 
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Enteritidis systemic infection. Our data also suggest that the SPI-1 based vaccine did not 
have a significant effect on the levels of Salmonella in the progeny from vaccinated hens 
using a seeder model of infection. Thus, PrgI and SipD may form important components 
of subunit vaccines that are used for reducing the prevalence of S. Enteritidis in poultry 
flocks. Further work needs to be done to investigate the protective capacity of the SPI-1 
antigens possibly via mucosal delivery and in combination with different vaccine 
adjuvants. 
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6.0 GENERAL DISCUSSION AND CONCLUSIONS 
 
6.1 General Discussion 
 
S. Enteritidis continues to be a major source of human Salmonella infections 
worldwide [9]. This is largely the result of the consumption of contaminated poultry meat 
and eggs [10]. Therefore, reducing the levels of S. Enteritidis in chickens is a critical 
component of a given Salmonella control program [160]. Vaccination, along with other 
intervention strategies, has proven to be an effective tool in lowering the levels of S. 
Enteritidis in chickens in the U.K., which has consequently reduced the rates of human S. 
Enteritidis infections [10]. However, the vaccines currently available have not always 
been consistent in reducing the levels of S. Enteritidis. In addition, the vaccines consist of 
either live attenuated strains which have safety concerns associated with them or are 
killed Salmonella strains whose protective antigens are not well defined. As well, few 
vaccines provide cross protection against the different Salmonella enterica serovars. 
Hence, there is still a need for vaccines that are safe, efficacious and well defined [170]. 
 
Many studies have shown that the SPI-1 T3SS is an important virulence 
determinant during S. enterica pathogenesis [86, 127, 128, 208]. However, this has been 
observed mainly in the mouse and bovine models of infection with S. Typhimurium. In 
chickens, the role of SPI-1 has not been well studied. Therefore, we hypothesized that the 
SPI-1 T3SS is important for virulence in chickens and that proteins associated with this 
system could be used as vaccine candidates to protect chickens against S. Enteritidis oral 
challenge. 
 
In order to study the role of SPI-1 in invasion, we constructed ∆SPI-1 and ∆invG 
mutants. The mutants were impaired in the secretion of effector proteins, as determined 
by Western blots using anti-SipD serum. To investigate the invasive properties of these 
mutants, we used polarized Caco-2 cells. The use of polarized cells was very useful since 
these cells form well defined apical and baso-lateral compartments that closely mimic the 
actual intestinal epithelial layer [190]. Data from the gentamicin protection assays 
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indicated that both ∆SPI-1 and ∆invG mutants were less invasive compared to the wild 
type strain. This was in agreement with other reports which have demonstrated that SPI-1 
is important for invasion of tissue culture cells [197, 212-214]. To further study the effect 
of the deletion of SPI-1, we used chicken small intestinal and cecal tissue. This ex-vivo 
model was very valuable since it allowed us to evaluate the role of SPI-1 during infection 
in the chicken gastrointestinal tract. The results suggested that the deletion of SPI-1 
reduced the invasiveness of the mutant strain. However, the difference in invasion 
between the mutant and wild type strain was smaller compared to the difference using 
polarized Caco-2 cells. The results from the tissue explants, along with the findings from 
the polarized cells imply that S. Enteritidis SPI-1 is important for invasion of intestinal 
tissue, especially in chickens. 
 
The ∆SPI-1 strain was also tested in chickens. Oral challenge of two-week-old 
chickens revealed that the colonization of the cecal contents on days 1-4 post challenge 
was not affected by the absence of SPI-1. This was in agreement with one study [89] but 
not with others [88, 130]. It is possible that a difference may be observed when the 
colonization is monitored over longer time periods. The levels of S. Enteritidis were 
lower in the livers and spleens of the ∆SPI-1 challenged group relative to the wild type 
challenged group. This finding indicated that SPI-1 also played a role in spreading 
systemically in chickens. Our observations are in accordance with a recent study that 
examined the role of five major S. Enteritidis pathogenicity islands where the authors 
illustrated that the absence of SPI-1 reduced systemic infection but did not affect 
colonization of the ceca [263]. Taken together, the aforementioned experiments establish 
that the S. Enteritidis SPI-1 T3SS is an important virulence determinant in vitro, in ex 
vivo tissue samples and in chickens, thus confirming our hypothesis.  
 
The prevailing view has been that SPI-1 is essential for intestinal pathogenesis in 
different animal models. In the mouse model of infection, it has been observed that SPI-1 
mutants were recovered at lower levels from intestinal contents and systemic sites 
relative to the wild type strain [198]. Likewise, other groups have reported that the 
presence of a functional SPI-1 T3SS is important for the induction of intestinal 
 127
inflammation and histopathological changes in the streptomycin-treated mouse model of 
infectious enterocolitis [128, 197, 199]. Recent work indicates that SPI-1 is critical in 
causing enterocolitis in mice at early timepoints but plays only a minor role in intestinal 
disease at later stages of infection [136]. In addition, several reports have demonstrated 
that S. Typhimurium SPI-1 mutants can cause disease in a SPI-1 independent manner in 
the murine model of infection [127, 201]. As well, it has been shown that SPI-1 mutants 
retain their ability to invade M cells in a murine gut loop model [224]. The 
aforementioned studies illustrate that Salmonella is able to breach the intestinal epithelial 
layer by employing other mechanisms besides the SPI-1 T3SS. Therefore, Salmonella 
translocates across the intestinal epithelial layer mainly by three different routes (Figure 
6.1): (i) invasion of enterocytes (SPI-1 dependent), (i) uptake through M cells, (iii) uptake 
through dendritic cells [136]. The fact that we did not see an effect of the absence of SPI-
1 on cecal colonization in chickens suggests that S. Enteritidis mainly uses SPI-1 
independent mechanisms for translocating across the chicken gastrointestinal tract. 
Further, our data imply that SPI-1 also plays a role in systemic infection in chickens. This 
is not surprising since two recent studies have shown that SPI-1 effector proteins were 
expressed during systemic infection in mice [86, 264]. Although, the murine model of 
salmonellosis is different from chickens, these findings suggest that the role of SPI-1 can 
also be extended to the systemic phase of infection. 
 
Prior to testing the efficacy of the SPI-1 T3SS proteins in protection, we wanted 
to determine if sera against these proteins could block invasion of Caco-2 cells by S. 
Enteritidis. Interestingly, serum against a fraction containing SPI-1 T3SS secreted 
proteins significantly inhibited invasion of S. Enteritidis relative to the control group. 
This was a vital finding since it suggested that antibodies directed against SPI-1 T3SS 
related components could be used as a therapeutic strategy for controlling the spread of 
this pathogen. In order to identify which components were involved in the invasion 
inhibition effect, we tested the effect of sera against different structural and secreted 
T3SS proteins. Our results indicate that anti-SipD serum blocks S. Enteritidis entry in 
vitro, while sera against InvG, PrgI, SipA, SipC, SopB, SopE and SopE2 did not. To 
verify that the invasion inhibition effect was SipD specific, we incubated anti-SipD 
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Figure 6.1. Schematic representation of Salmonella entry across the epithelial layer 
based on studies in mice. Salmonella translocates across the intestinal epithelial surface 
through enterocytes, M cells and dendritic cells. Salmonella then travels through the 
lymphatic system to the liver and spleen via macrophages and dendritic cells. Diagram 
was adapted and modified from [265]. 
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serum with a strain lacking sipD. As expected, the sera had no effect on the invasiveness 
of the mutant strain. Further, we depleted SipD specific antibodies from anti-SipD serum 
and found that the depleted serum restored S. Enteritidis invasion. The fact that anti-SipD 
serum blocked S. Enteritidis entry is also in agreement with a recent report which 
suggests that SipD forms the tip of the SPI-1 T3SS apparatus and that it is involved in 
intimate attachment to epithelial cells [38]. 
 
In order to evaluate the potential of SPI-1 T3SS proteins as vaccine candidates, 
we vaccinated chickens subcutaneously with PrgI (needle protein) and SipD. Although 
the anti-PrgI serum did not affect the invasion of S. Enteritidis in vitro, it is possible that 
antibodies against this protein may be important in protection since the PrgI needle 
protrudes about 50 nm above the surface of the bacterial cell [17]. Vaccination with the 
aforementioned proteins induced a significant antigen specific serum IgG response and 
resulted in lower levels of the challenge strain in the livers (3 log units lower on day 4 
postchallenge) and spleens of vaccinated birds. This suggested that these proteins were 
immunogenic and were capable of conferring protection against systemic spread of S. 
Enteritidis. The PrgI and SipD proteins provided better protection compared to a study in 
which S. Enteritidis type I fimbriae were used as a subunit vaccine where there was no 
difference in the levels of the challenge strain between the internal organs of vaccinated 
and control groups [184]. We were not able to compare the level of protection we 
observed from systemic infection with other vaccination studies in chickens that have 
used subunit vaccines like outer membrane proteins and the FliC flagella protein since 
these studies did not examine the levels of S. Enteritids in the internal organs [182, 183, 
185]. However, in our study vaccination with PrgI and SipD did not affect the levels of S. 
Enteritidis in the cecal contents. This is in line with a study in which vaccination of 
chickens with S. Enteritidis type I fimbriae did not affect the levels of the challenge strain 
in the cecal contents [184]. On the contrary, this is not in agreement with the 
aforementioned vaccination study where chickens were vaccinated with the FliC protein 
resulting in a 3 log unit decrease in the colonization of the cecal contents by S. Enteritidis 
[185]. Likewise, our data is not in agreement with a report which demonstrates that 
immunization of chickens with S. Enteritidis outer membrane proteins leads to a 2-3 log 
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unit decrease in the colonization of the ceca by S. Enteritidis [183]. This could be 
explained by the fact that the SPI-1 T3SS may not be very important for breaching the 
intestinal epithelial surface in chickens and that S. Enteritidis might be using SPI-1 
indpendent mechanisms to invade the chicken gastrointestinal tract.  
 
Similarly, we also tested the efficacy of SPI-1 T3SS proteins in conferring 
protection in progeny obtained from vaccinated hens using a seeder model of infection. 
This would allow us to determine if these antigens could be used for immunization of 
breeders. Moreover, a seeder model comes very close to the natural situation that the 
chickens would encounter at a poultry facility. Vaccination with the T3SS proteins 
induced significant antibody titers in the hen sera as well as in the egg yolks. However, 
there was significant protection in the livers of progeny obtained from vaccinated hens 
only in experiment III on day 2 postchallenge in the contact exposed group. This could be 
explained by the fact that the antibody titers to the SPI-1 proteins in the progeny from 
vaccinates may not be sufficient to induce protection. Alternatively, SPI-1 may not play 
an important role in day old chicks. In order to induce better protection in progeny 
obtained from vaccinated hens, oral immunization of the hens with the aforementioned 
antigens (possibly with a combination of subcutaneous immunization) may be more 
efficacious since this would induce a mucosal immune response as well. Mucosal IgA 
antibodies specific for SPI-1 T3SS proteins may not necessarily prevent SPI-1 mediated 
translocation since S. Enteritidis can breach the gastrointestinal tract of chickens via non-
SPI-1 mediated mechanisms. Further, data from our invasion inhibition study 
demonstrated that anti-SipD serum inhibited invasion of polarized Caco-2 cells in vitro. 
Although we were able to inhibit S. Enteritidis entry in vitro, we were not able to 
completely block entry of the bacterium. Therefore, a SPI-1 T3SS protein specific IgA 
antibody response alone may not be sufficient for providing protection against S. 
Enteritidis in chickens. 
 
To take these results further, it will be important to vaccinate chickens with PrgI 
and SipD alone and in combination to determine if both proteins are involved in 
protection against systemic infection. Once this has been determined, the vaccine 
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candidate(s) should be delivered orally, possibly in combination with a subcutaneous 
immunization, to determine if a mucosal immune response can enhance the protection 
against S. Enteritidis. Additionally, the vaccine candidate(s) can be formulated with 
known adjuvants that enhance not only the antibody response, but also the cell-mediated 
immune response since S. Enteritidis is an intracellular pathogen. An optimized vaccine 
formulation may then be used for testing for protection against other non-host adapted S. 
enterica serovars like S. Typhimurium since it is also highly prevalent in chickens. 
 
In summary, the results suggest that the SPI-1 T3SS is an important virulence 
factor in chickens and that the T3SS proteins can form important components of a subunit 
vaccine to reduce the prevalence of S. Enteritidis in poultry, confirming our initial 
hypothesis. 
 
 
6.2 General Conclusions: 
 
• S. Enteritidis ∆SPI-1 and ∆invG mutants are impaired in the secretion of effector 
proteins and in invasion. 
• S. Enteritidis ∆SPI-1 is less invasive compared to the wild type strain in chicken 
small intestinal and cecal tissue. 
• The absence of SPI-1 causes a delay in systemic infection in chickens but does not 
affect the colonization of the cecal contents. 
• Anti-SipD serum blocks S. Enteritidis entry in polarized Caco-2 cells. 
• Immunization of chickens with PrgI and SipD induces antigen specific IgG antibody 
responses and confers protection from systemic infection. 
• Vaccination of hens with SPI-1 T3SS proteins induces antigen specific IgG antibody 
responses but does not confer significant protection from systemic infection in 
progeny derived from the hens. 
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